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Abstract 
The gene encoding topoisomerase I (PfFopol) from the malarial parasite, Plasmodium 
falciparum was isolated using two methods. (a) PCR of a cDNA library using 
oligonucleotides modelled on highly conserved regions of sequences from other species, 
isolated a 900bp fragment of the gene. (b) The entire Pifopol open reading frame was 
obtained from a HinD fflJEcoRI genomic library after screening with a random-labelled 
heterologous Topol probe from Saccharomyces cerevisiae. DNA sequence analysis 
indicated an open reading frame of 2520 nucleotides, encoding a deduced protein of 839 
amino acids with no detectable introns. Two large amino acid inserts were present in the 
PfTopol gene sequence which were present in both the genomic and cDNA indicating that 
they were not introns. The predicted amino acid sequence was compared with homologous 
sequences of other type I topoisomerases. On average, PfTopol showed around 40% 
identity with all the sequences examined, with the Topol sequence from man showing the 
highest level of homology. The gene is present as a single copy on chromosome 5 and 
Northern analysis identified a transcript of 3.8kb. 
The PtTopol open reading frame was cloned into prokaryotic expression vectors in order 
to express, purify and assay the recombinant protein for Topol relaxation activity. Both 
the full length PfTopol protein and fragments were expressed, although no activity could 
be detected. However Topol and II activity was observed in both crude and nuclear 
parasite extracts. Inhibition of the Topol relaxation activity was observed when the type I 
topoisomerase specific inhibitor, camptothecin, was added to the assay. 
Stage specific expression of PfTopol during the intraerythrocytic stages of the 
Plasmodium falciparum life cycle was examined using synchronised parasites. Nuclear 
run on assays indicate that the promoter is inactive during the early ring stage and is active 
only in the later mixed trophozoite and schizont stages. Northern analysis show that the 
PtTopol transcript accumulates in the trophozoites and decreases on entering the schizont 
stages. Using stage-specific westerns and immunoflourescent assays the PfTopol protein 
was shown to be at a low level in rings, accumulating to equal levels in trophozoites and 
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CHAPTER 1 
Chapter 1. Introduction 
The sickness toll from malaria is rising rapidly with almost one half of the world's 
population at risk of contracting the disease. The exact figures regarding the number of 
people who develop malaria, and its subsequent mortality, are difficult to assess. 
Estimates of over 280 million infections leading to 2 million deaths have been made 
(Brown, 1992, Miller et al. 1994). Although malaria was previously widespread, the 
disease is now mainly confined to the tropical regions of the developing world (Brown, 
1992). The consequences of infection such as diagnosis, treatment and indirect costs in 
the form of morbidity and mortality are a heavy burden on the countries' economic 
development. 
Malaria is caused by the single celled protozoan of the genus Plasmodium which is 
transmitted by the Anopheles mosquito. Plasmodiumfalciparum causes the most severe, 
cerebral, form of human malaria. The emergence of insecticide resistant mosquitoes and 
drug resistant strains of the parasite have lead to an increase in the disease. The World 
Health Organisation estimates that the number of infected people world-wide is rising at 
a rate of around 5% annually. This highlights the urgent need to discover new antimalarial 
drugs and potential drug targets. One of the most promising approaches for combating 
parasitic diseases is the administration of drugs targeted against specific enzymes of the 
parasite. 
Topoisomerases have provided targets for a number of anticancer and antibacterial agents 
and recent work has suggested that certain topoisomerase II poisons may act selectively 
against the human malarial parasite (Chavalitshewinkoon et al. 1993 and Gamage et al. 
1994). Two antileishmanial drugs have also been found to inhibit the activity of the 
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parasites topoisomerase I in vitro (Chakraborty and Majumder, 1988). This raises the 
possibility that topoisomerases may be useful targets in the design of new antimalarials. 
The topoisomerase II gene from Plasmodiumfalciparum has previously been isolated 
(Cheesman et al. 1994) and is currently being studied in this laboratory. Therefore in 
view of its potential value, the cloning and characterisation of the topoisomerase I gene 
from P.falciparum was considered a worthwhile objective. 
In this introduction the topoisomerases will be discussed, in particular eukaryotic 
topoisomerase I and its structure, function and inhibitors. The malarial parasite, 
Plasmodiumfalciparum, will also be reviewed and current developments in antimalarial 
treatments outlined. Topoisomerases from other parasites have also been studied as 
potential drug targets and research in this area will be reviewed. 
1.1 Topoisomerases. 
The topological state of DNA, and the enzymes that control this state, play an 
important role in determining the function of DNA in cells. Supercoiled DNA molecules 
are torsionally stressed relative to their relaxed counterparts. Underwound DNA 
(negatively supercoiled) exerts a persistent torque leading to unwinding of the DNA 
molecules. This can facilitate the opening of the DNA helix at promoter sequences or 
replication origins. In contrast overwinding of DNA (positively supercoiled), shown by 
certain viral DNAs isolated from thermophillic Archeabacteria, forces the DNA strands 
together and may function to stabilise the DNA helix at high temperatures (Nakasu and 
Kikuuchi, 1985). 
Topoisomerases alter the topological state of DNA by catalysing the breaking and 
rejoining of DNA strands (Liu, 1989). They are classified as type I or type 11 enzymes 
depending on their mechanistic differences. Type I topoisomerases cleave a single strand 
of the DNA duplex and type II enzymes cleave both strands of the DNA. A consequence 
of this difference is that the reactions of type I enzymes occur in steps with linking 
number changes of one, while those of type II enzymes occur with a linking number 
change of two. The linking number can be defined as the number of times that the two 
DNA strands are interwound in a covalently closed molecule. DNA molecules that are 
otherwise identical and differ only in their linking number are termed topoisomers or 
topological isomers. Figure 1.1 shows the various forms of circular double stranded DNA 
topoisomers catalysed by DNA topoisomerases. Not all topoisomerases can perform all 
of the reactions. In the following section the reactions carried out by prokaryotic and 
eukaryotic topoisomerases of both type I and II are discussed. 
I Knotting - unknotting 
Figure I.I. Schematic representation of the interconversion of circular double stranded 
DNA topoisomers catalysed by DNA topoisomerases. 
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1.1.1 Type I Topoisomerases. 
Prokaryotic. 
The first topoisomerase discovered was Topol of E.coli (Wang, 1971). The enzyme is a 
97.4kDa monomer and requires the presence of exogenous magnesium cations for 
activity. The enzyme can only relax negatively supercoiled DNA under normal 
conditions although positively supercoiled DNA can be relaxed if a single stranded loop 
has been introduced into one of the DNA strands providing a binding site for the enzyme 
(Kirkegaard and Wang, 1985). 
A second type I topoisomerase was discovered in E.coli, termed Topoill (DiGate and 
Marians, 1988 and 1989). The two E. coli proteins have sequence homology within the 
central region of the coding sequence but are divergent outwith this region. Topolli is 
slightly smaller at 75kDa and the sites where the proteins cleave DNA are different 
(Dean et al. 1982 and Srivenugopol et al. 1984). TopoIll is more able to decatenate 
nicked DNA in vitro than to relax supercoiled DNA (DiGate and Marians, 1988). In 
contrast, Topol has a higher level of DNA relaxation activity. Another difference 
observed is the absence of a zinc finger domain in Topolli which is found in Topol (Tse 
and Beran-Steed, 1988). 
A third prokaryotic type I topoisomerase, reverse gyrase, has been identified in 
Archeabacteria and has been termed TopoV. Although this enzyme is a type I 
topoisomerase, it requires ATP to remove negatively supercoiled DNA and then to 
introduce positive supercoils (Nakasu and Kikuuchi, 1985 and Slesarev et al. 1994). 
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Eukaryotic. 
Many eukaryotic type I topoisomerases have now been isolated. The eukaryotic 
enzymes are active as monomers (Liu and Miller, 1981) as are the prokaryotic enzymes. 
The eukaryotic type I topoisomerases can however relax both negative and positively 
supercoiled DNA in the presence of EDTA (Champoux and Dulbecco, 1972). EDTA is a 
chelator of magnesium, indicating that the eukaryotic type I enzymes are magnesium 
independent although the addition of the cations can stimulate the reaction. There is very 
little sequence homology between the prokaryotic and eukaryotic type I enzymes, 
however, the homology among the eukaryotic topoisomerase I amino acid sequences is 
high. The domain structure, based on sequence homology and proteolysis experiments, 
of the mammalian topoisomerase I protein is discussed later (1.2.3). 
In Xenopus laevis two immunologically distinct topoisomerase I proteins have been 
identified (Richard and Bogenhagen, 1991). The larger, 165kDa, protein is found in the 
ovaries, however as the oocyst develops the protein disappears. The smaller protein is 
1 OOkDa and can be found in the somatic tissue. As the proteins are immunologically 
distinct it is unlikely that the smaller is a proteolytic fragment of the larger protein. 
Experiments to characterise cDNAs for the two forms of the enzyme are in progress in 
an attempt to determine their roles. 
A number of other genes have been isolated which may encode proteins with type I 
topoisomerase activity. The S.cerevisiae and human genes encoding topoisomerase III 
have been isolated (Wallis et al. 1989 and Hanai et al. 1996). They show high homology 
to the E.coli Topol gene and the proteins show similar activity. The enzymes are 
monomeric and catalyse the relaxation of negatively supercoiled DNA but not positive 
supercoils. 
In S.cerevisiae two genes encoding a protein with a topoisomerase related function (trf4 
and IriS) have been isolated (Castano et at. 1996). The genes show 55% identity and 72% 
similarity with each other. A region of both genes also shares homology to the N-
terminal region of the yeast Topol. trf4 and frJS null mutants are inviable and the cells 
were found to undergo aberrant nuclear division with the production of anucleate cells. 
This suggests that trf4 and trJS are required in mitosis. Database searches indicate that 
S.pombe and human homologues of these S.cerevisiae genes probably exist. 
hprl is a gene isolated from S.cerevisiae which has a domain which is homologous to the 
C-terminal region of the S.cerevisiae Topo I gene (Aguilera and Klein, 1990). The region 
of homology, however, does not contain a Topol active site region (1.2. 1) therefore this 
lowers the likelihood that HPR1 acts as a topoisomerase. 
1.1.2 Type II Topoisomerases. 
Prokaryotic. 
Prokaryotic type II topoisomerases are known as DNA gyrases. The protein has a 
tetrameric A 2B2 structure encoded by the genes gyrA and gyrB. The gyrase A protein 
has a molecular weight of 100-105kDa and can be divided into two subunits. The N-
terminal region is responsible for the breaking and rejoining of the DNA strands (Reece 
and Maxwell, 1991 b) while the C-terminal domain has DNA binding activity (Reece and 
Maxwell, 1991a). The gyrase B protein has a molecular weight of 90-95kDa and contains 
the ATP binding domain of the protein. DNA gyrase can hydrolyse ATP and introduce 
negative supercoils into DNA (Gellert et at. 1976). In addition to ATP the reaction 
requires a divalent cation such as magnesium. In the absence of ATP the enzyme can 
relax negatively supercoiled DNA, however the reaction is less efficient (Higgins et al. 
1978). Gyrases can also catalyse the interconversion of more complex topological forms 
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of DNA. It can unknot knotted DNA species and can both catenate and decatenate DNA 
(Hsieh, 1993, Hsieh et al. 1994 and Kreuzer and Cozzarelli, 1980). 
Two other E.coli genes, parC and parE, have been isolated and found to share homology 
to the gyrA and gyrB genes (Kato et a!, 1990). The gene products have been shown to 
relax supercoiled DNA and they have been termed TopoIV. 
Eukaryotic. 
The eukaryotic type II protein is active as two identical subunits forming a homodimer 
(A2), with each subunit acting on complementary DNA strands. The N-terminal region 
of the eukaryotic type II enzymes are highly conserved among other species, with the C-
terminal region being divergent. The gyrB gene shows homology to the first third of the 
eukaryotic type II genes and the N-terminal portion of the gyrA shows homology to the 
central region of the eukaryotic genes (Wyckoff et al, 1989). Eukaryotic Topoll proteins 
can perform many reactions, and like DNA gyrases, they require the addition of ATP 
and magnesium cations. They can decatenate, unknot DNA and relax supercoiled DNA 
(Liu et al. 1980). The eukaryotic type II topoisomerases cannot supercoil relaxed DNA, a 
reaction that is carried out by the DNA gyrases in prokaryotes. The reason for this 
difference is thought to be associated with the length of DNA that interacts with the 
protein during reactions. DNA gyrase has around 150 nucleotides wrapped around it 
whereas the eukaryotic Topoll enzyme only interacts with 25 nucleotides (Kirchhauseb 
etal. 1985 and Lee et al. 1989). Some human cell lines have been found to express two 
distinct isoforms of Topoll (Pflugfelder et al, 1988 and Tan et a!, 1992). The cx form has 
a molecular weight of 170kDa and the P form, 180kDa. Neither yeast or Drosophila 
were found to contain the f3 type, however avian and mammals do (Tan et a!, 1992). The 
reason for two forms of Topoll in higher eukaryotics has yet to be established. 
1.2 Eukaryotic Topoisomerase I. 
1.2.1 The Cleavage and Religation Reaction of Topoisomerase I. 
The relaxation reaction carried out by Topol is a three step procedure and is shown in 
figure 1.2. The enzyme first binds to DNA and introduces a nick in a single strand of the 
DNA duplex via a reversible trans-esterification reaction between the hydroxyl group of 
the active site tyrosine and the DNA phosphodiester bond, yielding a covalent 
intermediate. The eukaryotic type I enzymes are the only topoisomerase to link to the 
3'-terminus of the DNA. All other topoisomerases form a link to the 5'-terminus of 
DNA. Finally, the enzyme passes the unbroken strand of DNA through the nicked 
strand or, alternatively, the nicked DNA strand swivels around the unbroken strand. The 
exact mechanism of strand passage is unknown although both mechanisms would have 
the same topological effect. Finally the nicked DNA is resealed by the reformation of the 
phosphodiester bond, releasing the tyrosine molecule. 
The tyrosine molecule that binds to the DNA strand during this reaction has been 
identified in S. cerevisiae and S.pombe by mutation analysis (Eng et al, 1989). A mutation 
of Tyr 727  to Phe in S. cerevisiae removed the enzyme's activity. The same change in 
Tyr 
771 of S.pombe also resulted in an inactive protein. 
ZI 
5' 	 3' 
3' 
5 ,  
3 ,  
Figure 1.2. (a) Topoisomerase I becomes covalently bound to DNA, creating a DNA 




Figure 1.2. (b) The transesterification reaction of Topol. The tyrosine hydroxyl at the 
reactive site of Topol attacks the DNA phosphodiester bond and displaces the 5'-0 of 
the nucleotide residue which will become the 5' terminus of the resulting strand break 
(Pommier et al. 1994). 
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1.2.2 The Biological Role of Topoisomerase I. 
DNA Topoisomerase I has been implicated in DNA replication, transcription, 
recombination and chromosome structure. The Topol protein has been studied in various 
organisms. Existing evidence and current thoughts regarding the role of Topol in the 
eukaryotic cells are discussed here. 
RNA transcription and DNA replication are processes for which strand passage is 
essential to maintain or relieve a torsionally stressed state they create. Relief of the 
stressed state facilitates the translocation of RNA or DNA polymerases along the DNA. 
Purified mammalian DNA Topol, in the absence of Topoll, can support the complete 
replication of SV40 DNA in a cell-free replication system (Yang et al. 1987). However 
the resulting daughter DNA molecules remain interlocked suggesting that Topoll is 
required for the final decatenation step of the replication process. The Topol specific 
inhibitor, camptothecin, will be discussed in more detail later (1.3) but, using the SV40 
system, the presence of camptothecin rapidly produced broken replication forks 
(Snapka, 1987). Studies also showed that camptothecin induced a large number of single 
stranded DNA breaks in the presence, but not the absence, of mammalian DNA Topol 
(Hsiang et al. 1985., Hsiang and Liu, 1988). 
Genetic studies of yeast topoisomerase mutants have suggested roles for Topol. 
S.pombe and S.cerevisiae mutants defective in Topol activity (top 1) have been isolated 
(Uemura and Yanagida, 1984., Thrash et al. 1985., Goto and Wang 1985). The strains 
were found to be viable although they grew at a much slower rate than the wild type 
strain. Plasmids carrying trancriptionally active genes are found to be extremely 
negatively supercoiled when isolated from the top  mutant cells. During transcription 
positive supercoiling occurs ahead of the elongating transcript and negatively supercoiled 
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DNA forms behind the RNA polymerase (Liu and Wang, 1987 and Wu et al. 1988), 
(figure 1.3). 
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Figure 1.3. (a) RNA polymerase (RNAP) is shown transcribing a topologically isolated 
domain of DNA into mRNA, to which ribosomes become attached. This is shown 
schematically in (b) and leads to the formation of positive supercoiling ahead of the 
transcribing complex and negative supercoils behind (c). (d) Domains of supercoiling can 
also occur in plasmid DNA with two transcription complexes travelling in opposite 





H QQQQooQQoc H 
T  -) (-) (-) (+) (~) (+1 (+) 
13 
These results suggest that Topol is required to relax the transcription-induced negative 
supercoils but that another enzyme removes the positive supercoils from the DNA. 
Yeast mutants deficient in Topoll activity (top2) exhibited a defect in the segregation of 
newly synthesised daughter chromosomes (Di Nardo et al. 1984., Uemura and Yanagida, 
1984., Holm et al. 1985). top ltop2 double mutants were, however defective in both DNA 
and RNA synthesis (Uemura and Yanagida, 1986., Goto and Wang, 1985., Brill et al. 
1987). The results suggested that Topol serves as a swivel in yeast although Topoll is 
also able to carry out this process if the Topol enzyme is absent. 
Expression studies in D.melanogaster showed that a high level of Topol is associated 
with transcriptionally active regions of the chromosomes, implicating a role for Topol in 
transcription (Gilmour and Elgin, 1987). Memo et al. (1993) analysed the factors 
necessary to mediate the activation of RNA polymerase ii in vitro. They found that a 
number of factors, including Topol, were required to achieve activation at a level 
equivalent to that observed in vivo. The absence of Topol also repressed basal 
transcription. The DNA relaxation activity of Topol was not required for either 
repression or activation of transcription The mechanism of action must therefore involve a 
process other than that of DNA relaxation. 
The need for Topol in transcription of adenovirus infected HeLa cells was analysed using 
camptothecin as an inhibitor(Schaak et al. 1990). Transcription of both adenovirus and 
HeLa genes, by RNA polymerase II was reduced but not abolished when the cells were 
treated with camptothecin, suggesting that some transcription may occur independently 
of Topol activity. Inhibition of both Topol and Topoll did not increase the inhibition of 
mRNA accumulation over that observed when Topol alone was inhibited. Therefore it 
does not appear that Topoll can substitute for Topol during transcription in this case. 
The top  mutant also resulted in an increase in mitotic recombination at the rDNA locus 
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(Christman et al. 1988). This locus contains 200 tandem repeats of a highly transcribed 
rDNA unit. Topol may suppress recombination among the repetitive sequences thereby 
maintaining genome stability. 
A novel bacterial-like type I topoisomerase, TopollI, has been isolated in yeast (Wallis 
et al. 1989) whilst looking for mutants deficient in recombination. The gene shows 
similarities to E. coil Topol and the E. coil Topol protein was able to complement the 
slow growing top3 yeast mutant. top ltop3 double mutants were viable, however their 
growth was much slower than that of the single top  or top3 mutants. Sgsl (slow growth 
repressor) was found to suppress the growth defect and increase the stability of the top3 
mutants (Gangloffet al. 1994). Sgsl has high homology to the E.coii recQ gene which is 
a helicase. The results imply that Sgsl creates a substrate that Topolil preferentially 
resolves. A type I topoisomerase in association with a helicase domain resulting in a 
protein with reverse gyrase activity was also found in Sulfolobus acidocaidarius. The 
enzyme introduces positive supercoils as a result of relaxation of a negatively 
supercoiled DNA region by the helicase (Confalonieri et al. 1993). 
A mutation of the Topol gene in Drosophila melanogaster produced a male lethal 
phenotype (Lee et al. 1993). The Topol gene is located on the X chromosome and whilst 
screening for top  mutants it was noticed that female flies with the top  mutant always 
produced a number of progeny which were aneuploid for the sex chromosomes. It is 
possible that the mutant gene may have interfered with chromosome disjunction during 
meiosis in the female parents. 
Maul et al. (1986) found that Topol was preferentially located at the centromere of 
mouse cells which also suggests a function for Topol in mitosis. The association may be 
at the level of DNA as mouse satellite DNA has high sequence homology with a Topol 
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binding site (Reis and Biro, 1978). It was suggested that Topol may maintain the 
chromatin structure and allow chromatid separation at anaphase by nicking DNA. More 
recently, Morham et al. (1996) have studied the effect of a Topol gene knock out in 
mice. Gametes were found to be viable, however embryos died at the 4-16 cell stage. 
This suggests that Topol is essential for cell division and growth. 
Illegitimate recombination is a term used to describe processes in which chromosomal 
exchanges occur between regions having little or no sequence homology, thereby 
generating insertions, deletions' duplications, inversions and translocations of genetic 
material (Low, 1988). Such rearrangements must require cleavage and ligation of DNA 
ends. There are various pieces of evidence for the involvement of Topol in this process. 
Bullock et al. (1984 and 198 5) studied recombination in SV40. They discovered that the 
DNA sequences in close proximity to the crossover points were similar to the preferred 
cleavage sites for eukaryotic Topol. Topol also has the ability to catalyse the joining of 
non homologous DNA strands in vitro (Christiansen et al. 1993) further supporting the 
involvement of Topol in illegitimate recombination events. 
1.2.3 Cellular Regulation of Topol. 
The specific activity of Topol per cell has been reported to be higher in proliferating 
cells both in vitro and in vivo. In chicken cells, human lymphocytes and sea urchins, 
Topol was found to increase in GI followed by a further sharp increase in S-phase with 
the maximum Topol activity at mid S-phase. The activity then declines during late S-
phase, G2 and mitosis (Tricoli et al. 1985, Rosenburg et al. 1976, Poccia et al. 1978). 
Other reports, however, have found no change in Topol levels when the results are 
normalised against nuclear size (Baker etal. 1995, Champoux 1978). The different results 
observed may reflect differences in the methods used to examine the Topol levels, such 
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as the cell types used and protein extraction procedures. Cell cycle dependent differential 
release of Topol may be as important as the specific activity and the differences 
observed between studies may reflect changes in the association of Topol with 
chromatin or other cellular components. 
Most of the Topol activity in eukaryotic cells is present in the nucleus. Many nuclear 
proteins undergo changes in phosphorylation during G2IM and MIG1 cell cycle 
boundaries. In vitro studies using purified protein has shown that phosphorylation 
activates Topol. The Topol proteins from frog (Kaiserman et al. 1988), rodent (Samuals 
and Shimizu, 1992) and humans (Pommier et al. 1990) have been shown to be 
phosphorylated. Calf alkaline phosphatase treatment reduced the enzyme's ability to 
relax supercoiled DNA. This was reversed by phosphorylating the protein with either 
casein kinase H or protein kinase C treatment. Studies using calf thymus Topol have 
showed that tyrosine phosphorylation inactivated the enzyme in vitro (Tse et al. 1984), 
although serine phosphorylation enhanced its activity (Samuals et al. 1989., Pommier et 
al. 1990). D'Arpa and Liu, 1995, examined the phosphorylation state of mammalian 
Topol throughout the cell cycle. Phosphorylation of a protein produces shifts in 
electrophoretic mobility. Two electrophoretic forms of Topol were observed. Both 
forms were able to cleave DNA and relax supercoiled DNA with approximately equal 
activity. One of the Topol forms is specifically present during mitosis. On exit from 
mitosis two forms of Topol exist which persist throughout the remainder of interphase. 
The results suggested that dynamic phosphorylation and dephosphorylation regulate 
Topol during the cell cycle. A repertoire of Topol isoforms may exist which have 
different biological roles in the cell which depend on phosphorylation for their activity. 
A similar expression pattern has been reported for some of the proteins with a role in 
DNA replication. DNA polymerase a in rat cells is differentially phosphorylated 
throughout the cell cycle. The activity of the enzyme increases dramatically prior to 
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DNA replication in S-phase and this corresponds to the presence of a phosphorylated 
form of the enzyme (Donaldson and Gerner, 1987). The regulation of Topol 
phosphorylation may also be a mechanism by which kinases control gene expression. 
The effect of phosphorylation on the sensitivity to the Topol inhibitor, camptothecin, 
will be discussed later (1.3). 
Topol activity is severely inhibited when the enzyme is modified by poly(ADP-ribose) 
synthase (Ferro and Olivera, 1984). Poly(ADP-ribose) synthase uses NAD as a 
substrate to catalyse the formation of a nucleic acid like polymer, poly(ADP-ribose). 
The enzyme is implicated in an array of cellular events that may involve changes in the 
structure of chromatin. Polymeric chains of poly(ADP-ribose) are covalently attached to 
Topol and this may therefore be a cellular mechanism for modulating Topol activity in 
response to the state of DNA in the nucleus. Inhibitors of poly (ADP-ribosylation) 
increased the levels of DNA breaks and cytotoxicity in response to camptothecin 
(Mattern et al. 1987) and cell lines deficient in poly(ADP-ribose) are hypersensitive to 
camptothecin (Chatterjee et at. 1989). Since endogenous synthesis of poly (ADP-ribose) 
is triggered during DNA damage, it is possible that poly(ADP-ribosylation) of Topoi 
may decrease its catalytic activity and limit the occurrence of illegitimate recombination 
during DNA repair (Wall et al. 1986). 
Po!y(ADP-ribose) is also found to be associated with histone Hi and high mobility 
group proteins (HMG), factors which also have an affect on Topol activity. Histone Hi, 
HMG  and HMG2 all stimulate the activity of Topol (Rowe et al. 198 1., Javaherian and 
Liu, 1983). The mechanism whereby they stimulate Topol activity is unknown although 
it is thought that Hi and HMGs stabilise the DNA helix therefore providing a favoured 
site for Topol activity. 
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1.2.4 The Predicted Structure of Topol. 
The domain structure of the human Topol protein expressed in the baculovirus system 
has been studied (Stewart et al. 1996a and 1996b). Using limited proteolysis, the domain 
boundaries of the protein were found to be very similar to the domain organisation 
predicted from sequence comparisons with other eukaryotic Topol genes (Hsieh et al. 
1994). 
The human Topol protein has a mass of 91 kDa and can be divided into four domains 
(figure 1.4). 
Human Topol 91kDa 
V 
	
Nil, 	 CORE 	 LINKER (OOH 
Met' 	 Lys' 94 	 11e65 ' 	G1u698 	Phe 765 
I I I I I 
24kDa 	 54kDa 	 5kDa 	8kDa 
Figure 1.4. The predicted domain structure of the human Topol protein. Relevant 
amino acid positions are shown as well as the size of each domain. The active site 
tyrosine at position 723 is indicated (Y). 
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The 24kDa N-terminal domain shows little homology with other eukaryotic Topol 
enzymes. The domain is sensitive to proteolysis and has previously been shown to be 
dispensable for activity in vitro (D'Arpa et al. 1988 and Alsner et al. 1992). The region 
contains four putative nuclear localisation signals and may therefore be essential in vivo 
for the expression of the protein in the nucleus. The domain is mainly, if not completely, 
unfolded and has a high density of both positive and negatively charged residues. In vitro 
this region has been shown to act as a solubilising element. In vivo 95% of the cell's 
Topol is associated with the nucleus and within the nucleus the enzyme is known to be 
highly localised to specific regions such as those undergoing transcription (Muller et al. 
1985). It is therefore possible that the N-terminal domain is required in these regions for 
protein solubility. Two genes have recently been isolated from S.cerevisiae, trf4 and trJ5 
(Castano et al. 1996). Although the function of the proteins they encode is unknown, it 
is interesting that their sequences show similarity within the N-terminal domain of the 
yeast Topol enzyme. Database searches also indicated that S.pombe and human genes 
encoding proteins with a topoisomerase related function may exist. The core domain is 
54kDa in size and is highly conserved among its eukaryotic homologues. The third 
domain is a linker domain. The region is 5kDa in size and is not conserved among other 
eukaryotic Topol enzymes. This domain is thought to be involved in non-covalent 
binding to DNA since it is sensitive to proteolysis when it is bound to DNA. The final 
region is the C-domain which is 8kDa in size, resistant to proteolysis and is highly 
conserved among its Topol homologues. Removal of this domain renders the protein 
inactive which is not surprising as this is where the active site region, including the 
tyrosine which covalently binds to the DNA strand, is located. After proteolysis of the 
total protein, the protease resistant CORE and C-terminal domains are able to show 
limited topoisomerase activity. It has therefore been proposed that the domains remain 
associated with each other and that the linker region is not essential for activity. 
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1.3 Eukaryotic Topoisomerase I Inhibition. 
1.3.1 Camptothecin and its Derivatives. 
Camptothecin is a naturally derived compound from the Chinese tree Camptorheca 
acuminata (Wall et al. 1966). Camptothecin and some of its derivatives are shown in 
figure 1.5. 
R 	R1 	R2 
Camptothectn 	 H 	H 	H 
Topotecan 	 OH 	—CH2—N(CH3)2 






tnnotecan 	 SN-38 
Figure 1.5. Structures of Topoisomerase I inhibitors, camptothecin and its derivatives 
(Sinha, 1995). 
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Camptothecin undergoes a pH dependent reversible hydrolysis to yield an acid form of 
camptothecin. Both forms of the drug demonstrated antitumour activity, however the 
acid form, while more water soluble, was approximately 10 fold less potent than the 
lactone form. Due to its solubility the sodium salt of camptothecin acid was chosen for 
clinical evaluation as an antitumour agent (Gottlieb et al. 1970, Gottlieb and Luce, 1972., 
Moertel et al. 1972., Muggia et al. 1972). The drug showed promising activity against 
leukaemia and gastrointestinal tumours, however the studies were discontinued due to 
severe toxic side effects. Recently, more water soluble derivatives of camptothecin have 
been synthesised (Wall et al. 1986., Wani et al. 1986, 1987., Hsiang et al. 1989b., 
Kingsbury et al. 1991). 
Phase II studies of the camptothecin derivative, [9-dimethylaminomethyl- 10-
hydroxycamptothecin hydrochloride] (topotecan) are taking place. Topotecan has 
improved water solubility and like camptothecin the compound undergoes a pH 
dependent reversible hydrolysis of the pharmacologically active lactone form to the acid 
form. The results so far are promising in ovarian and colorectal cancer (Giantonio et al. 
1993., Ilson et al. 1993., Kudelka et al. 1993., Verweij et al. 1993). 
A phase I study of 7-ethyl- 10- [4-(piperidino)- 1 -piperidino] carbonyloxycamptothecin 
(CPT- 11 or Irinotecan) reported a response rate of 18% in 17 patients with advanced 
non-small-cell lung cancer (Negoro et al. 1991). In vivo, CPT-11 appears to be 
metabolised to a lactone form, 7-ethyl-l0-hydroxycamptothecin (SN-38), which is more 
potent than the parent compound. Phase II studies are now underway. 
A more recent derivative of camptothecin is 9-aminocamptothecin. The compound is a 
more soluble analogue of camptothecin and phase-I studies are presently underway. 
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1.3.2 The Mechanism of Action of Camptothecin and its Derivatives. 
As part of their interaction with DNA, both type I and II topoisomerases reversibly 
form a complex with DNA. When denatured, eukaryotic Topol is found to be covalently 
linked to the 3' end of the nicked DNA (Champoux, 1978) while all other 
topoisomerases are linked to the 5' end of the DNA (Liu etal. 1983., Sander and Hsieh, 
1983., Depew et al. 1978., Tse et al. 1980., Sugino etal. 1980). The formation of the 
topoisomerase-DNA complex in the cell can be monitored by lysing the cell with SDS 
which traps the complex and leads to protein-linked DNA damage. The cleavable 
complex can be stabilised by the addition of a number of topoisomerase inhibitors. A 
correlation between the level of protein-linked DNA damage and cell cytotoxicity in the 
presence of different topoisomerase poisons has been observed in several studies 
(Zwelling etal. 198 1., Wozniak and Ross, 1983., Rowe etal. 1985., Hsiang eta! 1989b). 
It is therefore likely that the formation of the cleavable complex in the cell is what 
induces cell death (D'Arpa and Liu, 1989., Liu, 1989). A large number of anticancer and 
antibacterial agents are now known to target topoisomerases. 
DNA Topol has been identified as the target for camptothecin and its derivatives 
(Hsiang et al. 1985., Hsiang and Liu, 1988). In vitro studies have shown that 
camptothecin induced a large number of single stranded DNA breaks in the presence, but 
not in the absence, of mammalian DNA Topol. The Topol protein was subsequently 
found to be covalently linked to the 3' end of the broken DNA strand. Also strains of 
S. cerevisiae deficient of an active Topol gene have been found to have a camptothecin 
resistant phenotype whilst the wild type strain is sensitive to the drug (Eng et al. 1988., 
Nitiss and Wang, 1988). When purified Topol from S.cerevisiae or human Topol 
(Bjornsti et al. 1989) is reintroduced to the cells deficient in their own Topol, the cells 
regain their camptothecin sensitivity. This demonstrates that both the yeast and human 
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Topol proteins are the target of camptothecin. Furthermore, two mammalian cell lines 
resistant to camptothecin were found to contain an altered form of Topol (Gupta et al. 
1988., Kjeldsen et al. 1988). Analysis of the gene encoding the resistant Topol revealed 
two points at which the amino acid sequence of the sensitive wild type and resistant 
mutant strains differ. Asparagine was changed to glycine at position 533. The same 
amino acid change was also observed at position 583 (Tamura et al. 1991). It is not 
known at present if both changes are required for resistance or if a single change is 
sufficient. The changes are both found in a region where there is a high level of 
conservation between species. The tyrosine residue implicated in binding to DNA is at 
position 773 of the human Topol (Lynn et al. 1989), therefore the site of interaction 
between the protein and camptothecin may by distinct from the DNA binding domain. 
Exposure of cells to camptothecin leads to inhibition of DNA and RNA synthesis, 
blocking cell cycle progression into mitosis, DNA fragmentation and cell death (Li et al. 
1972., Horwitz and Horwitz, 1973). Inhibition of RNA synthesis and fragmentation of 
chromosomal DNA are rapidly reversible when camptothecin is removed from culture 
(Abelson and Penman, 1972). Inhibition of DNA synthesis, on the other hand, is only 
partially reversed with the drug-treated cells being unable to divide (Kessel et al. 1972., 
Horwitz et al. 1971). Cells were exposed to camptothecin during different stages of the 
cell cycle and those undergoing DNA replication showed up to 1000 fold greater 
sensitivity compared to those at the other stages of the cell cycle (Li et al. 1972., 
Drewinko etal. 1974). Aphidicolon is an inhibitor of DNA synthesis and it stops the 
progression of the DNA replication fork. When aphidico!on is administered with 
camptothecin the cells are protected from camptothecin, although the formation of the 
cleavable complex still occurs (Holm et al. 1989., Hsiang et al. 1989a). This observation 
led to the fork collision model of cell killing which involves an interaction between the 
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camptothecin trapped topoisomerase-DNA complex and the moving replication fork, 
thus causing an irreversible double stranded break (figure 1.6). 
Due to the mechanism of drug action, the higher the physiological concentration of 
Topol, the more lethal the Topol poisons become. The level of Topol is generally 
elevated in cells that are undergoing rapid proliferation such as colon cancer cells which 
contain six times the normal level of Topol (Giovanella et al. 1989). This probably 







Figure 1.6. DNA synthesis is arrested by interaction of the drug trapped cleavable 
complex with the advancing replication fork resulting in a double stranded DNA break 
which is responsible for cell death. Figure from Creemers et al. 1994. 
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1.3.3 Resistance to Camptothecin and its Derivatives. 
Post-translational modification of Topol may also play a role in the antitumour activity 
of camptothecin (Pommier et al. 1990). As previously discussed, Topol 
phosphorylation has been found to correlate With the enzymes increased activity (1.2.3). 
The dephosphorylated protein has been found to be inactive and camptothecin resistant. 
Restoration of the enzyme's catalytic activity and sensitivity to camptothecin were 
achieved by the rephosphorylation of Topol by Protein kinase C. Poly(ADP-
ribosylation) severely inhibits the activity of Topol and has been discussed previously 
(1.2.3). Inhibitors of poly (ADP-ribosylation) increased the levels of DNA breaks and 
cytotoxicity in response to camptothecin (Mattem et al. 1987). Cell lines deficient in 
poiy(ADP-ribose) are hypersensitive to camptothecin (Chatterjee et al. 1989). These 
results suggest that both phosphorylation and poly (ADP-ribosylation) may play an 
essential role in determining the sensitivity of tumour cells to camptothecin. 
The P-i 70 glycoprotein, thought to be responsible for multi drug resistance, is expressed 
by the mdrl gene and is thought to come about when drug accumulation is decreased by 
an active pumping efflux process (Riordan and Ling, 1986, Ueda et al. 1986). Unlike 
several other anticancer agents, including the topoisomerase II inhibitors, camptothecin 
and most of its derivatives have been shown not to be subject to the multi drug resistance 
phenomenon (Chen et al. 1991., Tsuruo et al. 1988., Mattern et al. 1993). Camptothecin 
resistant tumour cells are, however, found frequently. They have been found to result 
from mutations in the amino acid sequence of the cells Topol gene. Camptothecin 
analogues may not therefore be curative as single agents and they may have greater 
success as part of a combination therapy. Evidence has shown that camptothecin 
resistant yeast cells, expressing a mutant Topol, showed increased sensitivity to 
saintopin, in comparison to the wild type strain (Knab et al. 1995). Saintopin is a drug 
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which inhibits both Topol and Topoll activity. Trials are also being carried out where 
topotecan is being administered in combination with etoposide, a Topoll inhibitor. 
1.3.4 Non Camptothecin Inhibitors of Topol. 
Compounds, other than camptothecin and its derivatives, also interfere with the catalytic 
cycle of Topol. These include intercalators such as ethidium, aminoacridine analogues 
(Pommier et al. 1987) and DNA binding drugs (Mortensen et al. 1990). The minor 
groove-binding ligands (MGBLs) include compounds such as netropsin, distamycin A, 
berenil and the Hoechst dyes (bisbenzimidazole dyes). A number of MGBLs are known 
to have antiviral, antibacterial, antitumour and antiprotozoal activity (Baguley, 1982., 
Zimmer, 1975). In the presence of calf thymus Topol, MGBLs induced single stranded 
DNA breaks with the 3'-ends of the broken DNA being attached to the Topol (Chen et 
al. 1993). The protein-linked DNA breaks are reversible by heating to 65 °C or by adding 
0.5M sodium chloride. These results are the same as those found for camptothecin. The 
cleavage sites of the MGBLs and camptothecin are, however, different. The amount of 
DNA cleavage was not found to correlate with the strength of the DNA binding of the 
compounds. This suggests that the compounds probably trap the cleavable complex 
although the exact mechanism is unknown. Binding of the DNA minor grooves may be 
responsible for the trapping of the Topol-cleavable complexes (Chen et al. 1993). 
During the course of the catalytic sequence of activity of Topol, a covalent bond is 
formed between a tyrosine group at the active site of the enzyme and a 3' phosphate 
group along the DNA backbone. This reaction is similar to the tyrosine phosphorylation 
process which is mediated by protein kinases. Tyrphostins are synthetic compounds 
which are selective blockers of protein tyrosine kinase (PTK). In vitro studies have 
shown that some tyrphostin compounds can inhibit the activity of Topol. The 
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compounds worked by stopping the enzyme from binding to the DNA by interacting 
with the enzyme and preventing the covalent bond forming between the active tyrosine 
of Topol and the phosphate of the DNA backbone (Afialo et al. 1994). 
1.4 Malaria. 
Malaria is caused by single celled protozoan parasites of the genus Plasmodium, which 
can be found in the blood of reptiles, birds and mammals. There are four main species 
which can infect man- P.vivax, P.ovale, P.malariae and P.falciparum. The distribution of 
these species and the range of clinical conditions that arise from their infections varies a 
great deal. The mortality caused by the disease can mainly be attributed to P.falciparum 
which causes the most severe, cerebral, form of the disease. 
The life cycle of P.falciparum takes place in two hosts; the asexual phase in the human 
vertebrate host and a sexual phase in the female Anopheles mosquito (figure 1.6), 
(Phillips, 1983, Bruce-Chwatt, 1985). Infection in the human host starts when 
sporozoites from the saliva of an infected mosquito are introduced into the blood stream 
during a blood meal. Many sporozoites that are injected into the host capillary bed are 
destroyed by phagocytosis, however some move to the liver where they attach and 
invade parenchymal cells. The entire process takes approximately 30 minutes. In the 
parenchymal cells the sporozoites undergo many mitotic divisions, in a process known 
as exoerythrocytic schizogony, which produces many thousands of merozoites. Around 
16-18 days later the parenchymal cells rupture, releasing the merozoites into the blood 
stream. The merozoites rapidly recognise, attach to and invade erythrocytes. Within the 
erythrocytes, the parasite undergoes intraerythrocytic schizogony which takes 48 hours. 
The merozoite develops into a small circular form of the parasite known as the ring stage. 
This grows in size and becomes irregular in shape as it develops into a trophozoite. The 
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trophozoite stage, sometimes referred to as the "feeding form", uses the erythrocytic 
haemoglobin as a nutrient source leaving a waste product known as haemozoin. DNA 
synthesis starts in the mid-trophozoite stage and the nucleus undergoes up to 4 rounds 
of division. As the trophozoites develop into schizonts the cytoplasm is divided. The 
nuclei and cytoplasm separate to give up to 16 merozoites which are released when the 
erythrocyte bursts. The rupture of the infected erythrocytes is synchronised and 
coincides with a peak in the fever symptoms. Falciparum malaria is particularly severe 
due to the ability of infected erythrocytes to attach to one another as well as to the 
epithelium of capillaries in a process known as "rosetting". Attachment to the epithelia 
of capillaries in the brain, resulting in their subsequent blockage, is thought to be 
responsible for the fatal coma found in either the young or in non-immune victims. The 
released merozoites may re-invade erythrocytes and undergo a further cycle of 
intraerytbrocytic schizogony or they may be committed to sexual differentiation as 
gametocytes. The factors that control the switch from the asexual to sexual stages are not 
understood. However, body temperature, host immunity and nutrient levels are all 
thought to be involved. Male microgametocytes or female macrogametocytes are formed, 
and both types of gametocyte are taken up into the mosquito mid-gut in a subsequent 
blood meal. The microgametocyte undergoes exflagellation, a process that gives rise to 8 
flagella or microgametes. The female gametocyte matures, shedding the red cell membrane 
forming the female macrogamete. The flagellum fertilises a macrogamete to produce a 
zygote. The zygote is the only developmental stage to be diploid and meiosis occurs 
soon after fertilisation. Over the following 12-18 hours the zygote develops into an 
ookinete which moves through the mid-gut epithelium to rest between the basement cell 
membrane and the basel lamina of the mid-gut wall. The ookinete undergoes many rounds 
of mitotic division, over the following 10-12 days, developing into an oocyst in which 
thousands of sporozoites are formed. When the sporozoites are released from a ruptured 
oocyst they travel through the haemocoel to the salivary glands. The sporozoites are 
then introduced into the human host when the next blood meal is taken and the cycle 
begins again. 
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Figure 1.7. The life cycle of Plasmodiwnfalciparwn. 
1.5 Drugs used to Combat Plasmodiumfalciparum. 
The major drugs used at present in the control of P.falciparum include the antifolates 
(pyramethamine and sulphadoxine) and the quinine like antimalarials (quinine, 
chioroquine, mefloquine and halofantrine). Resistant strains of the parasite have however 
emerged to most of the drugs currently available. 
The antifolates inhibit the parasites folic acid biosynthesis pathway. Malarial parasites 
acquire purines from the red blood cell but synthesise the pyrimidine bases themselves. 
Pyrimidine synthesis requires folate as a co-factor as does the synthesis of serine and 
methionine. Cycloguanil and pyrimethamine impair folate metabolism by ininhibiting 
dihydrofolate reductase (DHFR) (Ferone, 1970) causing a decrease in the synthesis of 
pyrimidines, blockage of DNA replication (Schellenberg and Coatney, 196 1) and a 
decrease in the production of senile and methionine (Gutteridge and Trigg, 1971). 
Examination of the DHFR gene in sensitive and resistant parasites has identified several 
mutations responsible for the resistance (Cowman et al. 1988, Peterson et al. 1988 and 
1990, Foote et al. 1990 and Basco et al. 1995). The sulfa drugs act on other enzymes in 
the folic acid biosynthetic pathway also. The most used sulfa drug is sulfadoxine which 
is thought to inhibit dihydropteroate synthase (DHPS) (Zhang and Meshnick, 1991). 
The DHPS gene has been cloned (Brooks et al. 1994, Triglia and Cowman, 1994) and 
sequence analysis from sulfadoxine resistant and sensitive P.falciparum has identified 
amino acid changes that may be involved in resistance. 
One of the most successful antimalarials to date is chioroquine, a quinine like drug. The 
drug is thought to act by inhibiting the digestion of haemoglobin to haemozoin and is 
therefore effective against the intraerythrocytic stages of the parasite life cycle which 
produce the pigment (trophozoites and schizonts). Resistance to this drug has however 
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now emerged, and a recent study in Senegal linked chioroquine resistance to a seven fold 
increase in malaria deaths over a five year period (Butler et al. 1997). The mechanism of 
resistance of malarial parasites to chloroquine is not clear, however P.falciparum 
parasites resistant to chloroquine contain less drug than those which are sensitive (Fitch, 
1970, Yayon et al. 1985, Verdier et al. 1985 and Krogstad et al. 1987). This observation 
has led to the view that resistance could be due to a decrease in the uptake of the drug, an 
increase in efflux or a combination of both. 
Attack on the vector has also suggested as a major means of reducing the incidence of the 
disease. Insecticide-impregnated bed nets are known to cut mortality and morbidity by 
15 to 33% in short term trials (Butler et al. 1997). It is, however, argued that in the long 
term this will only make the populations more vulnerable to severe disease as it would 
reduce the emergence of natural immunity. Methods such as bed-nets and genetically 
engineered mosquitoes would therefore have little impact on disease control. 
1.6 Topoisomerases - a potential drug target for an antimalarial. 
One of the most promising approaches for combating parasitic diseases is the 
administration of drugs targeted against a specific enzyme of the parasite, especially if 
the target is more sensitive than the host. Topoisomerases I and II are now being 
examined as the target for a variety of antiparasitic compounds. The topoisomerases are 
attractive candidates as they are known to be the targets of a number of antibacterial and 
antitumour agents. 
The most promising of these so far is Pyronaridine which has been used with great 
success for the treatment of P.falciparum malaria in China. The drug has also been found 
to be effective against parasites that are resistant to chloroquine. The use of the drug is 
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now expanding to Thailand where the parasites are resistant to almost all of the 
antimalarials currently available. Pyronaridme has been found to inhibit the parasite's 
Topoll activity in vitro (Chavalitshewinkoon et al. 1993). 
Pentamidine and its analogues are known to be effective antiparasitic agents (Schoenbach 
and Greenspan, 1948). Dykstra et al. (1994), has examined the effect of dicationic 
substituted bis-benzimidazoles on purified Topol and Topoll from Pneumocystis carinii. 
They found that there was no correlation between topoisomerase inhibition and 
antiparasitic activity, however compounds did show significant selectivity for the 
parasites Topol over that for their mammalian counterparts. In this case DNA 
topoisomerases may not be the primary targets for the drugs. The mechanism by which 
these drugs work on the parasite is unknown although the drugs are known to have 
potent minor groove binding properties. The minor groove binding ligands and the 
mechanism by which they are thought to inhibit Topol has been discussed previously 
(1.3). 
Two drugs currently in use against leishmaniasis are sodium stibogluconate and 
ureastibamine. Both compounds have been shown to target the parasite's Topol in vitro 
(Chakraborty and Majumder, 1988). The drugs were found to react with the protein 
rather than the DNA and the activities of calf thymus Topol, Topolli or DNA gyrase 
were not inhibited by the drugs suggesting that the drugs are specific to the parasite's 
Topol. 
Treatment of Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani with 
camptothecin created covalent adducts with nuclear and mitochondrial DNA resulting in 
an inhibition of DNA replication and cell death (Bodley and Shapiro, 1995). Studies 
using a selection of camptothecin derivatives found that certain compounds had 
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improved cytotoxicity against the parasite's Topol compared to the human host enzyme 
(Bodley et al. 1995). 
The need for the discovery of new antimalarial drugs and potential drug targets has 
previously been highlighted. The evidence from other parasites suggests that Topol may 
act as a target for a variety of antiparasitic compounds. Therefore Topol from 
Plasmodiumfalciparum may also provide a target in the design of new antimalarials. 
1.7 Scope of Thesis. 
The intention of the project was to clone and characterise the topoisomerase I gene from 
Plasmodiumfalciparum. As Topol is thought to be involved in several essential cellular 
processes, it makes the protein a potential drug target. The plan for the work can be 
summarised as follows: 
isolate, sequence and characterise the PfTopol gene. 
over express recombinant PfTopol in a suitable system and compare the activity of 
the recombinant and native protein. 
map the expression characteristics of the native protein. 





Chapter 2. Materials and Methods. 
2.1 Materials. 
2.1.1 Chemicals. 
Unless stated otherwise, chemicals were supplied by Sigma Chemical Co. Ltd., UK or 
BDH. plc., UK. Cell culture medium was supplied by Gibco-BRL, UK. Solvents were 
supplied by FSA Laboratory Supplies, UK and radio-labelled nucleotides were supplied 
by Amersham International plc., UK. 
2.1.2 Equipment. 
Benchtop centrifugation was carried out using a Heraeus Biofuge 13 (Eppendorf, 
Germany) or Juoan CR322 (Saint-Herbain, France). High speed spins (up to 12000rpm) 
were carried using a Sorvall RC5-B high speed centrifuge with a HB-4 rotor). Spins 
above 12000rpm were carried out using the Sorvall OTB50-B ultracentrifuge (DuPont 
Instruments). PCR reactions were carried out using a PHC-2 thermal cycler (Techne 
Instruments). Hybridisations were done in HB1/ HB2D heated cabinets (Techne 
Instruments). Plasticware and culture materials were supplied by Beckton Dickinson 
Labware, UK. 
2.1.3 Restriction and modifying enzymes. 
Restriction endonucleases and buffers were supplied by Boehringer Mannheim UK 
(Diagnostics and Biochemicals) Ltd, UK. One-phor-all restriction endonuclease buffer 
was supplied by Pharmacia Biotechnology, UK. Modifying enzymes were supplied by 
Gibco-BRL, UK, Boehringer Mannheim UK Ltd.,UK. 
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2.1.4 Imaging. 
KODAK X-OMAT AR and X-OMAT LS Autoradiography film was supplied by IBI 
Molecular Biology Products, UK. UV-irradiated ethidium bromide gels were 
photographed with either HP5 film, ILFORD Ltd, UK, or by a Mitsubishi Video 
Processor to heat sensitive film. 
2.1.5 Microbiology. 
2.1.5.1 Bacterial strains. 
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Table 2.1. Th icterial strains. 
W. 
2.1.5.2 Bacteriophage. 
The bacteriophage used was NM1 149 	with the genotype: A imm434 , b538, 
(Murray, 1983). 
2.1.5.3 P.falciparum DNA libraries. 
A genomic library was prepared by Mike Goman, University of Edinburgh, using 
Hindu! / EcoRI restricted K  genomic DNA cloned in NM! 149 (Goman et al. 1982). A 
cDNA library was prepared by A.Craig, 1MM, Oxford, using cDNA from trophozoites 
with X7w1 linkers, cloned into the vector pJFE14. 
2.1.6 Media. 
All media was supplied by the ICMB media service. 
BBL Bottom Agar 
1% Baltimore Biological Laboratories Trypticase, 0.5% sodium chloride, 1.5% agar. 
BBL Top Agar 
As for BBL bottom agar except contains only 0.65% agar. 
Luria- Bertani medium(LB) 
1% bacto-tryptone, 0.5% Bacto-yeast extract, 1% sodium chloride adjusted to pH7.2 
using 1M sodium hydroxide. 
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LB agar 
LB supplemented with 1.5% agar. 
Minimal Media 
1 x spitzen salts, 0.5% glucose and 1ig/ml of Vitamin Bi. 
Selective Media 
LB media or agar supplemented with the appropriate antibiotic, X-gal and IPTG as 
required. 
Ampicillin(AMP) 	I OOmglml stock solution prepared in dH 20. 
used at a concentration of 1 OOpg/ml. 
Chloramphenicol(CHL) 	20mg/ml stock solution prepared in 100% ethanol 
used at a concentration of 20pg/m1. 
Kanamycin(KAN) 	SOmg/ml stock solution prepared in dH 20 
used at aconcentration of 50j.tg/ml. 
X-gal 	 2% stock solution of in DMF 
used at a concentration of 2m111. 
IPTG 	 100mM stock solution prepared in dH 20 and filter 
sterilised 	 used at a concentration of 0.3mM. 
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2.1.7 Stock Solutions. 
Denaturation Solution(for plagues lifts and Southern blots). 
1.5M sodium chloride and 0.5M sodium hydroxide. 
Neutralising Solution (for plague lifts). 
1.5M sodium chloride and 0.5M Tris, pH7. 
Neutralising Solution(for Southern blots). 
1M ammonium acetate, 0.02M sodium hydroxide. 
Oligonucleotide Hybridisation Buffer. 
2XSSC, 0.2% SDS, 0.1% sodium pyrophosphate, 500j.tg/ml heparin. 
Phage buffer (supplied by ICMB media service). 
0.3% potassium dihydrogen orthophosphate, 0.7% disodium hydrogen orthophosphate 
(anhydrous), 0.5% sodium chloride, 1mM magnesium sulphate, 0.1mM calcium chloride, 
1% gelatin. 
Phosphate Buffered Saline (PBS). 
137mM sodium chloride, 2.7mM potassium chloride, 4.3mM disodium hydrogen 
orthophosphate, 1.4mM potassium dihydrogen orthophosphate. 
Random Label Hybridisation Buffer. 
0.25M sodium phosphate pH7.2, 7% SDS. 
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Standard Saline Citrate (SSC) 20x stock solution. 
3M sodium chloride, 100mM trisodium citrate pH7.0. 
Tris-Borate-EDTA (TBE) lOx stock solution. 
0.9M Tris, O.9M Boric acid, 20mM EDTA pH8.0. 
Tris-EDTA (TE). 
10mM Tris-HCI pH8.0, 1mM EDTA pH8.0. 
Tris-EDTA-Saline (TES). 
20mM Tris-HC1 pH7.5, 10mM EDTA, 100mM sodium chloride. 
Tris-saline(TS) i OX stock solution 
1.5M sodium chloride, O.1M Tris-HC1 p117.4. 
2.2 DNA Methods. 
Unless otherwise stated the methods described in the following text were based on those 
found in either Sambrook et al. (1989), Harlow and Lane (1988) or Ausubel et al. (1992). 
2.2.1 Isolation of DNA. 
2.2.1.1 Preparation of P.falciparum DNA. 
P.falciparum parasites were grown until 10 9 parasites were available. The parasites were 
harvested by centrifugation at 3000rpm for 10 minutes at 4°C. The culture was then 
washed in 2 volumes of incomplete medium and were collected again by centrifugation. 
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The erythrocytes were lysed by resuspending in 5 volumes of 1 xSSC/ 0.1% saponin and 
incubating at room temperature for 5 minutes. The released parasites were collected by 
centrifugation (3200rpm, 15 minutes, 4 °C) and washed with 1xSSC/0.1% saponin. The 
washed parasites were collected by centrifugation and resuspended in 9m1 of 1xSSC. 2m1 
of 20% sodium lauryl sarcosine was added, mixed carefully by inversion and then 
incubated on ice for 5 minutes. The suspension was then made up to 21m1 by the 
addition of 1xSSC containing 20.9g of caesium chloride, 0.2m1 of ethidium bromide 
(lOmgml') and divided into 2 heat sealed tubes (11 .5m1 tubes for Ti50 rotor). The DNA 
was banded by caesium chloride gradient ultracentrifugation (38000rpm, 48 hours, 18 0C). 
A single central band, visible under a UV light, containing the genomic DNA was 
collected and the ethidium bromide removed by repeated isoamyl alcohol extractions 
until no pink colour was visible. The DNA was dialysed against 2L of TE overnight at 
4°C, ethanol precipitated (2.2.1.6) and resuspended in 1 ml of TE. The DNA was 
analysed using UV spectroscopy(2.2. 1.4). 
2.2.1.2 Midipreparation of plasmid DNA. 
Approximately 100-1 50tg of plasmid DNA from Escherichia coil was prepared using 
the Plasmid Midi Kit commercially available kit from QiagenTM. A single colony was 
used to inoculate 50m1 of LB-AMP and grown overnight at 37°C with shaking. The cells 
were collected by centrifugation (3 000rpm, 10 minutes, 4 °C) and the pellet resuspended 
in 4m1 of buffer P1 (50mM Tris-HCI pH8.0, 10mM EDTA, 1OOj.tgml-1 RNase A). 4ml 
of buffer P2 (200mM sodium hydroxide, 1 %SDS) was added and the suspension 
incubated at room temperature for 5 minutes. 4ml of ice cold buffer P3 (2.55M 
potassium acetate pH4.8) was added to the suspension followed by a 15 minute 
incubation on ice. Cell debris were pelleted by centrifugation (10000rpm, 10 minutes, 
4°C) and the supernatant centrifuged again, as previously described, to ensure the debris 
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were completely removed. The supernatant was added to a QiagenTM Tip-100 column 
which had previously been equilibrated using 4ml of buffer QBT (750mM sodium 
chloride, 50mM MOPS, 15% ethanol pH7.0, 0.15% Triton X-100) which was allowed 
to enter by gravity flow. The column was washed using 2xlOmls of buffer QC (1M 
sodium chloride, 50mM MOPS, 15% ethanol pH7.0). The DNA was eluted using 5m1 of 
buffer QF (1.25M sodium chloride, 50mM MOPS, 15% ethanol pH8.2). 0.7 volumes of 
isopropanol was added and the DNA pelleted by centrifugation (10000rpm, 20 minutes, 
40C). The DNA pellet was washed using 2m1 of ice-cold 70% ethanol and allowed to air 
dry for 5 minutes before being resuspended in 1 OOj.il of TE. The DNA was analysed 
using UV spectrophotometry (2.2.1.4). 
2.2.1.3 Minipreparation of plasmid DNA. 
Approximately 1 0j.tg of plasmid DNA from Escherichia coli was made using the 
WizardTM Minipreps kit commercially available from Promega. A single colony was used 
to inoculate 5m1 of LB-AMP and grown overnight at 37°C with shaking. 3m1 of the cells 
were pelleted using a microcentrifuge for 2 minutes. The cells were resuspended in 200p1 
of cell resuspension buffer (50mM Tris-HC1 pH7.5, 10mM EDTA, 1 00pgml 1 RNase 
A) and lysed by the addition of 200 jil of cell lysis buffer (0.2mM sodium hydroxide, 1% 
SDS). 200111 of neutralisation solution (1.32M potassium acetate pH4.8) were then 
added and the suspension inverted. If using an endA positive strain, 400 jfl of neutralising 
solution was added and the mixed lysate incubated at room temperature for 10 minutes. 
The cell debris was pelleted by microcentrifugation for 5 minutes and the supernatant 
added to lml of DNA purification resin (contains 7M guanidine HC1) and mixed by 
inversion. The mixture was pushed through a column, using a 2m1 syringe, and washed 
with 2m1 of wash solution (100mM sodium chloride, 10mM Tris-FIC1 pH7.5, 1mM 
EDTA, 70% ethanol). If using an endA positive strain, 2m1 of 4.2M guanidium HCII40% 
isopropanol was added to the column prior to washing. The column was dried by 
microcentrifugation at 13000rpm for 2 minutes. 50tl of TB was added to the column and 
incubated for 1 minute at room temperature. The DNA was then eluted by 
microcentrifugation for 30 seconds. 
2.2.1.4 UV spectrophotometry. 
UV spectrophotometry is used for the quantification of nucleic acids and as a check of 
their purity. Typically, a sample of nucleic acid was diluted (1:200) into 1 ml of sdH20. 
Using the protocol supplied with the Perkin-Elmer 115 machine a sample of sdH20 was 
scanned between 200 and 300nm to give a base value against which a subsequent scan of 
the diluted nucleic acid was made. The nucleic acid concentration (mg/ml) of a sample 
was calculated using the following formula: 
DNA concentration = Absorbtion at 260nm (A260) X 50 X dilution factor. 
RNA concentration = Absorbtion at 260nm (A260) X 40 X dilution factor. 
The purity of the nucleic acid sample, with respect to protein contamination, was 
estimated by the ratio A260! A280, where a value greater than 1.8 indicates that the sample 
is free from protein contamination. 
2.2.1.5 Phenol/ chloroform extraction. 
An equal volume of chloroform (containing 1/25th volume isoamyl alcohol) was then 
added to phenol buffered with Tris pH8 (NBL) before being stored in the dark at 4°C. 
An equal volume of phenol/chloroform was added to the DNA solution to be treated and 
the mixture vortexed before microcentrifugation for 1 minute. The upper aqueous phase 
was transferred to a fresh eppendorf tube and a second phenol/chloroform extraction 
made on this. The aqueous phase was collected again and the DNA ethanol precipitated. 
2;2.1.6 Ethanol precipitation. 
0.1 volumes of 3M sodium acetate (pH5 .0) and 2 volumes of ice-cold 100% ethanol were 
added to the DNA solution to be precipitated. The DNA was pelleted by 
microcentrifugation for 20 minutes. The DNA pellet was washed with 1 OOp1 of 70% ice- 
cold ethanol air dried at room temperature for 5 minutes. The pellet was resuspended in 
the required volume of TE. 
2.2.2 Endonuclease restriction. 
DNA restrictions were typically carried out for 2-3 hours at 37 °C using commercially 
available restriction endonucleases. 3-10 units of enzyme were used to restrict 1 ig of 
DNA in a 20i.iJ volume with the recommended buffer. For larger quantities of DNA the 
reaction components were scaled up appropriately. Restriction endonuclease buffers 
were supplied at lox the final concentration. The Boehringer Mannheim incubation 
buffer range (Table 2.2) was used for single enzyme restrictions. Where more than one 
restriction endonuclease was required and the buffer compositions were incompatible 
"One-Phor-All" (Pharinacia) was used (100mM Tris-acetate, 100mM magnesium 
acetate, 500mM potassium acetate pH7.5). 
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Table 2.2. Composition of Boehringer restriction endonuclease buffers. (Final 
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Exceptions to the standard conditions were that Sma I restrictions were made at 30°C 
and Kpn I restrictions were supplemented with 100j.tgml BSA. 
2.2.3 Agarose gel electrophoresis and DNA fragment isolation. 
2.2.3.1 Preparation of agarose gels. 
Multipurpose agarose was supplied by Boehringer Mannheim and low melting point 
agarose by Sigma. A 1% agarose gel was typically used for separation of DNA. If 
however separation of DNA greater than approximately 5kb was required a 0.8% gel was 
prepared or for DNA less than around 1kb a 1.2% gel was used. The appropriate amount 
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of agarose was dissolved in 1 XTBE and heated while stirring until the agarose was 
completely dissolved. For each 50m1 of agarose solution ipi of ethidium bromide 
(1 0mg/mi) was added. The molten gel was poured into the appropriate casting tray and 
allowed to set at room temperature. 
2.2.3.2 Running agarose gels. 
The cast gel was submerged in 1XTBE. Samples were mixed with a 0.1 X volume of 
loading buffer (30% glycerol, 0.25% bromophenol blue, 0.25% xylene cyanol) and the gel 
run at 15V/cm until sufficient separation of the DNA bands had occurred. 
2.2.3.3 DNA markers. 
The DNA markers commonly used were; ? restricted with HinDu! supplied by NBL, 
4X 174 restricted with HaeIII supplied by Promega and a 1 OObp marker supplied by 
Gibco-BRL. 1pg of one of the DNA markers were used on each gel. 
2.2.3.4 Imaging of the gel. 
The DNA was visualised using a short wave UV transilluminator. The image was 
recorded on either heat sensitive film or a negative was produced with FP5 film. 
2.2.3.5 DNA fragment isolation from a low melting point agarose gel. 
DNA fragments were routinely isolated from low melting point agarose gels. The 
resolving capability of this gel is lower than those made with multipurpose agarose. In 
cases where DNA fragments did not separate readily in low melting point agarose gels 
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elution from multipurpose agarose gels was used. The band of interest was cut from the 
gel using a clean scalpel and added to an equal volume of 1XTBE/ 0.2M sodium chloride 
and incubated at 65°C for 15 minutes. 0.75 volumes of phenol saturated with 1 XTBE/ 
0.2M sodium chloride was added, vortexed, and briefly microcentrifuged. The upper 
aqueous layer was transferred to a fresh eppendorf tube and the phenol extraction 
repeated. 10Oil of butanol was added the aqueous phase, vortexed, microcentrifuged for 
1 minute and the butanol layer removed. The DNA in the remaining aqueous phase was 
ethanol precipitated (2.2.1.6). 
2.2.3.6 Electroelution of isolated DNA fragment. 
Dialysis tubing was prepared by boiling in 2% sodium bicarbonate! 1mM EDTA for 10 
minutes. After washing several times in sdH20 the dialysis tubing was boiled for 10 
minutes in 1mM EDTA. The prepared dialysis tubing was stored at 4°C in 70% ethanol 
Before use the dialysis tubing was washed with sdH 20. The agarose gel fragment was 
placed into a small piece of dialysis tubing with 300pi of 1XTBE. The tubing was 
submerged in 1XTBE and a current passed through for 30 minutes, typically at 100V. 
The current was reversed for 2 minutes at the end to help remove DNA attached to the 
dialysis tubing. Elution of the DNA was checked using a short wave UV 
transilluminator. The DNA solution was transferred into a fresh eppendorf tube and 
ethanol precipitated (2.2.1.6). 
2.2.3.7 Elution of DNA using Genelute Columns. 
A Gene lute column (Sigma) was inserted into a 1 .5m1 eppendorf and prewetted by 
adding 1 00.l of TE and spinning the column in a microcentrifuge for 2 minutes. The 
column was then transferred to a fresh eppendorf and the agarose gel fragment was 
placed into the column. The DNA was eluted by microcentrifugation for 10 minutes. 
The resulting DNA was in 1 xTBE at a volume proportional to the size of the gel slice. If 
the DNA was required to be in a smaller volume or a different buffer then the DNA was 
ethanol precipitated (2.2.1.6). 
2.2.4 Southern transfer. 
2.2.4.1 "Dry" southern transfer. 
This is a quick method of capillary transfer to a nylon membrane which could be used 
when the quantity of DNA in an agarose gel is sufficiently large (>75ng per band). When 
the DNA to be transferred was greater than around 5kb then the gel was first depurinated 
in 0.2MHC1 for 10 minutes followed by several washes in dH 20. The gel was then 
submerged in denaturing solution for 10 minutes with gentle shaking followed by being 
submerged in neutralising solution for 20 minutes with shaking. Genescreen Plus 
membrane (DuPont) cut to the size of the gel was prewetted with neutralising solution 
and placed on the surface of the gel. 4 pieces of Whatman (3MM) paper, cut to size, 
were placed on top. A small stack of paper towels, a glass plate and a light weight were 
then added. The transfer of DNA took place overnight. The membrane was removed, 
washed in 2XSSC for 2 minutes and air dried. It was then ready for 
prehybridisation(2.2 .4.3). 
2.2.4.2 "Wet" southern transfer. 
A "wet" transfer was used when the DNA of interest is present in small amounts (eg. 
genomic southern analysis). The initial preparation (depurination, denaturation and 
neutralisation) of the gel is the same as that described for "dry" southern transfer. The 
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prepared gel was placed on a "wick" consisting of 2 pieces of Whatman (3MM) paper 
cut to the same width as the gel, but longer, so that the ends could be submerged in a 
reservoir of neutralising solution (2.1.6). The gel was surrounded with saran wrap to 
prevent the neutralising solution by-passing the gel into the stack of paper towels. A 
piece of Genescreen Plus membrane (DuPont), cut to the correct size, was prewetted 
completely with neutralising solution and placed on the gel ensuring that air bubbles were 
excluded. Eight pieces of Whatman (3 MM) paper were cut to the correct size. Four of 
these were prewetted in neutralising solution and placed on the filter and then the 
remaining 4 pieces were added, again eliminating air bubbles. A stack of paper towels 
approximately 10cm high were added to the blot and a glass plate placed on top. A 300-
400g weight was placed on top of the glass plate. The transfer was left overnight. The 
next day the blot was carefully taken apart, the membrane washed in 2XSSC for 2 
minutes and air dried. The membrane was ready for prehybridisation (2.2.4.3). 
2.2.4.3 Prehybridisation and hybridisation of radio-labelled probes. 
Prehybridisation and hybridisation were done using the same buffer, although the 
composition of the buffer varied depending upon the type of radio-labelled probe used-
end-labelled oligonucleotide or random labelled (2.1.7). The membrane was placed in a 
hybridising tube, with 25ml of the appropriate hybridisation solution, and incubated 




2.2.4.4 End-labelled oligonucleotide probes. 
Typically prehybridisation and hybridisation were done at 37°C for an oligonucleotide of 
18 nucleotides. 
ljiJ oligonucleotide (20ng/.tl) 
4pi 5X Forward reaction buffer (300mM Tris-HC1 pH7.8, 50mM 
magnesium chloride, 1 .65p.M ATP, 75mM 2-mercaptoethanol) 
l3pi sdH2O 
ljii ['y.32P] ATP (lOmCi/ml) 
1p.! T4 Kinase (1 OU/pi) 
The reaction was incubated at 37 °C for 1-3 hours then added to the oligonucleotide 
hybridisation buffer. 
2.2.4.5 Random-labelled probes. 
Random labelled probes were prepared using the commercially available P rime ItTMII 
Random Primer Labelling Kit from Stratagene. The protocol and materials, with the 
exception of the T7 DNA polymerase, were supplied with the kit. 
1 00-200ng DNA 
3m1 DTT (0.1M) 
lOp.! random primers (9-mers at 8ngp.l) 
sdH20 to 36p.l 
These were heated to 95-100°C for 5 minutes before being allowed to cool slowly to 
room temperature. The following were then added; 
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lOpi 5X random label (dCTP) buffer (250mM Tris-HC1 pH8.0, 
100mM magnesium chloride, 20mM 2- mercaptoethanol, 0.5mM each of dGTP, 
dTTP and dATP) 
3pJ [a.32P] dCTP (lOmCiIml) 
0.5tl 17 DNA polymerase (8.5U/pi) 
This reaction was incubated at 37 °C for 1-3 hours. 
To remove the unincorporated dNTPs NucTrapTM Probe Purification Columns from 
Stratagene were used. 70jtl of IXTES (100mM sodium chloride, 20mM Tris-HC1 pH7.5, 
10mM EDTA) was pushed through the column using a 10m1 syringe. 20p.l of 1XTES 
was added to the prepared probe and then the reaction was pushed through the column 
and collected. Finally a further 70pi of 1XTESwas added to the column, pushed through 
and collected. The eluate from the column was heated to 95-100°C for 5 minutes before 
being added to 25m1 of fresh random label prehybridising solution. Random labelled 
probes were typically used at a hybridising temperature of 65°C. 
2.2.4.6 Washing and exposing a membrane. 
End-labelled oligonucleotide probes. 
The probes were poured off and stored at -20°C either for reuse or to allow the radiolabel 
to decay before safe disposal. 25m1 washes of 6XSSC/ 0.1%SDS were added to the 
membrane at 37°C. Usually 2-3 washes of 10 minutes were used. Monitoring of the 
membrane with a n-Geiger counter was used to detect the probed areas of membrane. 
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Random-labelled probes. 
The probes were stored as described for end-labelled oligonucleotides. Before reuse these 
probes require heating to 95-100°C for 5 minutes. 
25m1 washes at 65°C for 10 minutes each were used. Initial washes were made with 
6XSSC/ 0.1%SDS increasing the stringency in steps to 0.1-0.2XSSC/ 0.1%SDS. 
Monitoring the filter with a n-geiger counter defined the background noise to signal ratio 
and indicated whether increased stringency was required. 
Washed filters were sealed in a thin plastic bag and placed in an autoradiographic cassette 
with an image intensifying screen. The position of the filter was indicated using 
Stratagene fluorescent marker strips. Exposure to preflashed film was made at -70 °C. 
Exposure was usually overnight but longer exposures for weaker signals were sometimes 
required. After exposure the film was developed using a X-OGRAPH X  (IBI Ltd.) 
automatic X-ray film processor. 
2.2.4.7 Stripping a membrane. 
The membrane to be stripped was placed in a hybridising tube, at 65°C, containing 
1 OOml of 0.4M sodium hydroxide. After 30 minutes the sodium hydroxide solution was 
replaced with lOOml of a neutralising solution (0.1XSSC, 0.1%SDS, 200mM Tris-HC1 
pH7.5). Two 15 minute incubations, at 65°C, in neutralising solution were carried out. 
The membrane was exposed overnight to ensure all signals had been stripped. 
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2.2.5 Ligations. 
2.2.5.1 Ligation reaction. 
The vector and insert DNA molecules were restricted to be compatible with one another. 
Typically 50ng of vector was ligated to insert at a range of molar ratios, typically from a 
ratio of 1:1 to 3:1 (insert: vector). Vector and insert DNA were added to 1X ligation 
buffer (10 x = 500mM Tns-HC1 pH7.5, 100mM magnesium chloride, 100mM D1'T, 
10mM ATP) with 1 U of T4 DNA ligase in a 20il reaction and incubated overnight at 
15-16°C. 
2.2.5.2 Cloning of PCR fragments. 
PCR fragments were cloned using the TATM  Cloning Kit available from Invitrogen (Mead 
et al. 1991). 1 p.1 of a freshly prepared PCR reaction was added to 2pi of TA vector 
(25ng/pi), lpJ of lOX ligation buffer (60mM Tris-HC1 pH 7.5, 60mM magnesium 
chloride, 50mM sodium chloride, lmg/m1BSA, 70mM 2-mercaptoethanol, 1mM ATP, 
20mM DTT, 10mM spermidine), 5p.l of sdH20 and 1 p.1 of T4 ligase (4U/jil) and 
incubated overnight at 15-16°C. 2j.tl of 0.5M 2-mercaptoethanol was added to an aliquot 
of the supplied competent cells (INV(x F) and gently mixed. 2111  of the ligation reaction 
was added to the cells, mixed gently, and incubated on ice for 30 minutes. The cells were 
heat shocked at 42°C for 30 seconds before replacing on ice for 2 minutes. The cells were 
added to 450p.l of room temperature SOC (2% tryptone, 0.5% yeast extract, 10mM 
sodium chloride, 2.5mM potassium chloride, 10mM magnesium chloride, 10mM 
magnesium sulphate, 20mM glucose) and incubated for 1 hour at 37°C with rotation. 
25p.l and 1 00p.l samples of the transformed cells were plated on LB plates supplemented 
with X-gal. The TA vector carries markers for both amplicillin and kanamycin resistance 
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meaning either could be used for plasmid selection. If the template DNA in the PCR 
reaction was an ampicillin resistant plasmid then LB-KAN plates were used. Plates were 
incubated overnight at 37°C. White and light blue colonies were tested for the presence of 
the required insert. 
2.2.6 Preparation of competent Escherichia coil and transformation. 
2.2.6.1 Preparation of competent Escherichia coil. 
A single colony of E.coli was picked into 5m1 of LB and incubated, while shaking, 
overnight at 37°C. imi of the overnight culture was used to inoculate 50m1 of fresh LB 
which was incubated for 2 hours at 37 °C while shaking. The cells were collected by 
centrifugation (3000rpm, 10 minutes, 4 0C). The pelleted cells were resuspended in lOml 
of ice-cold sterile 100mM calcium chloride and the spin repeated. The washed pellet was 
resuspended in 2ml of 100mM calcium chloride in 14% glycerol and incubated on ice for 
a minimum of 4 hours. 200111 aliquots of competent cells were stored for up to 6 months 
at -70°C. 
2.2.6.2 Transformation. 
1/10 of the ligation reaction was added to 200111 of competent cells, mixed gently, and 
incubated on ice for 30 minutes. The cells were heat shocked at 42°C for 45 seconds 
before replacing them on ice for 2 minutes. 800111 of LB was added before incubation for 
1 hour at 37°C with rotation. Typically, 100111 and 300111 of transformed cells were 
spread on selective media and incubated overnight at 37°C. 
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2.2.7 Colony screening. 
2.2.7.1 Colony lifts. 
This protocol was adapted from that described by Buluwela et al. (1989). Hybond-N 
(Amersham) membranes, cut to the correct size, were placed on the surface of the colony 
covered plates and marked for orientation using a needle before being carefully lifted off. 
The membranes were placed colony side up on blotting paper soaked in 2XSSC/ 5% SDS 
for 5 minutes to denature the DNA. The membranes were microwaved at full power for 
45 seconds to fix the DNA. The membranes were then ready for prehybridisation 
(2.2.4.3). 
2.2.7.2 Patching. 
Hybond-N (Amersharn) was marked with a grid and placed onto a selective media plate. 
A second plate was marked with the same grid on its base. A single colony on the surface 
of the agar was patched onto plate 1 then onto the same square of plate 2. This was 
repeated for all the colonies to be screened. Both plates were then incubated overnight at 
37°C. The membrane from plate 1 was then lifted and the DNA denatured and lysed as 
described. Once positive colonies were identified through hybridisation, using an 
oligonucleotide or random labelled probe, the colony on the corresponding square from 
plate 2 could be selected for further analysis. 
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2.2.8 Phage Library Screening. 
2.2.8.1 Preparation of Plating Cells. 
A single colony of the appropriate strain of cells (2.1.5.2) was used to inoculate 5ml of 
LB medium. The cells were grown overnight at 37°C with shaking. The following day 
2ml of the cells was added to lOOml of LB medium containing 2ml of 20% maltose. The 
cells were then incubated, with shaking, at 37 °C for 2 hours. The cells were collected by 
centrifugation at 2500rpm for 15 minutes at 4 °C and resuspended in lOmi of cold, sterile. 
10mM MgSO4. The cells were stored at 4°C for up to two weeks. 
2.2.8.2 Plating out of Library. 
A serial dilution of the library was carried out in phage buffer(2.1.7). lOp.l from each of 
the dilutions was added to lOOj.tl of plating cells and incubated at 37°C for 20 minutes. 
3m1 of molten BBL-top agar was added and then poured onto BBL plates and allowed to 
set before incubating overnight at 37 0C. The following day the phage dilution giving 
around 6000 plaques/plate was selected and another 30 plates prepared at this dilution. 
This was calculated to be the amount of total phage required to insure representation of 
the entire P.falciparum genome. 
2.2.8.3 Lifting of Plaques. 
After overnight incubation the plates were placed in the fridge to harden the agar. 3 trays 
were prepared with 1 layer of blotting paper on each. Tray 1 was soaked in denaturing 
solution and the other trays in neutralising solution(2. 1.7). Hybond-N (Amersham) 
membranes cut to the size of the plates were placed on top of the plaques and their 
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position marked using a sterile needle. After a 3-5 minutes the filter was lifted off the 
plate and placed, DNA up, onto tray 1 for 5 minutes. The filters were then moved onto 
tray 2 then tray 3, incubating for 5 minutes on each. Any agar remaining on the filters 
was washed off using 2xSSC and then the filters dried on blotting paper. The DNA was 
fixed by placing the filter, DNA down, for 3 minutes on a UV-transilluminator covered in 
saran wrap. The filters were then ready for pre-hybridisation (2.2.4.3). 
2.2.8.4 Picking Positive Plaques. 
Positive plaques were picked using a sterile straw and placed into lml of phage 
buffer(2.1.7). After 1 hour's incubation at room temperature to allow diffusion of the 
phage into the buffer, lOp! of the suspension was diluted in to 1 ml of phage buffer and 
5 p1 of this was used to reinfect the plating cells. Plating and screening was repeated until 
a "pure" clone was obtained. 
2.2.8.5 DNA Preparation from a Plaque. 
A single colony of the required plating cells was used to inoculate 5m1 of LB media (LB-
AMP if Y1090 cells used). The cells were grown overnight at 37°C with shaking. The 
following day the 5m1 of cells was added to 50m1 of LB medium containing 1 ml of 20% 
maltose. The cells were incubated for 1 hour at 37°C with shaking. Meanwhile a single 
plaque was added to 200p1 of phage buffer and allowed to stand for 1 hour at room 
temperature. lOOp1 of the phage suspension was added to 200p1 of the bacterial cells 
and 300p1 of adsorption buffer (2.1 .7).After 10 minutes incubation at 37 °C, 1 Oml of LB 
medium containing 10mM M902  and 0.1% glucose was added and incubated overnight 
with rotation at 37°C. The suspension was then centrifuged at 3000rpm for 10 minutes 
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at 4°C and then the supernatant centrifuged again at 27000rpm for 2 hours at 4°C. The 
pellet was resuspended in 200 p.1 of phage buffer and 200til of proteinaseK solution( 
1mg/mi) and incubated for 2 hours at 37°C. The suspension was phenol/ chloroform 
extracted (2.2.1.5 ) and the DNA ethanol precipitated(2.2.1.5 ). The DNA was 
resuspended in approximately 100p.l TE (2.1.7). 
2.2.9 DNA sequencing and analysis. 
2.2.9.1 Sequencing of double-stranded DNA template. 
DNA sequence determination was made using the chain termination method described by 
Sanger etal. (1977). The commercially available Sequenase®v.II kit (USB) was used. 
Sequencing primers were supplied by OSWEL DNA service (Chemistry Dept., 
University of Edinburgh). The double stranded DNA template was denatured. 10p.g of 
template was resuspended in 30111 of denaturing solution (200mM sodium hydroxide, 
2mM EDTA) and incubated for 30 minutes at 37°C. The template was ethanol 
precipitated (2.2.1.6) and resuspended in 7j11 of sdH20. The 7,.ii of template was 
quickly mixed with 2j.tl of reaction buffer (200mM Tris-HC1 pH 7.5, 100mM magnesium 
chloride, 250mM sodium chloride) and lpJ of oligonucleotide primer (20ngIp.l). The 
annealing mix was incubated at 37 °C for 15 minutes then cooled to room temperature. 
2p.l of dGTP labelling mix (1.5p.M of dGTP, dTTP and dCTP), ijil of 100mM DTT, 
0.5p.1 [cx. 35S] dATP (l0mCiml-1) and 2p.l of Sequenase® DNA polymerase (1.6 U/p.l) 
was then added to the reaction. This was incubated at room temperature for 5 minutes 
before 3.5p.l aliquots were removed and added to 2.5p.1 of each termination mix (ddG, 
ddA, ddT and ddC) which were prewarmed to 37°C. Each termination mix consisted of 
the following; 80p.M dGTP, dCTP, dATP and dTTP, 50mM sodium chloride and 8pM 
of the appropriate dideoxynucleoside (ddGTP, ddCTP, ddATP and ddTTP). The 
termination reactions were incubated at 37°C for 5 minutes and then stopped by the 
addition of ice-cold loading buffer (95% formamide, 20mM EDTA, 0.05% bromophenol 
blue, 0.05% xylene cyanol FF). The reactions were stored at -20°C until use. 
2.2.9.2 Sequencing gel electrophoresis. 
Sequencing reactions were separated on a 6% polyacrylamide gel (20:1 acrylamide 
:bisacrylamide) containing 7M urea in 1 XTBE available commercially from Scotlab. 
50m1 of polyacrylamide mix was polymerised by the addition of 300xl of 10% 
ammonium persulphate and 30.ii TEMED. The gel was cast between a pair of plates 
(380mm X 170mm) separated by spacers (0.3mm). 2.5pi of each reaction was heated for 
2 minutes at 95-100 °C before being quickly cooled on ice. The reactions were loaded 
onto a "sharks tooth" comb, in the order; ddGTP, ddATP, ddTTP and ddCTP. 
Electrophoresis was carried out at a constant 50 Watts. After the appropriate length of 
run the gel was lifted onto Whatman 3 M paper soaked in fix (10% glacial acetic acid, 
12% methanol) and dried under vacuum for 1 hour at 80°C. Gels were exposed to film 
overnight at room temperature. 
2.2.9.3 Sequence analysis. 
Storage of sequence, mapping of restriction sites and sequence comparisons were made 
using the University of Wisconsin Genetics Computer Group Sequence Analysis 
Software Package v.7 and v.8 (Devereux etal. , 1984). 
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2.2.10 Polymerase Chain Reaction (PCR). 
A typical PCR reaction (Saiki etal., 1988, Innis et al., 1990) was modified to allow for 
the extreme A-T richness of the template DNA. PCR reactions were assembled in 
500xl eppendorf tubes as described: 
lOOng template DNA 
io1±i lox PCR buffer (200mM, Tris-HC1 pH8.4, 500mM 
potassium chloride) 
1 Op1 Primer #1 (20ngIpi) 
1 Opi Primer #2 (20ng4tl) 
3j.tl 50mM magnesium chloride 
2.5pJ 40mM dNTP (10mM each of dATP, dTTP, dCTP and 
dGTP) 
0.5jil Taq DNA Polymerase (5U/pi) 
sdH20 to a total of lOOpi 
The Taq DNA polymerase and buffer were supplied by Gibco-BRL. The reaction was 
overlaid with 50.tl of mineral oil. A typical programme for the thermocycler for a pair of 
1 8-mer oligonucleotide primers to a genomic DNA template to amplify a 1kb product is 
described below. Modifications were made to this basic programme to allow for the 
optimisation of each reaction. 
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95°C for  minutes 
40°C for 1 minute 	 1 cycle 
72°C for 2 minutes 
93°C for 3 minutes 
40°C for 1 minute 	 1 cycle 
72°C for 2 minutes 
93°C for 1 minute 
40°C for 1 minute 	 28 cycles 
72°C for 2 minutes 
72°C for 5 minutes 	 1 cycle 
The maximum ramp rate (1 °C/mm) between each step was used in all PCR reactions. 
1 Ojil of each reaction were analysed by agarose gel electrophoresis. 
2.2.11 Pulsed Field Gel Electrophoresis. 
Approximately 1 x 10 9 parasites were harvested and washed as described (2.3. 1) and the 
parasites were resuspended to a density of 1010  parasites per ml. An equal volume of 2% 
low melting point agarose in 0.5 x TBE (2.1.6) at 45°C was added and blocks formed in a 
perspex mould. The block was treated with Proteinase K at 250tg/ml for 48 hours at 
37°C in 10mM Tris-HC1, pH7.6, 0.5M EDTA, 1% SDS. The block was then loaded 
onto a 1% agarose gel in 0.5 x TBE and subject to pulsed field gel electrophoresis in a 
CHEF II apparatus (Biorad) at 80 V, 14°C, with pulse times ramped from 3-15 minutes 
over 7 days. The gel was then depurinated and wet Southern blotted (2.2.4.2). 
2.3 RNA METHODS 
2.3.1 Total RNA isolation. 
This protocol was based on the acidic guanidinium- phenol- chloroform protocol 
described by Chomczynski and Sacchi (1987). P.falc4arum culture was grown until 
approximately 10 9 parasites were available. The culture was harvested by centrifugation 
(3000rpm, 10 minutes, 4 0C). The erythrocyte pellet was resuspended in 5 volumes of 
incomplete medium and the spin repeated. The washed pellet was then resuspended in 5 
volumes of 1XSSC, 0.1% saponin, mixed by inversion and incubated on ice for 5 
minutes. The released parasites were collected by centrifugation (3200rpm, 10 minutes, 
40C). The parasite pellet was resuspended in 7m1 of solution D (4M guanidinium 
isothiocyanate, 0.5% sodium lauryl sarcosine,25mM sodium citrate and 100mM 2-
mercaptoethano 1-added just before use) and repeatedly passed through an 18 gauge 
needle to completely disrupt the parasite pellet. 0.7ml of 2M sodium acetate (pH4.0), 
7m1 of water equilibrated phenol (pH5.0) and 1.4ml of chloroform/ isoamyl alcohol (49:1 
v:v) were sequentially added and mixed by inversion. The suspension was incubated on 
ice for 15 minutes before centrifugation (10000rpm, 10 minutes, 4°C) to separate the 
phases. The upper aqueous phase was collected making sure not to remove material from 
the DNA interphase. An equal volume of ice cold isopropanol was added before 
incubation at -20°C for 2 hours. The RNA was pelleted by centrifugation (10000rpm, 20 
minutes, 4°C) then resuspended in 500 j.tl of TE, 0.1%SDS.The RNA was ethanol 
precipitated (2.2.1.6) and the pellet resuspended in 1 00-200.tl of TE, 0.1 %SDS and 
stored at -70oC. The RNA was analysed using UV spectrophotometry (2.2.1.4). 
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2.3.2 Northern analysis. 
Total RNA was fractionated on a 1% agarose/ 1.85% formaldehyde gel prepared and run 
in 1XMOPS (3-[N-Morpholino]propane suiphonic acid) buffer (10 X = 200mM 
MOPS, 5mM sodium acetate, 1mM EDTA, pH7.0). Typically lO.tg of total RNA and 
RNA markers (Gibco-BRL) were added to 15j.tl of formaldehyde sample buffer 
(2XMOPS, 50% formamide, 25% formaldehyde, 0.25% bromophenol blue, 0.25% 
xylene cyanol,) and incubated at 65°C for 5 minutes. The sample was cooled quickly on 
ice and ipi  of 2mg/mi ethidium bromide added before loading on the gel. The gel was run 
at 1 OOV for 4 hours using a pump to circulate the 1 XMOPS buffer. When the run was 
complete the gel was washed for 10 minutes in 1XSSC to remove the formaldehyde and 
soaked in 50mM sodium hydroxide/1xSSC for 10 minutes. A blot was assembled 
essentially as described for a wet southern blot (2.2.4.2) except that the transfer was 
made with 1 OXSSC. The following day the Genescreen Plus membrane was washed 
with 1 OXSSC before prehybridisation. The hybridisation was made using the conditions 
for a random labelled probe (2.2.4.3). 
2.3. Nuclear Run On Analysis. 
All steps were carried out on ice. 5 x 109 parasites from rings and a mixture of 
trophozoites and schizonts were harvested and washed in 5 volumes of PBS buffer 
(137mM sodium chloride, 2.7mM potassium chloride, 4.3mM disodium hydrogen 
orthophosphate, 1.4mM potassium dihydrogen orthophosphate). The erythrocytes 
were lysed by adding 5 volumes of ice cold 1xSSC/0.1% saponin. The released parasites 
were washed once in 5 volumes of buffer A (20mM PIPES pH 7.5, 15mM sodium 
chloride, 60mM potassium chloride, 14mM 2-mercaptoethanol, 0.5mM EGTA, 4mM 
EDTA, 0.15mM spermine, 0.5mM spermidine, 0.125mM phenylmethylsuiphonyl 
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fluoride). The parasites were pelleted by centrifugation ( 4000rpm, 10 minutes, 4°C) and 
resuspended in 3mls of buffer A. 200m1 of 10% NP-40 solution was added then the 
mixture was treated to 20 strokes of a B pestle in a dounce homogeniser. The nuclei 
were collected by centrifugation (10000rpm, 10 minutes, 4 °C)and washed once in 3mls 
of buffer A. The spin was repeated and the nuclei containing pellet was resuspended in 
600ml of buffer B (50mM HEPES pH7.9, 50mM sodium chloride, 10mM magnesium 
chloride, 1.2mM dithiothreitol, 10mM creatinine phosphate, 1mM GTP, 1mM CTP, 
4mM ATP, 25% glycerol, 25U/ml RNasin (Promega), 0.2mglml creatinine kinase, 
0.5mM((x-32P)UTP 3000 Cilmmol). and then the nuclei were allowed to transcribe for 20 
minutes at 37°C. Radio-labelled RNA was collected as described (2.3. 1) and hybridised 
to a membrane on which 1 j.tg of denatured DNA from each of the genes of interest had 
previously been fixed. The filter was hybridised for 24 hours at 60 °C in 0.25M NaP, 
pH7.2, 7% SDS, then washed and exposed to film. 
2.4 PROTEIN METHODS. 
2.4.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
2.4.1.1 Preparation and running SDS-PAGE. 
Protein extracts were fractionated by SDS-PAGE with a discontinuous buffer system. 
Atto gel rigs (GRI Instruments) 150mm x 150mm x 1mm and Mighty Small II rigs 
(Hoefer) 80mm x 70mm x 0.75mm were used. The gel mixes were prepared as shown in 
table 2.3. The solutions were degassed for 10 minutes prior to the addition of the APS 
and TEMED. Large gels were cast with a 130mm resolving gel and a 20mm stacking gel 
while small gels were cast with a 50mm resolving gel and a 10mm stacking gel. The 
resolving gel was poured and overlaid with a small volume of water-saturated butanol. 
The resolving gel was allowed to set for an hour before pouring off the butanol and 
washing the top with sdH 20. The stacking gel was then added and the comb added 
before leaving the stacking gel to set. The comb was removed and the wells rinsed with 
sdH20 before use. 
Table 2.3. SDS-PAGE resolving and stacking gel mixes (Volumes sufficient for 3 
large gels or 10 small gels, in ml). 
Component Resolving gel Stacking gel 
7.5% 10% 
Acrylamide/ bis acrylamide 15 20 2.6 
(30:2.67) 
sdH20 29.4 24.3 12.3 
1.5M Tris-HC1 pH8.8 15 15 - 
0.5M Tris-HCI pH6.8 - - 5 
20% SDS 0.6 0.6 - 
10% Ammonium persuiphate 0.3 0.3 0.09 
TEMED 0.03 0.03 0.018 
Protein samples were added to an equal volume of 2x sample buffer (125mM Tris-HC1 
pH6.8, 4%SDS, 20% glycerol and 10% b-mercaptoethanol, 0.25% bromophenol blue) 
and heated to 95-100°C for 2 minutes. Gels were run in running buffer (25mM Tris, 
192mM glycine, 1% SDS) at 20mA per gel and approximately bOy. Gels were usually 
run until the blue dye reached the bottom of the gel. 
67 
2.4.1.2 Protein molecular weight markers. 
Two types of protein markers were used; SDS-6H markers (Sigma) for gels which were 
stained with coomassie brilliant blue or, if the gels were to be western blotted, prestained 
broad range markers (New England Biolabs). 1 Op.l of SDS-6H markers in a sample buffer 
(0.0625M Tris-HC1 pH6.75, 2% SDS, 5% f3-mercaptoethanol, 10% glycerol, 0.001% 
bromophenol blue) were loaded on a minigel rig, 20tl were used for the larger Attorigs. 
The range of markers were; 205, 116, 97.4, 66, 45 and 29kDa. 5tl of the prestained 
markers were added to 10xl of sample buffer (187.5mM Tris-HC1 pH6.8, 50mM sodium 
chloride, 1mM EDTA, 1mM sodium azide, 125mM dithiothreitol) and heated at 95-
100°C for 2 minutes before loading on a minigel. For larger gels the volumes were 
doubled. The range of markers included were; 175, 85, 62, 47.5, 32.5, 25, 16.5 and 
6. 5kDa. 
2.4.1.3 Coomassie brilliant blue staining (fixing). 
In order to visualise proteins a gel was submerged in coomassie fixing stain (0.25% 
coomassie brilliant blue R-250 in 10% methanol/ 10% acetic acid) for 30 minutes at 37 °C. 
The coomassie fixing stain was poured off and replaced with destain (10% 
methanol/i 0%acetic acid). The destain was replaced every 30 minutes until the 
background was clear. The gels were dried, under a vacuum, against Whatman 3MM 
blotting paper at 80°C. 
2.4.2 Western blot analysis. 
Western blots were done using the method of Towbin et al. (1979) using a Hybond-C 
membrane (Amersham). The SDS-PAGE gel was run and then assembled in a blotting 
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cassette submerged in transfer buffer(25mM Tris, 150mM glycine, 20% methanol, 0.1% 
SDS); Scotchbrite pad, 3 sheets of blotting paper (cut to the size of the gel), the gel, 
Hybond-C membrane (cut to the size of the filter and carefully placed on the gel), 3 
sheets of blotting paper and a second Scotchbrite pad. The blotting cassette was 
submerged in a transfer chamber (Biorad) containing transfer buffer and blotted at 40inA 
for 4-15 hours. The filter was carefully removed from the cassette and submerged in 
blocking solution ( 1xTS [150mM sodium chloride, 10mM Tris-HC1 pH7.4] and 5% fat-
free milk powder) for 1 hour. The filter was allowed to dry completely and stored at 4°C 
until use. If the filter was to be used immediately then the blocking solution was removed 
and replaced with blocking solution containing the appropriate dilution of the first 
antibody. After incubation, while being gently shaken, at room temperature for 2 hours, 
the filter was washed once with 1xTS, twice with 1xTS/ 0.05% NP-40 and once with 
1xTS for 5 minutes each while gently shaking. The filter was then submerged in blocking 
solution containing a 1:7500 dilution of alkaline phosphatase conjugated to 
immunoadsorbant-purified anti immunoglobin specific to the first antibody used (AP-
anti IgG, Promega). This was incubated and washed as described for the first antibody. 
5m1 of alkaline phosphatase buffer (100mM Tris-HC1 pH9.5, 100mM sodium chloride, 
5mM magnesium chloride) containing 33.tl of NBT (nitro-blue tetrazolium) and 16.5pl 
BCIP (5-brom-4-chloro-3-indolyl phosphate) was added to the filter. The filter was 
shaken gently at room temperature until the signal developed, for a maximum of 10 
minutes. The reaction was stopped by adding an excess of sdH 20. The filters were then 
left to dry on blotting paper. 
2.4.3 Indirect immunofluorescence assay (IFA). 
Thin blood smears were prepared from culture with a parasitaemia of between 8-12%, 
dried overnight at room temperature and stored at -20 °C in a bag with silica gel until 
required. Slides were defrosted before use, fixed in acetone for 5 minutes and allowed to 
dry at room temperature. 40pJ  of the appropriate first antibodies diluted in PBS was 
added to the slide and incubated, in a moist chamber, for 1 hour. The antibodies were 
aspirated off and the slide washed for 5 minutes, twice with PBS and once with sdH 20. 
The slide was then left to air dry before 40iil of a 1:80 dilution in PBS of rhodamine 
isothiocyanate conjugate of immunoadsorbant-purified anti-rabbit immunoglobin (RITC-
anti IgG, Sigma) containing 5j.tg/ml DAPI was added to the area of slide where the first 
antibody was positioned. The slides were incubated, washed and dried as previously 
described. The slide was mounted in Citifluor (City University, London) and examined 
by fluorescence microscopy using a RITC filter set (Leitz). 
2.4.4 Recombinant protein Expression 
2.4.4.1 Glutathione-S-Transferase (GST) expression and harvesting. 
pGEX 1, containing the Schistosomajaponicum glutathione-S-transferase open reading 
frame, was transformed (2.2.6.3) into the E.coli strain BL21 (DE3) and grown overnight 
at 37°C while shaking in 50m1 of LB supplemented with lOOj.tgml-1 ampicillin. 50m1 of 
pGEX1 culture was added to 500m1 of LB supplemented with lOOj.tgml-1 ampicillin and 
grown at 37°C while shaking for 1 hour. A imi sample was removed before induction 
with 0.5 ml of 100mM IPTG (final of 0.1mM). The culture was shaken for a further 1-3 
hours, at 37°C, before pelleting the culture by centrifugation (3000rpm, 10 minutes, 
40C). The bacterial pellet was resuspended in 5m1 of ice-cold PBS. The resuspended 
culture was lysed and the proteins solubilised by sonication for 20 seconds on ice 
ensuring that the sample did not froth. 0.5m1 of 10% triton X-100 was added to the 
lysed culture and gently mixed by inversion. The culture was centrifuged (9500rpm,5 
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minutes,4°C) to pellet the cell debris and insoluble proteins. The supernatant contains 
the soluble proteins. 
2.4.4.2 Purification of GST Fusion proteins. 
The protein purifications were all carried out at 4°C. The supernatant from the above 
was added to a Glutathione Sepharose-413 column (Sigma) which had been equilibrated 
with PBS/0.1% triton X-100. The material was passed through the column 2-3 times and 
then washed using 10 bed volumes of PBS. The bound protein was eluted using lOml of 
10mM reduced glutathione in 50mM Tris-HC1, pH7.2 and 1 ml fractions were collected. 
If the protein of interest was required at a high concentration or is required to be in a 
small volume the reduced glutathione was incubated in the column for approximately 30 
minutes. Most of the protein bound to the column was eluted in the first 1 ml fraction. 
All protein fractions were stored in 20% glycerol, 1mM DTT, 0.1mM EDTA and 
0.5mM PMSF except for the fractions to be put through the desalting and buffer 
exchange column. 
2.4.4.3 Desalting and buffer exchange column. 
PD- 10 columns (Pharmacia Biotech) containing Sephadex G-25 M were equilibrated with 
25mls of buffer (10mM Tris.Cl, pH 7. 1, 0.1mM EDTA, 1mM DTT). 2.5mls of protein 
fraction from the Glutathione column was added to the column and the flow through 
eluates were collected. 3.5mls of buffer (as above) was added and the protein containing 
eluates were collected in approximately Imi fractions. The fractions were stored in 20% 
glycerol and 0.5mM PMSF. 
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2.4.4.4 pRSET Expression System. 
A single colony was grown overnight at 37 0C in 5m1 of minimal media containing 
ampicillin and chloramphenicol (2.1.6). The cells were then pelleted by 
microcentrifugation and washed in Imi of LB-AMP media. The cells were then added to 
50m1 of minimal-AMP.CMP media and grown at with shaking at 370C until the OD at 
600nm was between 0.7 and 0.8. Samples were induced by the addition of 100mM IPTG 
to a final concentration of 0.5mM. The cells were allowed to continue to grow for 1-3 
hours at 370C. 0.5m1 aliquots were taken and the cells pelleted by microcentrifugation. 
The cells were then resuspended in 50.tl of 2x SDS loading buffer plus 50pJ of distilled 
water and analysed by SDS-PAGE electrophoresis (2.4.1). 
2.4.5 Preparation of Total Protein from P.falciparum. 
2.4.5.1 For Western Blotting. 
Approximately 109 parasites were cultured and released from erythrocytes by saponin 
lysis (2.2.1.1). The parasites were collected by centrifugation (3200rpm, 10 minutes, 
4°C) and the pellet washed in 5 volumes of ice cold PBS to remove erythrocyte debris. 
The washed parasites were collected by centrifugation as before. The parasite pellet was 
lysed by the addition of an equal volume of sdH 20 and an equal volume of 2 x loading 
buffer (2.4.1.1). The lysed parasites were passed through a 25 gauge needle to break up 
chromosomal DNA and stored until use at -70 °C. The parasite preparation was heated at 
95-100°C for 3 to 5 minutes and approximately lx 108  parasites were loaded onto a 
polyacrylamide gel. 
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2.4.5.2 For Topoisomerase I Assays. 
Parasites were collected as before (2.2.2.1) and washed in 5 volumes of ice cold PBS 
buffer. The parasites were pelleted by centrifugation (3200rpm,10minutes, 4°C) and the 
pellet stored at -20°C until required. The pellet was defrosted on in ice and resuspended 
in an equal volume of lx topoisomerase I assay buffer (2.4.7.1). The parasite debris was 
pelleted by microcentrifugation at high speed for 5 minutes and the supernatant was used 
for topoisomerase assays (2.4.7). 
2.4.6 Preparation of Nuclear Protein from P.falciparum. 
Parasites were collected as before (2.2.2.1). The parasite pellet was lysed in lml of lysis 
buffer (10mM HEPES (pH7.9), 10mM potassium chloride, 0.1mM EDTA, 0.1mM 
EGTA, 1mM DTT, 0.65% NP-40) containing protease inhibitors (2.1.6). The material 
was then passed through a pre-chilled Dounce Homogeniser 20 times. The material was 
then layered over 3ml of lysis buffer containing 0.35g sucrose (0.34M) and centrifuged 
(10,000rpm, 2 minutes, 4°C with no brake on). The supernatant, containing the 
cytoplasmic fraction, was removed. The pellet, containing the nuclei, was washed in lml 
of lysis buffer and centrifuged as before. The proteins were extracted from the nuclei by 
resuspending them in 200pl of extraction buffer (20mM HEPES (pH7.9), 0.4M sodium 
chloride, 1mM EDTA, 1mM EGTA, 1mM DTT) containing protease inhibitors (2.1.6). 
The material was gently agitated on ice for 15 minutes followed by centrifugation 
(10000rpm, 2 minutes, 4 0C). The supernatant contains the nuclear proteins and was 
stored in aliquots at -70°C. 
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2.4.7 Topoisonierase Assays. 
2.4.7.1 Topoisomerase I Relaxation Assays. 
Topoisomerase I activity was assayed by measuring the relaxation of supercoiled 
pBR322 plasmid DNA. The standard reaction mixture contains 500ng of DNA, which 
consists of mainly the supercoiled form, lx topoisomerase I assay buffer (1, 2 or 3) with 
various amounts of protein in a total volume of 20p1. protein. 
Buffer 1 (1 X=500mM Tris-HC1 (pH7.5), 1mM EDTA, 5mM DTT, 500mM KC1, 
100mM MgC12, 300 jtg/ml BSA) 
Buffer 2 (10 X=500mM Tris-HC1 (pH7.5), 1mM EDTA, 5mM DTT, 500mM KC1, 
300ig/m1 BSA) 
Buffer 3 (10 X100mM Tris-HC1 (pH 7.9), 10mM EDTA, 1.5M sodium chloride, 
10mg/mi BSA, 1mM spermidine, 50% glycerol) 
After incubation at 37°C for 30 minutes, the reaction was stopped by the addition of 2.tl 
of 10% SDS, ld of 0.5M EDTA and ipi of 10mg/mi Proteinase K. The reaction was 
then incubated for 30 minutes at 50°C followed by the addition of 3j.xl of assay stop 
solution (5% sarcosyl, 0.0025% bromophenol blue, 25% glycerol). The samples were ran 
on a 1% agarose gel in lx TBE at 100 volts for 3 hours. The gel was then stained with 
ethidium bromide (1ig/m1) and photographed under UV transillumination. 
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2.4.7.2 Inhibition of Topoisomerase I Relaxation Assay. 
Camptothecin was examined for its ability to inhibit the relaxation properties of 
topoisomerase I. Camptothecin (Sigma) was prepared in DMSO at 100mM 
concentration and stored at -20°C for 2-3 weeks. The drug was diluted to the appropriate 
concentration in distilled water before use. The final concentration of camptothecin 
ranged from 1-500j.tM with the concentration of DMSO constant at 0.5%. The drug was 
added to the otherwise standard relaxation reactions (2.4.6.1) prior to the addition of the 
protein. The reaction conditions were carried out as with the relaxation reactions. 
2.4.6.3. Topoisomerase II Decatenation Assays. 
Topoisomerase II activity was assayed by measuring the protein's ability to decatenate 
kinetoplast DNA (Topogen). The standard reaction mixture contains 300ng of DNA, 
lx topisomerase II assay buffer (50mM Tris-HC1(pH 8), 120mM potassium chloride, 
10mM magnesium chloride, 0.5mM ATP, 0.5mM DTT, 30Lg/m1 BSA) and various 
amounts of protein in a total reaction volume of 20tl. The reaction was treated as with 
the topoisomerase I relaxation assays. The samples were run on a 1% agarose gel with lx 
TBE and ethidium bromide for 1 hour at 100 volts. The DNA was then photographed 
under UV transillumination. 
2.4.7.4 Topoisomerase I Cleavage Assays. 
The protocol for Topoisomerase I cleavage assays was adapted from Austin et al. 1992. 
End-labelled pBR322 was prepared by digesting the DNA with EcoRI. The 5'-ends were 
radio-labelled with {y-32P)ATP using polynucleotide kinase and phosphate exchange 
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buffer (2.2.4.4). The labelled DNA was digested with Hindlil and the 4333bp 
EcoRI/HindIII was separated from the 3 1 b fragment using the SpinBind® PCR 
Purification System (FMC Bioproducts, Denmark). The larger fragment of labelled DNA 
was then used in the cleavage reaction. The standard reaction consisted of 40ng of DNA, 
lx topol assay buffer 3, 5% DMSO, camptothecin at the required concentration and 
various amounts of protein. The reaction was incubated at 37 °C for 30 minutes and then 
treated with SDS, Proteinase K and EDTA as described previously (2.4.6.1). After 
incubation for 30 minutes at 50°C the DNA was ethanol precipitated (2.2.1.7) and 
resuspended in 2.tl loading dye (2.2.3.2), Sjil of distilled water and 1.5pi of 100% 
formaldehyde. The samples were heated to 100°C for 2 minutes before loading onto a 1% 
agarose gel in 1 xTBE. Approximately 40ng of ?JIindIII markers were end-labelled 
(2.2.4.4) and loaded onto the gel. After running the gel for 2-3hours at 100 volts, a dry 
southern blot (2.2.4.1) was setup without denaturing or neutralising the gel. The gel was 
then sealed in a bag and exposed to film. 
2.5.1 Parasite culture. 
2.5.1.1 Parasite Source. 
The K  isolate of Plasmodiumfalciparum (Thiathong and Beale, 198 1) was used during 
the course of this work. Stocks were either from samples stored at -70 °C at ICMB or 
from the WHO Registry of Standard Strains of Malaria Parasites held at the Centre for 
Parasite Biology, University of Edinburgh. 
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2.5.1.2 Human Erythrocytes and Serum. 
The erythrocytes and serum used in this work was obtained from the Edinburgh and 
Southeast Scotland Blood Transfusion Service. Fresh whole blood, group 0 Rh +ve and 
pooled serum was used in parasite culture. Whole blood was washed in 4 volumes of 
incomplete RPMI 1640 medium (Gibco-BRL) and centrifuged (3000rpm at 4°C for 10 
minutes). The "buffy coat" of white blood cells was removed after each wash step. The 
erythrocyte pellet was resuspended in complete medium (RPMI 1640 supplemented 
with 10% human serum, 50j.tglml gentamycin sulphate, 50j.tg/ml hypoxanthine, filtered 
through a 0.22 j.tm membrane) to give a 66% haematocrit. The washed blood was stored 
at 4°C for up to 2weeks. 
Human serum packs were pooled, usually 6 to 10 packs, and centrifuged (3000rpm, 10 
minutes, 4°C) to pellet any blood cells. The serum was removed and incubated at 56°C 
for 1 hour. 50m1 aliquots were stored at -20°C for up to 6 months. 
2.5.1.3 P.falciparum Asexual Stage Culture. 
This protocol was originally described by Trager and Jensen (1976) and Zolg et al. 
(1982) described a range of conditions which improve parasite yields. Cultures were 
maintained in 50m1 of complete medium at a 3-5% haematocrit. The average percentage 
parasitaemia, as determined using methanol fixed thin blood smears stained with 10% 
giemsa, was usually kept at 1-2%. Cultures were maintained at 37°C and gassed with 
3%02, 2%CO 2 and 95% N2 . When large numbers of parasites was required the average 
percentage parasitaemia would be allowed to increase up to 10%. To maintain a healthy 
culture the numbers of flasks were increased rather than allow the haematocrit to increase 
while maintaining a small number of flasks. 
77 
2.5.1.3 Synchronisation of Asexual Cultures. 
Sorbitol treatment of asexual stages of the parasite to obtain a synchronous culture of 
ring forms was made using a protocol adapted from that described by Lambros and 
Vandenberg (1979). A culture with an average percentage parasitaemia of 5% containing 
predominantly ring forms was used as the starting material. The culture was centrifuged 
(3000rpm, 10 minutes, 4°C) and the erythrocyte pellet resuspended in 5 volumes of 
sterile 5% sorbitol. The culture was incubated at room temperature for 5 minutes and the 
culture collected by centrifugation (3000rpm, 10 minutes, 4 0C). The erythrocyte pellet 
was washed in 5 volumes of complete medium, collected by centrifugation (3000rpm, 10 
minutes, 4°C) and resuspended in complete medium at a 5% haematocrit. The culture 
was gassed then incubated at 37T. The culture was examined after 48 hours, and if 
necessary the protocol repeated to ensure tight synchrony. 
Percoll gradients is also a method whereby distinct parasite stages can be separated. The 
gradient is prepared by the addition of 1 5ml 90% percoll, 1 2ml of 80%, 8m1 of 70% and 
finally 8ml of 60% percoll to a 50ml falcon tube. The percoll solutions are prepared by 
diluting a 90% percoll stock solution in PBS/6% sorbitol. Approximately 5mls of 
parasite infected blood was collected at 3200rpm at 4°C for Sminutes, washed in 5 
volumes of PBS and the blood collected again by centrifugation. The Sml of blood was 
mixed with 5m1 of PBS/6% sorbitol and added to the percoll gradient. The gradient was 
centrifuged for 30 minutes at 400rpm at 20 0C. The schizonts layer on top of the 60% 
percoll layer. The rings are found on top of the 90% layer and the trophozoites are 
located as a broader band in the middle of the gradient. The parasite layer of interest was 
collected by centrifugation, washed in PBS and centrifuged again. The parasites could 




Chapter 3. The cloning and characterisation of the Topoisomerase I gene from 
Plasmodiumfalciparum. 
A deeper understanding of the parasite's molecular biology may help in the design of 
antimalarial drugs. In order to evaluate PfTopol as a potential drug target, the gene must 
first be isolated and its primary structure elucidated. Topol may also be involved in 
DNA replication this work therefore complements the other work being carried out in 
the laboratory where the DNA replication of the parasite is being studied. The genes 
cloned so far encode DNA polymerase a and 8, PCNA and Topoll (White et al. 1993., 
Ridley at al. 1991., Kilbey et al. 1993., Cheesmanet al. 1994). 
In this chapter the methods used to isolate the PfTopol gene will be described together 
with the work carried out to characterise the gene and to examine its relationship with 
other type I eukaryotic topoisomerases. Analysis of this gene could identify unique 
amino acid sequences which may ultimately provide useful information for drug design. 
3.1 Cloning of the Gene Encoding Topoisomerase I from Plasmodiumfalciparum. 
Two strategies were employed in the isolation of the PfTopol gene from existing DNA 
libraries. The first was to design oligonucleotides based on conserved regions in the 
Topol genes from other species and to use these in PCR with a cDNA library as a 
template. This method was used successfully to isolate the gene encoding Topol from 
Drosophila melanogaster (Hsieh et al. 1992). The second method was to screen a 
genomic library with a random-labelled fragment of the Saccharamyces cerevisiae Topol 
gene (Thrash et al. 1985). This method of heterologous probing was chosen as this was 
the method used to isolate the Topol gene from Schizsaccharomyces pombe (Uemura et 
al. 1987). 
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3.1.1 PCR from a eDNA library 
A comparison of the topoisomerase I amino acid sequences from man, Drosophila 
melanogaster, Saccharomyces cerevisiae and Schizsaccharomycespombe was made. A 





h 	GLTAKVFRTYNAS ITLQQQLKELTAPDENI PAKILSYNRANRAVAILCNHQ 
Dm GLTAKVFRTYNASKTLQSQLDLLTDPSATVPEKLLAYNRANRAVAILCNHQ 
Sc GLTKVFRTYNASKTMQDQLDLIPNKGSvAE .KILKYNAANRTVAILCNHQ 
Sp GLTAKVFRTYNASYTMAEELKKMpKNLTLAD . KILFYNRANRAVAILCNHQ 
G9025 	 G9024 
Figure 3.1. Amino acid sequences in a region of extensive homology of eukaryotic 
topoisomerase I genes. Pile up of human (h), D. melanogaster (Dm), S. cereivisiae (Sc) 
and S.pombe (Sp). Conserved amino acids are in bold. The arrows indicate the direction 
and amino acid sequence used in the design of oligonucleotides G9025 and G9024. The 
region corresponds to amino acids 588 to 638 of the human Topol sequence. 
Oligonucleotides were designed to the conserved sequences AKVFRTYN and ILCNHQ. 
The AT bias and the preferred codon usage of P.falciparum was considered (Hyde et al. 
1989) and the oligonucleotide primers were designed with the following nucleotide 
composition: 
G9025 5 '-GCWAAAGTWTTYAGAACWTAYAAYGC 
G9024 5' -YTGRTGRTTRCANAADAT 
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Both primers were used in PCR. The template was a cDNA library prepared and kindly 
supplied by Alister Craig, Oxford, in the vector pJFE14. Various conditions were used in 
the PCR such as a range of annealing temperatures, oligonucleotide concentration, 
concentration of template and magnesium ions, however no product was obtained in any 
of the reactions. In order to remove one of the primer ambiguities, a third primer was 
designed with complete identity to the vector sequence adjacent to the multiple cloning 
site and has the following nucleotide composition: 
JRSP 5' -GTAGGTATGGAAGATCCCT 
The oligonucleotides, G9025 and JRSP were used in PCR with the cDNA library as a 
template. The conditions for PCR were as described (2.2.10). A product of 900 
nucleotides was obtained which when Southern blotted (2.2.4), probed positive with the 
primer G9024. This oligonucleotide served as an internal control for the possibility of 
false priming by the oligonucleotides resulting in a non specific product. From the other 
Topol sequences, the product appears to be approximately 240bp larger than expected. 
The PCR product was cloned using the Invitrogen TA cloning kit (2.2.5.2) and 
sequenced. 
3.1.2 Genomic library screening with a heterologous probe. 
The second method employed to isolate the PfTopol gene, was heterologous probing. A 
fragment of the S.cerevisiae Topol gene was used successfully to clone the S.pombe 
homologue (Uemura et al. 1987) and the same technique was employed in an attempt to 
isolate PfTopol. A random-labelled (2.2.4.5) probe was prepared from a 1.4kb EcoRV 
fragment of the Topol gene of S. cerevisjae (Thrash et al. 1985) kindly supplied by Rolf 
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Sternglanz. This was used to screen a HinDlII/EcoRI genomic library of P.falciparum 
(2.1.5.3) as described (2.2.8). The probe detected bacteriophage containing a 5kb 
fragment. The fragment was excised with EcoRI and HinD!!! and ligated into pUC 19 
(Yanisch-Perron et al. 1985) restricted with the same enzymes, to give the construct 
pUC 1 9.PfTopol. 
3.1.3 Is the cDNA Clone Present Within the Genomic Clone? 
pUC 1 9.PfTopol was restricted with HinDu! and EcoRI, to release the 5kb insert, and 
Southern blotted. The blot was probed with the PCR product cloned previously (3. 1), 
(data not shown). The 5kb genomic clone probed positive indicating that the region 
cloned by PCR was also present in the genomic clone. This was subsequently confirmed 
when both the genomic and cDNA clones were sequenced. 
3.2 Sequence Analysis of the Pffopol Gene. 
The 900bp cDNA clone was sequenced using G9025, G9024 and JRSP. The genomic 
sequence was initially obtained using G9024 and G9025. A series of synthetic primers 
(figure 3.2) was then designed from the data obtained to extend the sequence which was 
determined in both DNA strands (2.2.9). The genomic clone was found to contain the 
entire open reading frame of PfTopol and also it contained the region isolated by PCR. 
The sequence revealed on open reading frame of 2520 nucleotides which predicts a 
protein of 839aa (figure 3.3) and a molecular mass of 116kDa. The open reading frame is 
approximately 70% AT rich which is consistent with other P.falciparum genes (Goman 
et al. 1982). The first ATG of the open reading frame was designated as the putative 
translational start. It is preceded by two in frame stop sites, set in a region which is 96% 
AT rich and characteristic of non coding DNA of P.falciparum (Goman et al. 1982). 
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Figure 3.2 Representation of the PfTopol gene. 
The location of synthetic oligonucleotide primers designed towards the sense DNA 
strand in the 5' to 3' direction ( 	')and the antisense strand, also in the 5' to 3' 
direction are indicated ( 	). Key restriction enzyme recognition sites are also 
represented. The figure is drawn to scale where 10mm represents 20 nucleotides. 
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Figure 3.3 The complete nucleotide sequence of PfTopol (EMBL accession 
number X83758). 
The translated amino acid sequence is shown below the nucleotide sequence. Nucleotide 








M Q S M E I N D N N S I K N E S T S D D D I L I N K I 27 
aaacaaaacttgggtaataataaatcatgtaattctagatcttccaaaaaggaatctataaaaaagcaaaagagcaattct 162 
K Q N L G N N K S C N S R S S K K E S I K K Q K S N S 54 
gaac ttggtataaaaaagaacacaagaaatcattaggtataaaaaaagaggaagaaaaaaacaaataagcaaga 243 
E L G I K K N T K K S L G I K K E E E K K K Q I S K R 81 
324 
K S N E L K E K N N L K E G K K K Y V E K K S R T V K 108 
gatgaaaccaagttaacgaatgttataaaaaaagaaactcaaataatgacc taaaaaattac ttaaaaaatcagaa 405 
D E T K L T N V I K K E T Q N N K K P K K L L K K S E 135 
gaaaattttgaaccaataaatagaeggtgggaaaaaatagatgatcaaacagatatacaatggaattatttagaacatcga 486 
E NF E P I N R W W E K I D D Q T D I Q W N Y L E H R 162 
ggattaatattttcccctccatacgttcaacatcatgtaccaattttttataaaagtataaaaattgaattaaatgcaaaa 567 
G L I F S p p y V Q H H V P I F Y K S I K I E L N A K 189 
tcagaagaattagctacctattggtgtagtgcaattggtagtgattattgtacaaaagaagtttatattaaattttttt 648 
S E E L A T Y W C S A I G S D Y C T K E K F I L N F F 216 
aaaacatttataaatagtttagaaaatgataatattataaacaagagaatgaaacgaaattaaaggagatatat 724 
K T F I N S L E N D N I I K Q E N E T K L K K G D I S 243 
aattttaagtttattgattttatgccaatcaagatcatttattaaaattaagagaagaagttaaataacaagaa 810 
N F K F I D F M P I K D H L L K L R E E K L N K T K E 270 
gaaaaagaagaggaaaaaaaaatgagaatggaaaaagaattaccatatacatatgcgttagttgattggattcgtgaaaag 891 
E K E E E K K M R M E K E L P Y T Y A L V D W I R E K 297 
atatcaagtaataaagcagaaccacctgggttat ttagaggaagaggagaacatccaaaacaaggtt tattaaaaaaaaga 972 
I S S N K A E P P G L F R G R G E H P K Q G L L K K R 324 
atttttccagaagatgttgtaattaatattagtaaagatgcacctgtaccacgattatatgataatatgtgtggacataat 1053 
I F P E D V V I N I S K D A P V P R L Y D N M C G H N 351 
tggggtgatatatatcatgataataaagtaacatggttagcttattataaagatagtataaatgatcaaataaaataact 1134 
W G D I Y H D N K V T W L A Y Y K D S I N D Q I K Y T 378 
tttttatctgctcaatcaaaatttaaaggatataaagatcttatgaaatatgaaaatgctcgaattaatcatgtgtt 1215 
F L S A Q S K F K G Y K D L M K Y E N A R K L K S C V 405 
cataaaattagggaagattataaaaataaaatgaaaaataaaaatattattgataaacaattaggaacagctgtttattta 1296 
H K IRE D 	K N 	MK N K 	lID K 	L G 	A V Y L 432 
atagattttctagcattaagagtaggaggagaaaaagatatcgatgaagaagcagatactgtaggttgttgtagtttaaga 1377 
I D F L A L R V G G E K D I D E E A D T V G C C S L R 459 
gtagaacatattagttttgcacacgatataccttttaaaagtgtagattcaaaagaacaaaaaacaaatgatgaaaaagta 1458 
V E H I S F A H D I P F K S V D S K E Q K T N D E K V 486 
aataaaataccattaccaacaaatttagaaagtatttcatcagaagattgttatataactttagattttttaggaaaagat 1539 
N K I P L P T N L E S I S S E D C Y I T L D F L G K D 513 
agtatacgatattttaatacagtcaaaatagataaacaagcatatattaatataataatattttgtaaaaataaaaataga 1620 
SIR Y FN TV KID K Q AY IN III F C K 	K 	R 540 
gatgaaggagtttttgatcaaataacttgttcaa aattaaatgaatatcta aaagaaattatgcctactt tatcagctaaa 1701 
D E G V F D Q I T C S K L N E Y L K E I M P T L S A K 567 
gtgtttcgtacatataatgcttcaattacattagatcaacaattaaaaagaataaaagaagtttatggaaaaacaacatat 1782 
V F R T Y N A S IT L D Q Q L K R I KEVYGKTTy 594 
tcattatattctggtgaaacagaattacacaaatcgaaaaaaagaaaatctagccatttaacttcagatacaaatatatta 1863 
S L Y S G E T E L H K S K K R K S S H L T S D T N I L 621 
agtgatgcaagtgattctactattaatgatgtaaataacgagtatgatgaaaatggaataaataaaaaactatcatatgct 1944 
S D A S D S T I N D V N N E Y D E N G I N K K L S Y A 648 
actactgtaggaaaagaaaatgatgtcgatgataaaaactcaccaatagaagttgacgtttcaaatataaatgaacttatt 2025 
T T V G K E N D V D D K N S P1 E V D V S N I N E L I 675 
aatttttacaataatgcaaatagagaagtagccatattatgtaaccatcaaagaagtattccaaaacaacatgatacaact 2106 
N F Y N N A N R E V A I L C N H Q R S 	P K Q H D T T 702 
atgtcaaaaataaaaaaacaaattgaattatataatgaagatataaaagaatataaaaaatatttgcaacatttaaaaaaa 2187 
M S K I K K Q I E L Y N E D I K E Y K K Y L Q H L K K 729 
aatagtgataaaaaatttatctttgtttcgaaagtttctactttagatggaactttaagaccaaataaagtcaaagaaaat 2268 
N S D K K F I F V S K V S T L D G T L R P N K V K E N 756 
atgaaagaagaatcttgtaaaaaaaaactaattactcttataaaaagttgaattattaaccatgaaagtaaga 2249 
M K E E S C K K K 	I TL I K K V E L L N N Q M K V R 783 
gatgataataaaactattgctttaggtacatctaaaattaattatatggatccaagaataactgttgctttttgtaaaa 2430 
D D N K T I A L G T S K I N Y M D P R I T V A F C K K 810 
tttgaaatacccatagaaaaagtatttaatagaagtttaagacttaaatttccttgggccatgtttgctacaaaaaatttt 2511 
F El P1 E K V F N R S L R L K F P W A M F A T K N F 837 
acattttaa 2520 
T F * 	840 
A UWGCG Pileup (Devereux et al. 1984) comparison of the P.falciparum, 
D.melanogasrer, S. cerevisiae, S.pombe and human topoisomerase I amino acid 
sequences were made (figure 3.4). PfTopol was found to be around 140-280aa shorter in 
length at the N-terminus when compared to the human and D.melanogaster amino acid 
sequence. Therefore the possibility of an intron near the 5 'terminus of the gene was 
examined. PCRs were performed using cDNA and genomic DNA as alternative templates 
with the same oligonucleotide primers situated 5' to the first in frame nonsense codon 
(primer M628 1, figure 3.2) and 331 nt into the coding sequence (primer M5604, figure 
3.2). Both templates gave the same size of PCR product which probed positive with an 
end-labelled internal oligonucleotide (primer M5829, figure 3.2) when Southern blotted 
(figure 3.5). The same template preparations were tested in reactions in which the intron-
containing region of DNA encoding the DNA Polymerase a sequence was amplified in 
PCR and probed with an end-labelled internal oligonucleotide (White et al. 1993). This 
control showed that there was no detectable contamination of the cDNA with genomic 
DNA. 
The domain structure of the human Topol protein has been reported (figure 1.3). The 
pile up shows that the PfTopol amino acids are highly conserved in the regions 
corresponding to the essential CORE and C-terminal domains of the human protein. 
Very little conservation is observed between species outwith these regions. This suggests 
that the domain structure determined for the human Topol protein is probably 
applicable to the parasite Topol. 
A region with an identified function at present is the small C-terminal block in which a 
single tyrosine residue of the S.cerevisiae enzyme has been shown to be the amino acid 
residue through which the protein becomes covalently linked to DNA when one of the 
011 
strands of the DNA duplex is cleaved (Thrash et al. 1985). A Pileup of the consensus 
active site region implicates Tyr 798  of the P.falciparum sequence for this role (figure 3.7). 
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Figure 3.4 Sequence alignment of Topol amino acid sequences from human, 
D.melanogaster, S.cerevisiae, S.pombe and P.falciparum. 
Conserved amino acid regions are underlined. Numbering begins at the first methionine 
residue of the human Topol sequence. The tyrosine residue thought to be involved in the 
linkage to the cleaved DNA strand is indicated (+). 
1 	 40 	 80 
Human MSGD ...... .HIJHNDSQIE .. . .ADFRLN DSHKHKDKHK DREHRHKEHK . . KEKDREKS KHSNSEHKD. SEKKHKEKEK 




81 	 120 	 160 
	
Human 	.......... 	....... TKH KDGSSEKHKD .......... 	.......... 	.......... 	.......... 	........ KH 




161 	 200 	 240 
Human KDRDKEKRK. . . EEKVRASG DAKIKKEKEN GFSSPPQIKD EPEDDGYFVP P ............................. 
D.melanogaster SSSSRDKERS SSSHKSSSSS SSSKSKHSSS RHSSSSSSKD HPSYDGVFVK PEPVSQQLMH SGSVDAFQMQ QLGSYEAAAA 









280 	 320 
AGANYKNGYE ESIVDIKKEE ESFNNLSQAS SCDYSMSQFR ADEPPFVVKH EQSYAEEDST MNYNDHDDDA 
M TIADASKVNH ELSSDDDDDV PLSQTLKKRK 
.......... .......... . MSNSSSKKR 
MQSM EINDNNSIKN ESTSDDDILI NKIKQNLGNN 
321 	 360 	 400 
Human ......KEDI KPLKRPRDED DVD ....... .......... ...... YKPK KIKTEDTKKE KKRKLEEEED G .....KLKK 
D.xnelanogaster DEDDEEDV PLANRKRKQE ATDRPDGGMD N. .DDDDDIP LLARKKVKKE KIKKESKEKS KKRVKEEPSD DYGNVKPKKK 
S.cerevisiae VASMNSASLQ DE. .AEPYDS DEAISKISKK K. .TKKIKTE PVQSSSLPSP PAKKSATSKP KKIK. .KEDG DVKVKTTKKE 
S.pornbe AKVMGNGGLK NGKKTAVVKE EEDFNEIAKP S. . PKHKRVS KANGSKNGAK SAVKKEESDT DDSVPLRAVS TVSLTPYKSE 
P.falciparurn KSCNSRSSKK ESIKKQKSNS ELGIKKNTKK SLGIKKEEEK KKQISKRKSN ELKEKNNLKE GKKKYVEKKS RTVKDETKLT 
401 	 440 	 480 
Human PKNKDKDKKV PEPDNKKKKP KKEEEQKWKW WEEERYPEGI KWKFLEHKGP VFAPPYEPLP ENVKFYYDGK VMKLSPKAEE 
D.melanogaster KNKKEPEPAV SPGKRQKAKA KVEEEEVWRW WEEEKRADGV KWSTLEHKGP VFAPRYERVP RNVRFYYDGK PLELSEETEE 
S.cerevisiae . . EQENEKKK REEEEEEDKK AKEEEEEYKW WEKENEDDTI KWVTLKHNGV IFPPPYQPLP SHIKLYYDGK PVDLPPQAEE 
S.Pombe LPSGASTTQN RSPNDEED.....EDEDYKW WTSENIDDTQ KWTTLEHNGV IFAPPYEPLP KNVKLIYDGN PVNLPPEAEE 
P.falciparurn NVIKKETQNN KKPKKLLKKS EENFEPINR_W 1EKIDDQTDI QNYLEURL ISPP. .VQ HHVPIFXKSI KIELNAKSEE  
481 	 520 	 560 
Human VATFFAKNLD HEYTTKEIFR KNFFKDWRKE MTNE ...... .EKNI .... 1 TNLSKCDFTQ MSQYFKAQTE ARKQMSKEEK 
D.rnelanogaster AATFYAKNLN HDYCTKEVFN NNFFKDFRKS MTPR ...... .EREI .... 1 KDFRKCNFQE MFNYFQAESE KRKAASKEEK 
S.cerevisiae VAGFFAALLE SDHAKNPVFQ KNFFNDFLQV LKES ...... . GGPLNGIEI KEFSRCDFTK MFDYFQLQKE QKKQLTSQEK 
S.ponthe VAGFYAAMLE TDHAKNPVFQ DNFFRDFLKV CDEC ...... . NFNHN...1 KEFSKCDFTQ MFHHFEQKRE EKKSMPKEQK 
P..falciparum LTYWCSAIG SDYCTKEKEI IjNEEKTFINS LENDNIIKQE NETKLKKGD_j SNFKFIDEMP IKDHLLKLRF, EKLNKTKEEJj  
561 	 600 	 640 
Human LKIKEENEKL LKEYGFCIMD NHKERIANFK IEPPGLFRGR GNHPKMGMLK RRIMPEDIII NCSKDAKVPS . .PP.PGHKW 
D.melanogaster LIKKNENEAL MKEFGFCMID GHKEKIGNFR LEPPGLFRGR GEHPKNGMIK RRIQASDVSI NCGKDSKVPS . .PP.PGSRW 
S.cerevisiae KQIRLEREKF EEDYKFCELD GRREQVGNFK VEPPDLFRGR GAHPKTGKLK P.RVNPEDIVL NLSKDAPVPP . .AP.EGHKW 
S.pornbe KAIKEKKDEE EEKYKWCILD GRKEKVGNFR IEPPGLFRGR GSHPKTGSLK RRVYPEQITI NIGEGVPVPE . .PL.PGHQW 
P.falciparum EEEKKNRNEK ELPYTYALVD WIRKISSNK AjjGLFRGR EQLLK KIFPEDWI..IISKDAPLR LYDNNCHN1 
641 	 680 	 720 
Human KEVRHDN}CVT WLVSWTENIQ GSIKYIMLNP SSRIKGEKDW QKYETARRLK KCVDKIRNQY REDWKSKEMK VRQRVALYF 
D.melanogaster KEVRHDNTVT WLASWIENVQ GQVKYIMLNP SSKLKGEKDH IKYETARRLD KVIDKIRATY RDEWKSKEMR VRQRAVALYF 
S.cerevisiae GEIRHDNTVQ WLANWRENIF NSFKYVRLAP NSSLKGQSDY KKFEKARQLK SYIDAIRRDY TRNLKSKVML ERQKAVAIYL 
S.pombe AEVKHDNTVT WLATWHENIN NNVKYVFLAA GSSLKGQSDL KKYEKSRKLK DYIDDIRKGY RKDLKNELTV ERQRGTANYL 






721 	 760 
IDKLALRAGN EKEEGETADT VGCCSLRVEH INLHPE. 
IDKLALRAGN EKDEDQ.ADT VGCCSLRVEH VQLHKE. 
IDVFALRAGG EKSEDE.ADT VGCCSLRYEH VTLKP ..... 
IDVFALRAGN EKGEDE.ADT VGCCSLRYEH VTLKP ..... 






SVDSKEQKTN DEKVNKIPLP TNLESISSED CYITLPELGK  
801 	 840 	 880 
Human DSIRYYNKVP VEKRVFKNLQ LF.MENKQPE DDLFDRLNTG ILNKHLQDLM EGLTAKVFRT YNASITLQQQ LKELTAPDE. 
D.melanogaster DSIRYYNEVE VEKRVFKNLE LF.MEHKKEG DDLFDRLNTQ VLNEHLKELM EGLTAKVFRT YNASKTLQSQ LDLLTDPSA. 
S.cerevisiae DSIRFYQEVE VDKQVFKNLT IFKRPPKQPG HQLFDRLDTS ILNKYLQNYM PGLTAKVFRT YNASKTMQDQ LDLIPN.KG . 
S.pombe DSIRYYNEVE VDPQVFKNLK IFKRPPKKEG DLIFDRLSTN SLNKYLTSLM DGLSAKVFRT YNASYTMAEE LKKMPK.NL . 
P.falciparurn DSIRYFNTMK IDKQAYII IZCK.NNRD EGVQITCS KLUEYLKEIN PTLSAKVFRT_CNASIILDQQ J 4KRIKEVYGK 
881 	 920 	 960 
Human..............................................................................NI 
	
D.melanogaster 	.............................................................................. TV 
S.cerevisiae .......... 	.......... 	.......... 	.......... 	.......... 	.......... 	.......... 	........ sv 
S .pornbe 	.............................................................................. TL 
P.falciparurn TTYSLYSGET ELHKSKKRKS SHLTSDTNIL SDASDSTIND VNNEYDENGI NKKLSYATTV GKENDVDDKN SPIEVDVSNI 
961 	 1000 	 1040 
Human PAKILSYNRA NRAVAILCNH QRAPPKTFEK SMMNLQTKID A ......... .......... .......... .......... 
D.melanogaster PEKLLAYNRA NRAVAILCNH QRSVPKSHEK SMENLKEKIK A ......... .......... .......... .......... 
S.cerevisiae AEKILKYNAA NRTVAILCNH QRTVTKGHAQ TVEKANNRIQ ELEWQKIRCK RAILQLDKDL LKKEPKYFEE IDDLTKEDEA 
S.pornbe ADKILFYNRA NRTVAILCNH QRSVTKNHDV QMERFAERIK ALQYQRMRLR KMJLNLEPKL AKSKPELLAK EEGITDSWIV 
P.falciparurn NELINFN 	REVAILCNH QRSIPIJQHDT TMSKIKKQE 	LY ........ .......... .......... .......... 
1041 	 1080 	 1120 
Human .......... .......... .. KKEQLADA RRDLKSAKAD AKVMKDAKTK KVVESKKK.. ......... A VQRLEE. 
D.melanogaster 	.......... .......... .. KREAIEKC ESEYHS .... 	.... RDEK.. ..... KGK.. ......... Q LERLRD. 
S.cerevisiae TIHKRIIDRE IEKYQRKFVR ENDKRKFEK. EELLPESQLK EWLEKVDEKK QEFEKELKTG EVELKSSWNS VEKIKA. 
S.pombe KHHETLYELE KEKIKKKFDR ENEKLAAEDP KSMLPESELE VRLKAADELK KALDAELKSK KVD. .PGRSS MEQLEK. 
P.falciparuin .......... .......... ... NEDIKEY KKYLQ ..... . HLKKNSDKIJFIFVSKVSTL DGTLRPNKVK ENMKEESCKK 
1121 
Human QLMKLE .... ... VQATDRE ENKQIALGTS 
D. melanogaster QLKKLE .... ... LQETDRD ENKTIALGTS 
S.cerevisiae QVEKLEQRIQ TSSIQLKDKE ENSQVSLGTS 
S.pornbe RLNKLNERIN VMRTQMIDKD ENKTTALGTS 
P.falciparurn KLITIKKVE LLNNQMKVRD DIKTIALGTS 
t 1160 
KLNYLDPRIT VAWCKKWGVP 





IEKIYNKTQR EKFAWAIDMA DEDYEF*... 
IEKIFNKTQR TKFLWAVHMA DENYRF*... 
IEKIFTKTLR EKFKWAIESV DENWRF*... 
IEKLFSKTIR DKFNWAADTP PDWKW*. 
IVFNRSLP LP4.FA TKNFTF*... 
Figure 3.5 Is there an intron at the 5' terminus of the Pffopol? 
Genomic DNA (1 and 3) and cDNA (2 and 4) was used as the template in PCR. The 
oligonucleotide primers M6281 and M5604, designed to the PfTopol sequence, were 
used in reactions 1 and 2. Oligonucleotide primers designed to the DNA polymerase a 
sequence were used to amplify the DNA in samples 3 and 4. The gel was Southern 
blotted and probed with end-labelled M5829 (1 and 2) or an internal oligonucleotide from 
DNA polymerase a (3 and 4). The results from the Southern blot are shown. 
Figure 3.6 PCR across a possible intron containing region of PfTopol. 
The primers M4680 and M3173 were used to amplify the possible intron containing 
region of PfTopol DNA using pUC19.PfTopol (1), genomic (2) and cDNA (3) as 












D. melanogas ter ENKTAILGTSKLNYLDPRI 
S. cerevisiae ENKTTALGTSKINYIDPRL 
S. pombe ENSQVSLGTSKINYIDPRL 
P. falciparurn DNKTAILGTSKINYMIJPRI 
Figure 3.7. Topoisomerase I amino acid pile up of the active site consensus sequence. 
The region corresponds to amino acids 785-803 of the P.falciparum protein. The 
tyrosine residue thought to be involved in the linkage to the cleaved DNA strand is in 
bold. 
A feature of the PfTopol sequence is the presence of two unique stretches of amino acid 
sequences which lie in the CORE domain. The first stretch is 29-34 amino acids in length 
(figure 3.4., amino acid numbers 755-789). PCR of cDNA and of genomic DNA across - 
this region confirmed that the DNA sequences encoding the extra amino acids are not 
part of an intron (figure 3.6). The same template preparations were used as those 
described previously to check for an intron at the 5' terminus. The possibility that the 
cDNA had been contaminated with genomic DNA could therefore be ruled out. The 
second of the amino acid insertions is 79 amino acids in length (figure 3.4., amino acid 
numbers 879-95 8) and falls within the region originally amplified from cDNA, explaining 
why the PCR product was larger than anticipated. This result also confirms that the 
insert is present in the mature message and is not an intron. The insertions do not contain 
asparagine rich regions or repetitive sequences which have previously been suggested to 
play a role in immune evasion (Ridley et al. 1991), therefore their function is unknown at 
present. 
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Sequence comparisons of PfTopol and the type I topoisomerases from other species 
were made and they show very high homology to PfTopol (table 3.1). The human amino 
acid sequence shows the highest level of similarity with parasites protein. 
% identity % similarity EMBL accession number 
Human 42 63 J03250 
Mus musculus 41 62 L20632 
Xenopuslaevis 40 61 L07777 
Drosophila melanogasrer 40 60 M74557 
Schizsaccharomyces pombe 40 60 X06201 
Arabidopsisthaliana 41 60 X57544 
Saccharomyces cerevisiae 36 56 K03077 
Ustilagomaydis 30 49 L32017 
Table 3.1. The homology between PfTopol and other type-I eukaryotic 
topoisomerases. The similarity between the amino acid sequences takes into account 
identical residues and conservative replacements. 
3.3 Gene Copy Number 
Southern analysis of DNA digested with SmaI, PstI, BamHI, AccI and ScaI was carried 
out. The blot was hybridised with a random-labelled 1.66kb PCR fragment of DNA from 
PtTopol (PCR between the primers M3173 and M5829, figure 3.3), (figure 3.8). The 
restriction enzymes used do not have restriction recognition sites within the PfTopol 
ORF except for BamHI and AccI. The PCR generated fragment used as a probe does not 
include the region of sequence where the BamHI site exists however AccI cuts within this 
region. The results show a single band in each lane except for the AccI restricted DNA 
which shows two bands as expected. The results suggest that the gene is present as a 
single copy. 
Figure 3.8 Gene copy number of PfFopol. 
Genomic DNA was restricted with the enzymes SmaI (1), PstI (2), BamHl (3), AccI (4) 
and ScaI (5), Southern blotted and hybridised with a fragment of DNA from PfTopol. 
The size of the X.HinDlII DNA markers are indicated in kb. 




3.4 Chromosomal Location 
Malarial parasites contain 14 chromosomes which vary in size from between 63 0kb and 
3Mb and total around 30Mb of genetic information (Goman et al. 1982). In comparison 
the human genome is approximately 3000Mb and the E.coli genome around 4Mb in size. 
Individual chromosomes may vary in size between different parasite isolates because of 
differences in the length of subtelomeric regions (Foote and Kemp, 1989). These regions 
contain repetitive sequences which appear to be unstable. 
Chromosomes from Ki parasites separated by PFGE (2.2.11) and blotted to Genescreen 
plus membranes were kindly supplied by Mike Goman of this laboratory (Kilbey et al. 
1993). The blot was hybridised with a random-labelled PCR-generated 886bp fragment 
from the PfTopoI gene (primers M4480 and M3598, figure 3.2). The probe hybridised 
to chromosome 5 (figure 3.9). This was verified by stripping the membrane (2.2.4.7 ) and 
reprobingit using a fragment of DNA encoding PfTBP (TATA Binding Protein), 
(McAndrew et al. 1993) which is known to be present on chromosome 5. The same 
experiment was carried out using chromosome blots prepared from two other isolates of 
P.falciparum, Dd2 and 3D7. The PfTopol gene was also found to be present on 
chromosome 5 of these isolates. These blots were kindly supplied by Jane Canton, 
Edinburgh. 
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Figure 3.9 Chromosome Location. 
Three P.falciparum isolates Ki (A), Dd2 (B) and 3D7 (C) were ran on PFGE to separate 
the chromosomes. The gel was stained with ethidium bromide (1) and Southern blotted. 
The membranes were probed with a fragment of DNA from PfTopol (2) then stripped 
and reprobed with a fragment of DNA from PtTBP (3). 
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3.5 Northern Analysis 
Total RNA was isolated from unsynchronised parasites (2.3. 1) and 10.tg was used to 
prepare a Northern blot (2.3.2). The membrane was probed using a random-labelled 
1.66kb PCR generated fragment of the PiTopol gene (primers M3173 and M5829, figure 
3.2). A single band of approximately 3.8kb was identified (figure 3.10). This is 
approximately 1kb larger than the open reading frame but is in line with other genes 
isolated from P.fczlciparum (Levitt et al. 1993 and Lanzer et al. 1993). Possible functions 
of these large untranslated regions of RNA include the regulation of transcript stability, 
stage specific expression or even the targeting of the message (Lanzer et al. 1993). 










1 	2 3 
Figure 3.10 Northern analysis. 
Size fractionated total RNA probed with a random-labelled 1.66kb PCR generated 
fragment of the PfTopol. The positions of the Gibco-BRL size markers are indicated in 










Part of the PfTopol gene was isolated by PCR from cDNA using primers designed to 
highly conserved regions of other eukaryotic Topo I genes from other species. The entire 
gene was obtained by screening a genomic library with a random-labelled heterologous 
probe from the S.cerevisiae Topol gene. Sequence analysis revealed an open reading 
frame of 2520 bp encoding a deduced protein of 839 amino acids with no detectable 
introns. The amino acid sequence has around 40% identity with the eukaryotic Topol 
homologues examined with most of the conservation located within the CORE and C-
tenninal domains. The tyrosine residue in the PtTopol sequence thought, on the basis of 
alignment of residues, to be involved in forming the covalent linkage with the cleaved 
DNA strand is Tyr798 . In contrast to the type I topoisomerases of other species, the 
predicted amino acid sequence of the parasite enzyme has two tracts of additional amino 
acids. Comparisons between cDNA and genomic DNA shows that the sequences which 
encode these regions are present in the mature message and neither is part of an intron. 
The insertions do not contain asparagine rich regions or repetitive sequences which have 
previously been suggested to play a role in immune evasion (Ridley et al. 1991), 
therefore their function is unknown at present. The PfTopol gene was found to be 
present as a single copy on chromosome 5 in three separate P.falciparum isolates, Ki, 
Dd2 and 3137. Northern analysis identified a transcript of approximately 3.8kb 
suggesting that approximately 1kb of message is untranslated. Possible functions of these 
large untranslated regions of RNA include the regulation of transcript stability, stage 




Chapter 4. Expression of Recombinant PfFopol. 
One of the main reasons for isolating and characterising the PfTopol gene was to express 
it in a heterologous system where the proteins activity could subsequently be examined. 
As will be apparent in the next chapter, PfTopol activity is present in parasite extracts 
and it is possible to test the effects of potential inhibitors of Topol in this test. 
However, the expense and time involved in producing sufficient extract to support a 
routine screening of potential inhibitors of PfTopol is unacceptable and might be avoided 
by the overexpression of the recombinant enzyme. 
In this chapter the attempts made to express and purify the full length PfTopol and its 
sub-fragments will be discussed. The bacterial expression vectors chosen were pGEX 
and pRSET. Both systems are frequently used, with success, for the expression of 
fusion proteins in E.coli. The systems are particularly useful as the expressed fusion 
proteins can be purified away from the bacterial proteins by their fusion tags. Also, 
antibodies recognising the fusion tags are commercially available allowing the expressed 
proteins to be detected by Western blotting. 
The pGEX vector (figure 4.1) expresses a piece of cloned DNA as a fusion with 
glutathione S-transferase (GST) (Smith and Johnson, 1988) in E.coli. The pGEX plasmid 
contains a mutant LacI gene (LacY') which produces high levels of lac repressor. The 
repressor binds to the tac promoter therefore repressing the expression of the GST 
fusion protein. Expression is induced by the addition of IPTG. The GST fusion proteins 
can then be purified using glutathione sepharose columns (Pharmacia). The GST tag of 
the fusion protein binds to the column and the protein can subsequently be eluted by the 
addition of reduced glutathione. The expressed fusion proteins can then be detected by 
Western blotting using an affinity purified antibody recognising the GST tag (SIGMA). 
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The pRSET vectors (figure 4.2) contain a strong T7 promoter and terminator and DNA 
sequences cloned into the plasmid are expressed as N-terminal hexa-histidine [(HIS) 6] 
fusion proteins. pRSET constructs are transformed into BL21DE3[pLysS] cells for 
expression of the protein. DO is a phage lambda derivative that carries the gene for T7 
RNA polymerase which is under the control of the lacUV5 promoter. Addition of IPTG 
induces the promoter to produce T7 RNA polymerase which in turn transcribes DNA 
under the control of the T7 promoter. Leaky expression in cells is prevented by the 
pLysS plasmid which provides lysozyme, an inhibitor of the cell's T7 RNA 
polymerase. Nickel agarose columns are available for the subsequent purification of the 
Histidine tagged fusion proteins and a monoclonal antibody recognising the Histidine tag 
is available (SIGMA) for detection of the proteins by Western analysis. 
4.1 Preparation of Expression Constructs. 
The preparation of all constructs were carried out in DH5a competent cells unless stated 
otherwise. Prior to expression the constructs were transformed into BL2 1 DE3 (pGEX 
constructs) or BL21 DE3 [pLysS] (pRSET construct). Figure 4.3 shows the regions of 
PfTopol cloned, the location of the oligonucleotide primers and endonuclease restriction 
sites used in the construction of the expression constructs. 
The region of the PfTopol DNA, encoding the open reading frame, was amplified using 
PCR between the primers N0481 and N0482 (figure 4.3). Both N0481 and N0482 
primers were designed with EcoRI restriction sites at their 5'-ends. The PCR product 
was cloned into the pCRTMII  cloning vector (Invitrogen, figure 4.4) to give the construct 
pTA.ORF. The TA cloning system makes use of the ability of Taq polymerase to add a 
single adenosine residue at the 3'- ends of PCR products. The pCRTMII  vector supplied 
WIZ 
by Invitrogen is linearised with a single thymine residues at the 3'- ends. This allows 
PCR inserts to ligate efficiently with the vector. The ORF region of the construct was 
fully sequenced to ensure no PCR induced mutations had been introduced. 
pTA.ORF DNA was cut using the restriction enzyme EcoRI releasing the PfTopol ORF 
DNA insert. Attempts were made to subclone the DNA into the pGEX2 vector (figure 
4.1) and pRSETA vector (figure 4.2), also restricted with EcoRI. Initial attempts to do 
this were unsuccessful. PCR across the vector and insert junction using a vector specific 
oligonucleotide and M5604 (figure 4.3), using the ligation mixture as a template, indicated 
that the ligation was successful. The reasons why the construct could not be recovered 
from the ligation mixture after transformation into E.coli was unknown. Several strategies 
were employed in an attempt to identify the problem. 
Overexpression of the human Topol in both E. coli and S. cerevisiae was found to be toxic 
to the cells expressing the protein (D'Arpa et al. 1988., Bjornsti et al. 1989., Tamura et 
al. 1991). In this case the DNA to be ligated into the expression vectors had EcoRI 
endonuclease restriction sites at both the 5' and 3' ends. This would allow the DNA to 
be inserted in either the forward or reverse orientation. Constructs with the DNA 
inserted in the reverse orientation, however, would not express the topoisomerase 
protein and the translation would stop very early in the sequence. Constructs in neither 
the forward nor reverse orientation were recovered from the ligation experiments 
suggesting that toxicity of the gene product is an unlikely explanation. Attempts were 
also made to clone the ORF region of PfTopol into pGEX 1. This would create a 
construct which contained the DNA, however the protein would be expressed out of 
frame and therefore in an inactive form. The pGEXI constructs containing the region of 
DNA encoding the ORF could not be recovered. 
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These experiments suggest that the problems encountered in the cloning of the PfTopol 
gene into the expression vectors was due to a problem at the DNA level and not protein 
toxicity. 
The genome content of P.falciparum is remarkably AT rich with an average GC content 
of 18%. The PtTopol gene has been found to have a GC content of 30% (chapter 3). By 
way of comparison the GC content of E. coli DNA is 50%. The unusual base 
composition of P.falciparum DNA appears to make fragments unstable when cloned into 
E.coli hosts. So far it has proved impossible to construct a conventional genomic library 
of P.falciparum in E.coli that consists of the entire genome. In order to establish whether 
a particular region of the PfTopol DNA is responsible for the problems encountered it 
was decided to clone sub-fragments of the gene into the pGEX vector. 
Due to the convenient position of the BglII and BamHI restriction sites the 3' end of the 
DNA was examined first. This region contains both the inserted tracts of DNA and it 
encodes the active site region of the protein. The fusion protein pGEX 1 .frag4 was 
prepared by restricting pTA.ORF with BglII and BamHI restriction enzymes. The 
1273bp fragment was gel purified (2.2.3.6) and ligated into pGEX1 restricted with 
BamHI. The restriction sites of BglII and BamHI are compatible, however once the 
opposite restriction sites are ligated together, both restriction recognition sites are 
removed. pGEX1 .frag5 was prepared using the construct pGEX1 .frag4 restricted with 
BamHI and EcoRl. A PCR product was obtained by amplifying PfTopol DNA between 
the primers N0482 and M3882 using the standard conditions (2.2.10). The product was 
then restricted with the enzymes EcoRI and BamHI releasing a 1 2Obp fragment. This 
fragment was gel purified and ligated into the restricted pGEX1 .frag4. The PCR 
generated region was fully sequenced to ensure that no PCR induced mutations had 
occurred. The vector and 5' end of the DNA insert was sequenced to ensure that the 
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insert was in the correct reading frame for expression of the protein. Restriction analysis 
was also carried out to check for deletions or rearrangements of the DNA. All the results 
showed that pGEX1 .frag4 and pGEX1 .frag5 were cloned successfully. 
Fiona Gregory, a summer student in the laboratory, studied the 5' region of the PfTopol 
DNA. Three PCR products were cloned into the pCRTMII  cloning vector (Invitrogen, 
figure 4.4). The PCR conditions were as described (2.2.10). pTA.ORF DNA was used as 
a template with the primer N0481 and either M5604, M5356 or M5034 (figure 4.3). All 
three PCR products were successfully cloned into pCRTMII.  The subsequent constructs 
were restricted with EcoRl and the released PCR products ligated into pGEX2, also 
restricted with EcoRI. Only the PCR product corresponding to the region of DNA 
between the primers N0481 and M5604 was cloned successfully into pGEX2 creating 
the construct, pGEX2.fragl. The construct was then fully sequenced to ensure that no 
PCR induced mutation were introduced, that the insert was in the correct reading frame 
and that no deletions or rearrangements had occurred. The data suggested that there was a 
region of DNA between the primers M5604 and M5356 which may be causing the 
problems. This region contained a potential stem loop structure: 
5' GGTGGGAAAA.AAT 3' nucleotides 430-442 
3 1 CCTCCCTTTTATA 5' nucleotides 506-494 
In order to examine this, a region between the primers M5829 and M5356 was amplified 
by PCR using the standard conditions (2.2. 10) and pTA.ORF DNA as a template. The 
PCR product was cloned into the pCRTMII  cloning vector and digested with the 
restriction enzyme, EcoRI. The released fragment of DNA was then ligated into pGEX2 
also restricted with EcoRI to give the construct, pGEX2.frag3. The construct was then 
fully sequenced to ensure that no PCR induced mutation were introduced, that the insert 
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was in the correct reading frame and that no deletions or rearrangements had occurred. 
The region of DNA was cloned successfully suggesting that the region of DNA, thought 
to create a stem loop structure, was indeed "clonable" and was not responsible for the 
problems encountered. 
The only region of DNA remaining to be cloned into the pGEX vector lay between 
nucleotides 580 and 1160 of the PfTopol ORF (figure 4.3). The cloning of this region 
was achieved by PCR amplification of pTA.ORF DNA in the region between the 
primers M5605 and M4681. The PCR product was subcloned into the pCRTMII  vector 
then into pGEX1 as described for the construction of pGEX2.fragl. The resulting 
construct, pGEX1.frag2, was sequenced across the vector and insert junction to confirm 
that the insert was positioned in the correct reading frame for protein expression. The 
entire, PCR derived insert was also sequenced to ensure that no PCR induced mutations, 
rearrangements or deletions had occurred. 
As the entire region of the PfTopol DNA encoding the ORF had been successfully 
subcloned into the pGEX vectors, this suggested that the problems in cloning the full 
length protein into an expression vector was not due to a particular part of the DNA 
sequence. The previous experiments showed that the expression of a protein, toxic to the 
cell, was also not responsible for the difficulties encountered. It was therefore decided to 
attempt the cloning of the DNA region encoding the entire open reading frame using 
different strains of E. coli cells. The INVa F cells (Invitrogen) were used as these were 
provided with the TA cloning kit (Invitrogen) and were used successfully in the 
construction of pTA.ORF. The INVa F' cells are of the same genotype as the DH5a 
cells previously used, however they are prepared to be ultracompetent therefore 
increasing the efficiency of the transformation by approximately 1000 times. 
pGEX2.ORF and pRSETA.ORF were successfully constructed and recovered from the 
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transformation in this experiment. The exact reason why the constructs could not be 
recovered from DH5a cells is unknown, however the fact that the cells were 
ultracompetent may have increased the possibility of recovering rare constructs. 
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pGEX1 TCG GAT CCC CGG GM TTC ATC GTC ACT GAO TGA 
II 	 I 	 I 
BarnHI Smal EcoRl 
Thrombin 
pGEX2 TCG GAT dTG G1T CCG CGT GGA TCC COG GGA AlT CAT CGT GAO TGA 
I 	 , I 	 I • 	 I 
BaniHi Smal EcoRl 
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Figure 4.2 The pRSET vector series. 




GGT TCC CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC 
gly ser his his his his his his gly met ala ser 
ATG ACT GGT GGA CAG CAA ATG GGT CGG GAT CGT TAC 
met thr gly gly gin gin met gly arg asp ieu tyr 
BamHI 
GAC GAT GAT GAT AAG GAT CGA TGG GGA TCC GAG CTC 
asp asp asp asp lys asp arg trp gly ser glu ieu 
BgiII 
I PvuII 	 EcoRI 
GAG ATC TGC AGC TGG TAC CAT GGA ATT CGA AGC TTG 
glu lie cvs ser trp tyr his gly lie arg ser leu 
PstI 	 NcoI 	 Hin.DIII 
KpnI 
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Figure 4.3 The regions of PfTopol expressed as fusion proteins. 
The region of the DNA encoding the ORF and its nucleotide numbers are shown. The 
oligonucleotides and restriction sites are indicated. The name of the constructs are 
positioned down the right hand side. The predicted size of the fusion proteins in kDa is 
shown in brackets. 
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pGEX1 .frag3 (61 kDa) 
pGEX2.frag2 (46kDa) 
pGEX1 .frag4 (85kDa) 
I 	pGEX1 .frag5 (89kDa) 
Figure 4.4. The pCRTMII  TA cloning vector. 
M13 Reverse Primer 	 Sp6 Promoter 
CAG GM ACA 3CT ATG Ad C ATG Arr ACG CCA AGC 1 AT 17A '37 GAC ACT7ATT
GTC CTT TGr CGA TAC T G TAC TAA T3C QT TCG Al TA AAT CCA CIG TGA 	CIT 
Nsil 	Hindill 	KpnI 	Sacf 	Barrtll Spel 
TAC TCA A3C TAT 3CA TCA A3C TTG GrA CCG A3C TOG GAT CCA CTA GTA ACG 3CC 
ATG AGT TCG AlA CGT AGT TCG AAC CAT GGC TCG AGC CIA GGT GAT CAT TGC C33 
BstXI 	 EcoRl 	 EcoRl 	 EcoRV 
3CC GM TTC TGC AGA TAT 3CC AGT GTG CTG G.M TrC I:17• 
TI Ct CIT AAG ACG TCT ATA CGG TCA CAC GAC CIT AAG CCG 
Aval 
PaeR7I 
BstXI 	 Noti 	XhoI 	NsiI 	XbaI 	ApaI 	 ________ 
CCA TCA CAC TG3 CC33 CCG CTC GAG CAT GCA TCT AGA GC33 CCC AAT TCG CCC TAT 
r AGT GIG ACC 3CC Q3C GAG CTC GTA CGT AGA TCT CCC 3(33 TTA AGCIGGG AlA 
17 Promoter 	 M13 (-20) Forward Primer 	 M13(-40) Forward Primer 
AGT GAG TOG TAT TAI C AAT TCA dIG 3CC GIC GTT TTA CAA CGIT CGT GAC TGG GM MC 
TCA CTC A3C ATA All G TTA AGI IGAC C(33 CAG CAA MT G IT 3Cf A GCA CTG ACC CTT 113 
+1 
pCR TM I I  
3.9 kb 
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4.2 Expression of Recombinant Fusion Proteins. 
4.2.1 GST Fusion Protein Expression. 
The constructs pGEX1 .fragl, pGEX1 .frag2, pGEX2.frag3 and pGEX.frag5 were 
expressed using the standard conditions (2.4.4.1). Uninduced and induced samples of the 
proteins, prior to purification, were separated by SDS-PAGE and either visualised by 
Coomassie staining or Western blotting using an anti-GST antibody (figure 6.8, A and 
B). The fusion proteins were expressed at levels detectable by both Coomassie staining 
and Western blotting in the induced but not the uninduced samples. The sizes of the 
fusion proteins expressed were as predicted (pGEX2.fragl, 44kDa., pGEX2.frag3, 
46kDa., pGEX1.frag2, 61kDa and pGEX1.frag5, 89kDa). The amount of protein 
expressed appeared to be inversely correlated with the size of the fusion protein with the 
smaller protein being expressed at a higher level than the larger proteins. Degradation 
products were clearly visible by Western blotting of the pGEX2.fragl and pGEX2.frag3. 
As the fusion proteins span the entire ORF of PtTopol they were used later to examine 
the PfTopol specificity of antisera (see chapter 6). 
pGEX2.fragl was expressed, solublised and purified using the standard conditions 
(2.4.4.1) for use as a negative control in Topol activity assays (chapter 6). The fusion 
protein expressed does not include the active site region of PiTopol therefore no activity 
should be observed. If any activity was detected this would suggest that the bacterial 
Topol protein was responsible. The soluble protein sample was put through a 
Glutathione column then 2mls of the protein-containing eluates were then passed 
through a desalting column (Pharmacia). The columns contain Sephadex G-25M for rapid 
desalting and buffer exchange. This process removed the reduced glutathione and changed 
the buffer conditions to those suitable for topoisomerase assays (chapter 6). The column 
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fractions were analysed by SDS-PAGE to check for the presence of protein of the 
expected size. A Coomassie stained gel showing eluates 1-4 from the Glutathione column 
and eluates 1-3 from the desalting column are shown in figure 4.5. No protein of 44kDa, 
the expected size ofpGEX2.fragl, was observed in the eluates although slightly smaller 
proteins were present at a high level. This may suggest that degradation of the protein 
had occurred. However, as the samples were to be used as a control, it was not essential 
to have full length expression of this fusion protein. 
pGEX1 .frag5 was expressed, solublised and purified using the standard conditions 
(2.4.4.1) in order to examine the fusion protein for PfTopol activity (chapter 6). The 
protein sample was put through a Glutathione column then 2mls of the protein 
containing eluates were passed through a desalting column. This process removed the 
reduced glutathione and changed the buffer conditions to those more suitable for 
topoisomerase assays (chapter 6). The column fractions were analysed by SDS-PAGE 
to check for the presence of protein. Coomassie stained gels showing elution's 1-4 from 
the Glutathione column and elution's 1-3 from the desalting column are shown in figure 
4.5. The location of the eluted fusion protein was determined by comparing the elution 
profile of the pGEX2.fragl fusion protein and also by examining the uninduced and 
induced protein samples by Western analysis (figure 6.8). The region expressed contains 
the active site region of PfTopol as well as the regions encoded by the DNA inserts. The 
fusion protein does not however contain the region corresponding to the N-terminal 
domain and it also has a large region of the CORE domain absent. In chapter 1 the 
domain structure of the human Topol protein was discussed. Experiments have shown 
that the N-terminal and Linker region is not essential for activity however the C-terminal 
and CORE domain is (Stewart et al. 1996a and 1996b). The pGEX1.frag5 fusion protein 
was examined as it would be interesting to see if Topol activity was possible with such a 
truncated protein. 
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The pGEX2.ORF was expressed using the standard conditions (2.4.4.1). Uninduced and 
induced samples were separated by SDS- PAGE and Western blotted using the anti-GST 
antibody. No protein could be detected by Coomassie staining. A very faint band of 
145kDa, the predicted size of the fusion protein, was detected in the 3 hour induced 
sample by the anti-GST antibody (data not shown). The conditions of expression were 
varied in an attempt to increase the expression of the full length protein. The standard 
induction times of 1, 2 and 3 hours were examined as well as 30 minutes and 5 hours. 
The temperatures after induction were also changed from 37°C to 30 °C, however no 
significant increase in protein expression was observed. As a very faint band was 
detected using the standard induction of 3 hours at 37°C it was decided to carry out the 
purification procedure using samples induced under these conditions. The conditions for 
purification using the Glutathione column and desalting column were as described 
(2.4.4.1). The protein sample was held in the Glutathione column for 15 minutes, prior 
to elution, in order to increase the concentration of protein eluted in the first fraction 
sample. 2mls of the protein-containing eluates were then passed through a desalting 
column. This process removed the reduced glutathione and changed the buffer conditions 
those more suitable for topoisomerase assays (chapter 6). The column fractions were 
analysed by SDS-PAGE to check for the presence of protein. A Coomassie stained gel of 
eluates 1-4 from the Glutathione column and eluates 1-3 from the desalting column are 
shown in figure 4.5. The location of the eluted fusion proteins specific to each of the 
fusion proteins was determined by comparing their SDS-PAGE profiles (data not 
shown) and also by Western blotting using the anti-GST antibody (figure 6.9.A). 
pGEXI .frag5 is visible by both Coomassie staining (figure 4.53) and Western blotting 
(figure 6.9.A). The Coomassie stained gel (figure 4.5.C) shows that pGEX2.ORF is 
present in a single fraction, however, when tested with the anti-GST antibody (figure 
6.9.A., lane 1) extensive degradation is observed. 
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Figure 4.5 Coomassie stained gels of the fractions from the purification of 
pGEX2.fragl(A), pGEX1.frag5(B) and pGEX2.ORF(C). Lanes 1-4 represent eluates 1-
4 from the Glutathione column. Lanes 5-7 represent eluates 1-3 from the desalting 
column. I Otl of each 1 ml fraction was analysed. The positions of the expressed fusion 
proteins were previously located by Western blotting using the anti-GST antiserum and 
their positions are marked with an arrow. The molecular weight markers are indicated at 
the right hand side of the gels in kDa. 
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4.2.2 Histidine Tagged Fusion Protein Expression. 
The pRSET clone with the full length PfTopol, pRSETA.ORF, was expressed using the 
standard conditions (2.4.4.2). Samples of the resulting protein preparations were 
separated by SDS-PAGE and Western blotted. Western analysis using an antibody to 
the (HIS)6 tag (Sigma) of the fusion protein is shown on figure 4.6. A sample of a 
pRSETA PtTopoII fusion protein was also ran on the same gel as a positive control. 
pRSETA alone was used as a negative control as a protein of I l6kDa, the expected size 
of pRESETA.ORF, should not be detected in this sample. The results show that the 
positive control protein is expressed and that the anti-HIS antibody recognises this 
protein. The samples of the pRSETA.ORF however show no protein by either 
Coomassie staining or Western blotting (figure 4.6., lanes I and 2). The construct was 
fully sequenced to check for the introduction of a mutation which may have created a 
stop site within the sequence. No mutations were discovered. It was also possible that 
there are signals in the Pfalciparum sequence which are recognised by E. co/i as a 
transcription stop site causing the message to terminate prematurely. In order to examine 
this further the message size of the Topol fusion protein was examined by Northern 
blotting. 
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Figure 4.6 Western analysis of pRSETA.ORF expression using an anti-HIS 
antibody. 
10111 of protein extract from each sample were loaded onto each lane. The molecular 
weight size standards are shown at the right hand side in kDa. 
1= pRSETA.ORF induced for 3 hours 
2= pRSETA.ORF induced for 1 hour 
3= pRSETA.ORF uninduced 
4= pRSETA induced 
5= induced pRSETA PfTopoII fusion protein control 






4.2.3 Northern Analysis of Histidine Tagged Fusion Protein Construct. 
50m1 cultures of induced pRSETA.ORF and pRSETA were prepared (2.4.4.2). The cells 
were pelleted and RNA was prepared (2.3.1). The pRSETA sample was included as a 
negative control for non-specific binding of PfTopol DNA to bacterial RNA. I 5xg of 
each sample was used to prepare a Northern blot (2.3.2). The membrane was probed 
using a random labelled 1.66kb PCR-generated fragment of the PfTopol gene (primers 
M3173 and M5829, figure 3.2), (figure 4.7). The results show that the PtTopol DNA 
probe does not recognise a transcript in the RNA sample from pRSETA. In the induced 
pRSETA.ORF RNA the probe recognises two transcripts. The first transcript is 
approximately 2.5kb and is the expected size of the transcript from pRSETA.ORF. The 
second transcript is around 10kb. This is far larger than expected and it was thought that 
this signal could be due to DNA contamination of the RNA. However, DNAase I 
treatment of the RNA sample did not remove the 10kb band (data not shown) and the 
band remains unexplained. A possible explanation is that the termination by T7 
polymerase was inefficient allowing transcription to continue past the termination stop 
site. 
These results suggest that the lack of expression is probably not due to a problem at the 
RNA level but at the protein level. It is known that overexpression of human 
recombinant Topol in both E. coil and S. cerevisiae is extremely toxic to the host cells 
(D'Arpa et al. 1988., Bjornsti et al. 1989., Tamura et al. 1991). The PfTopol protein 
may also be toxic to the bacteria cells which express the protein. 
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Figure 4.9 Northern analysis of pRSETA.ORF expression. 
Panel A shows the ethidium bromide stained gel. Panel B shows the Northern blot 
probed with a fragment of DNA encoding PfTopol. Lane 1 shows the RNA from 
induced pRSETA and lane 2 shows the RNA from induced pRSETA.ORF. The arrows 
show the location of the transcript and the size is indicated in kb. 
A 	 B 





Various fragments of the PfTopol gene were expressed using the expression vector, 
pGEX successfully. There appeared to be an inverse correlation between the size of 
fusion protein and the level of expression, with the smaller proteins being expressed at a 
much higher level that the larger ones. The full length PfTopol protein expressed in 
pGEX2 was expressed at a very low level and was barely detected by an anti-GST 
antibody prior to purification. However, when the protein was partially purified using a 
Glutathione column, a protein of the expected size, 145kDa, was observed. This protein 
will be examined for PfTopol activity in the next chapter. Purification of pGEX2.fragl 
and pGEX1 .frag5 was also carried out and the products were examined later for Topol 
activity (see chapter 5). 
Attempts to express the full length PfTopol in the pRSETA vector were unsuccessful. 
No protein was detected either by Coomassie staining or Western blotting. Northern 
analysis of RNA prepared from induced pRSETA.ORF suggests that the message is 
present indicating that the lack of expression may be caused by a problem at the level of 
translation rather than transcription. One possible explanation for the failure may be that 
the PfTopol expressed protein is toxic to the bacterial cells, as has been found when the 
Topol protein from man is overexpressed in both E.coli and S.cerevisiae. Deletion of an 
N-terminal portion of the hTopol gene had no effect on activity in vitro however it 
suppressed the lethal consequence of the protein's overexpression in S. cerevisiae 
(Aisner et al. 1992). N-terminal deletions of the PfTopol gene may allow the expression 
of the parasite protein in the pRSET expression system, however, time did not allow 




Chapter 5. Topoisomerase I Activity Assays. 
Topoisomerases alter the topological state of DNA by catalysing the breaking and 
rejoining of DNA strands (Liu, 1989). They are classified as type I or type II enzymes 
depending on their mechanistic differences. Type I topoisomerases cleave a single strand 
of the DNA duplex and type II enzymes cleave both strands. A consequence of this 
difference is that the reactions of type I enzymes occur in steps with a linking number 
change of one, while those of type II occur with a linking number change of two. The 
linking number can be defined as the number of times that two DNA strands are 
interwound in a covalently closed molecule. DNA molecules which are otherwise 
identical and differ only in their linking number are termed topoisomers or topological 
isomers. 
The relaxation reaction carried out by Topol is a three step procedure and is shown in 
figure 1.2. The enzyme binds to DNA and introduces a nick on a single strand of the 
DNA duplex and a covalent intermediate is formed. The enzyme can then pass the 
unbroken strand of DNA through the nicked strand or alternatively the nicked DNA 
strand can swivel around the unbroken strand. The exact mechanism of strand passage is 
unknown, however both mechanisms would have the same topological effect. Finally the 
nicked DNA is resealed by the re-formation of the phosphodiester bond. 
The eukaryotic type I topoisomerases can relax both negative and supercoiled DNA 
without the addition of any other cofactors such as ATP and divalent cations. The 
reaction of the enzyme can however be stimulated by the addition of divalent cations in 
some cases (Keller, 1975., Vosberg et al. 1975). The prokaryotic type I enzymes do, 
however, require the addition of divalent cations for relaxation to occur. The eukaryotic 
type II enzymes also require divalent cations as well as the addition of the energy 
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cofactor, ATP. As the type II enzymes cleave both strands of a DNA duplex they can 
carry out the decatenation of two catenated DNA molecules. All these mechanistic 
differences allow us to identify which type of topoisomerase is responsible for activities 
observed under certain reaction conditions. 
An assay was developed by Thrash etal. in 1985 where the relaxation of supercoiled 
plasmid DNA by Topol could be visualised by agarose gel electrophoresis (2.4.7). In the 
presence of Topol enzyme, supercoiled plasmid DNA becomes relaxed, with the extent 
of relaxation increasing as the concentration of protein increases. The linking number of 
the plasmid DNA changes progressively, revealing a range of topoisomers (figure 5.1). 
increased concentration 
of protein 
- 	i- relaxed DNA 
topoisomers 
- 	 supercoiled DNA 
Figure 5.1 Diagrammatic representation of a Topol activity assay. 
As the amount of protein increases, the supercoiled DNA becomes more relaxed. The 
topoisomers are revealed giving a ladder effect before the DNA becomes completely 
relaxed. 
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Various compounds can be added to the Topol assay and their ability to inhibit the 
activity of Topol tested. Camptothecin and its specific ability to inhibit eukaryotic 
topoisomerase I has been discussed earlier (chapter 1). The compound works by 
trapping the Topol bound DNA, stabilising the cleavable complex. A second assay 
which examines the ability of compounds to stabilise the covalent intermediate of the 
topoisomerase I reaction is termed the Cleavage Assay. The assay reveals the DNA 
strand breaks when the complexes are denatured with a detergent such as SDS. If the 
DNA strands used in the assay are linear and end labelled with radioactivity, the specific 
sites of drug induced cleavage can be mapped. 
In this chapter experiments will be discussed in which nuclear, cytoplasmic and crude 
parasite extracts were examined for Topol activity. The primary location of Topol 
activity within the cell will be described. Also, cleavage assays and inhibition of Topol 
relaxation activity by camptothecin will be discussed. Results from these experiments 
provided the basis for a system in which PfTopol activity can be visualised and 
potential antimalarial compounds screened. The recombinant PfTopol fusion proteins 
previously expressed and purified (chapter 4) will also be examined for there ability to 
relax supercoiled DNA and cleave DNA. 
5.1 Topol Relaxation Assays. 
Purified Topol from S.cerevisiae (yTopol) was kindly supplied by Dr. Caroline Austin 
(University of Newcastle), for use as a positive control for active relaxation by Topol. 
Three buffers were examined in order to ascertain the optimal conditions for yTopol 
activity. The composition of the three buffers tested and assay conditions have been 
described (2.4.7.1). Buffer 1 and 2 differ only in the magnesium content, with buffer 2 
containing no magnesium. Buffer 3 is also absent of magnesium and is a commercially 
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available buffer supplied by Topogen, USA. yTopol shows activity in buffers 1 and 3, 
but not in buffer 2. As nucleases and prokaryotic type I topoisomerases require 
magnesium cations for activity it was decided to use buffer 3 in future assays as this 
buffer does not contain magnesium. 
5.1.1 Plasmodiumfalciparum Protein Extracts. 
Parasite protein extracted from crude, cytoplasmic and nuclear parasite preparations was 
examined for Topoisomerase I and II activity. The methods for obtaining the extracts 
were described in sections 2.4.5.2 and 2.4.6. 
Cytoplasmic and Nuclear Extracts. 
Nuclear and cytoplasmic protein were examined for their ability to relax supercoiled 
DNA (2.4.7.1), (figure 5.2.A). Attempts were made to equalise the amount the protein 
used in the assays by measuring the absorbance of each sample at 280nm. The samples 
were also separated by SDS-PAGE electrophoresis and the levels of protein visualised 
by Coomassie staining. It was expected that the assays would determine the primary 
location of Topol activity within the parasite. Buffer 3 was used as this was found to be 
optimal for yTopol activity. The results showed that both the yTopol and nuclear 
protein had the ability to relax supercoiled DNA. The parasite cytoplasmic fraction, 
however, did not have the ability to relax supercoiled DNA. The result suggests that the 
majority of Topol activity is present in the nucleus of the parasite. This is consistent 
with the results found in other studies. Stewart et al. (1996) calculated that over 95% of 
Topol in HeLa cells is present in the nucleus. Other studies have shown that the protein 
is preferentially associated with actively transcribing genes within the nucleus (Muller et 
al. 1985). 
134 
Nuclear extracts were examined further for their ability to relax supercoiled pBR322 
DNA (figure 5.2.B). The results show that relaxation activity is detectable when ipi of a 
1/20 dilution of the extract is used in the assay. Almost all of the supercoiled DNA is 
relaxed with 2pJ of protein. Amounts of protein between 0.2 and 2j.tl show the 
intermediate activity. 
In order to examine the possibility that Topoll might be responsible for the relaxation 
activity observed, decatenation assays were carried out. Topoll activity requires 
exogenous magnesium cations and ATP for activity whereas Topol does not require 
these co-factors. Topol cleaves only a single strand of the DNA duplex and Topoii is 
able to cleave both DNA strands. Topoll is therefore able to decatenate kinetoplast 
DNA. Topol can only do this when a one of the strands of DNA is already nicked. 
These differences allow the Topoi and Topoll activity to be distinguished. 
Nuclear extracts were examined for their ability to decatenate kinetoplast DNA in the 
presence of magnesium and ATP (lx topoisomerase II assay buffer) and in their absence 
(lx topoisomerase I assay buffer 3). The results are shown in figure 5.2.C. The nuclear 
extract was unable to decatenate the DNA in the absence of magnesium and ATP 
however decatenation was observed on their addition. This indicates that there is 
insufficient magnesium and/or ATP present under the protein extracts for Topoll to be 
active in the conditions used for the Topol assay and make it unlikely that PfTopoII is 
responsible for the relaxation of the supercoiled DNA observed in the Topol assay. 
135 
Figure 5.2.A. Nuclear and cytoplasmic Topol relaxation assays. 
Equal amounts of nuclear (lane 3) and cytoplasmic (lane 4) protein from parasite extracts 
were examined for their ability to relax supercoiled DNA. Lane 1 shows supercoiled 
DNA in the absence of protein and lane 2 shows the activity of yTopol. 
Figure 5.2.B. Topol relaxation assays using nuclear extracts. 
Lane 1 shows supercoiled DNA in the absence of protein. Lane 2 shows relaxation by 
yTopol. Lanes 3-9 show the activity of O.lpJ, 0.2j.fl, 0.4.tl, 0.6.i1, 0.8jx1, lj.il and 2j.il of 
undiluted nuclear extract. 
Figure 5.2.C. Topoll decatenation assay using nuclear extracts. 
Lane 1 shows kinetoplast DNA in the absence of nuclear protein. Lanes 2 and 3 show 
kinetoplast DNA in the presence of 1 jil of undiluted nuclear extract. The reaction in lane 
2 was carried out under Topol assay conditions and the reaction in lane 3 was carried out 




Crude Parasite extracts. 
The reason for examining crude extracts was that the preparation procedure is much 
faster and less complicated than that for nuclear extracts, thus decreasing the chance of 
the protein degrading. The crude protein extraction process also requires a smaller 
number of parasites and has the advantage that the number of parasites is directly related 
to the amount of the protein extracted. Even if equal numbers of parasites are used in the 
preparations, the amount of nuclear protein obtained can vary. Using an equal number of 
parasites is of particular importance when carrying out stage-specific assays. These will 
be described in a later section (6.4). 
Topol and II assays using crude parasite extracts were carried out as with the nuclear 
extracts (figure 5.3). The results showed that relaxation of supercoiled DNA is detectable 
when liil  of a 1/10 dilution of extract is used in the assay. Complete relaxation was 
apparent when 1 .tl of undiluted parasite extract was used. The decatenation assay results 
show that the Topoll protein is again only active in the topoisomerase II buffer which 
contains magnesium and ATP. This result excludes the possibility of Topoll being 
responsible for the relaxation activity observed. Topol is therefore responsible for the 
activity found in crude parasite extracts. 
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Figure 5.3.A Topol relaxation assays using crude parasite extracts. 
Lane 1 shows supercoiled DNA in the absence of protein. Lane 2 shows activity in the 
presence of yTopol. Lanes 3-6 show relaxation activity in the presence of 1/l000pi, 
l/lOOj.tl, 1/1O.tl and ijil of undiluted protein. 
Figure 5.3.B Topoll decatenation assays using crude parasite extracts. 
Lane 1 shows kinetoplast DNA in the absence of protein. Lanes 2 and 3 show 
kinetoplast DNA in the presence of 1 p.1 of undiluted crude parasite extract. The reaction 
in lane 2 was carried out in under Topol assay conditions and the reaction in lane 3 was 
carried out under Topoll assay conditions. 
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5.1.2 Recombinant PiTopol Relaxation Assays. 
The fusion proteins pGEX2.ORF, pGEX2.fragl and pGEX1.frag5 were tested for the 
presence of Topol relaxation and cleavage activity. The construct pGEX2.fragl was used 
as a negative control as it does not contain the active site region of the topoisomerase I 
protein. A negative control was necessary to exclude the possibly that bacterial 
topoisomerases may be present in the protein eluates being examined for activity. 
pGEX1 .frag5 contains the active site region however approximately 50% of the full 
length protein is absent. The N-terminal domain of topoisomerase I has previously been 
shown to be non-essential for the protein's activity (D'Arpa et al. 1988). However a 
comparison of the Topol amino acid sequences of the parasite and the human enzyme, it 
can be seen that the region absent from the fusion protein encompasses part of the 
CORE domain which is essential for the activity of the human protein (Stewart et al. 
1996b). 
Topol relaxation of supercoiled DNA was tested using various amounts of the purified 
GST fusion proteins (chapter 4) as described (2.4.7.1). The fractions from both the 
glutathione and desalting columns were assayed for Topol activity. The fractions 
identified by Coomassie staining as containing most of the protein were examined 
further. No activity was ever observed using the PiTopol fusion proteins, pGEX2.fragl, 
pGEX1 .frag5 or pGEX2.ORF, although the yTopol control relaxed supercoiled DNA 
under the same conditions. The results of assays carried out using the full length 
pGEX2.ORF protein is shown in figure 5.4. The full length protein is expressed at the 
expected size (145kDa) and was visible, after purification, by Coomassie staining. It is 
unlikely that insufficient protein is present, however evidence of degradation is visible. 
As the active site tyrosine is located at the extreme C-terminus of the protein, loss of the 
region may not significantly alter the overall size of the protein but still result in an 
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inactive protein. The GST tag which is required to attach the recombinant protein to the 
glutathione column in the purification process is at the N-terminus. The active site region 
would therefore not contain the GST tag if N-terminal degradation had occurred and the 
recombinant protein would therefore be lost during the purification process. An 
antiserum that was raised against the active site region of Xenopus laevis did not 
recognise the full length protein on a Western blot (figure 6.7). The antiserum may not 
have recognised the protein because the levels were too low to be detected or because the 
active site region is no longer present. This experiment is discussed in more detail in 
chapter 6. If the full length protein was expressed, it is still probable that it may have 
been folded incorrectly. The GST tag must be folded correctly for it to attach to the 
glutathione column but it is still possible that the bacterium does not fold the 
recombinant protein in the correct way. The GST tag itself may also affect the structure 
and activity of the protein. The pGEX vectors have Thrombin cleavage sites which 
would allow the removal of the GST tag. This however would require that the 
purification process be carried out in the absence of protease inhibitors. As the 
pGEX2.ORF protein shows degradation even in the presence of protease inhibitors it is 
likely that a greater level of degradation would occur if they were not added. As 
discussed in chapter 1, evidence has suggested that phosphorylation is required for full 
Topol activity. If the bacteria do not phosphorylate the protein or alternatively 
phosphorylate different residues, activity may be lost. Studies using calf thymus Topol 
have shown that tyrosine phosphorylation inactivated the enzyme in vitro (Tse et al. 
1984) however serine phosphorylation enhanced its activity (Samuals et al. 1989., 
Pommier et al. 1990). Other post-translational modifications may also be of importance 
in promoting activity of the protein and further work is required in order to examine the 
reasons for fusion proteins inactivity. 
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Figure 5.4 Topoisomerase I relaxation assays using recombinant pGEX2.ORF. 
1tl of each Imi fraction during the pGEX2.ORF purification process was examined 
for its ability to relax supercoiled pBR322. 
I = supercoiled DNA in the absence of protein 
2= yTopol 
3= first flow through fraction from the glutathione column 
4= wash fraction from the glutathione column 
5= flow through after addition of reduced glutathione 
6-12= elution's 1-7 from the glutathione column 
13= flow through fraction from the desalting column 
14-16= elution's 1-3 from the desalting column 
Various amounts of purified pGEX2.ORF from elution 2 from the glutathione (3-7) 
and desalting columns (8-12) were examined for their ability to relax supercoiled 
pBR322. 
1 = supercoiled DNA in the absence of protein 
2= yTopol 
3 and 8= lOpi of protein 
4 and 9= 1.tl of protein 
5 and 10= 1/lOjil of protein 
6 and 1 1=1/lOOjil of protein 
7 and 12= 1/1000pJ of protein 
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5.2 Inhibition of Topoisomerase I Relaxation Assay. 
To further clarify that the activity observed in parasite extracts is Topol a type I 
topoisomerase inhibitor was added to the relaxation reactions (2.4.7.2). Camptothecin is 
such an inhibitor and its mechanism of action has been discussed earlier (chapter 1). 
Crude parasite extracts were used in the assays at a constant amount with increasing 
concentrations of camptothecin being added. The assays were photographed under UV 
illumination and a FP5 negative picture taken. Using a densitometer the negative was 
scanned down each lane and the absorbency read at 550nm. The ethidium stained gel and 
corresponding densitometry results are shown in figure 5.5. The results show that the 
untreated pBR322 plasmid consists of mainly supercoiled DNA. On addition of protein 
the amount of supercoiled DNA decreases and the relaxed form of DNA increases. An 
increase in the supercoiled DNA can be detected at the lowest concentration of 
camptothecin examined, 1 ,.tM, through to the highest of 500.tM. Since the topoisomer 
positions are not shifted in the presence of camptothecin, the drug does not bind 
extensively to DNA by intercalation or by another mode of binding. The concentration 
of DMSO was constant in each reaction, including the no drug control, therefore DMSO 
is not responsible for the observations seen. Camptothecin is known as a eukaryotic 
Topol inhibitor and, at present, no other targets for the drug have been discovered. As 
camptothecin inhibits the relaxation activity of the parasite extract this provides 
additional evidence for PfTopol being responsible for the activity observed. 
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Figure 5.5 Inhibition of Topol relaxation by camptothecin. 
Lane 1 shows supercoiled DNA in the absence of protein. Lane 2 shows activity in the 
presence of ijil crude parasite extract. Lanes 3-7 show the same reaction as lane 2 with 
the addition of 1p.M. 10p.M, 50p.M, 100p.M and 500j.tM camptothecin. 
A. Ethidium bromide stained gel. 
1234567 
146 
Figure 5.5.13 Inhibition of Topol relaxation by camptothecin. 
Densitometry scanned gel (A). 
Samples 1-7 are as for figure 4.12.A. 
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5.3 Topoisomerase I Cleavage Assay Using Camptothecin. 
5.3.1 Plasmodiumfalciparum Extract Cleavage Assays. 
Cleavage assays using crude parasite extracts were carried out (2.4.7.3), (figure 5.7). 
Various concentrations of camptothecin were examined for their ability to trap the Topol 
cleavable complex and subsequently map the DNA cleavage sites. Figure 5.6 shows a 
brief outline of the experimental procedure involved in carrying out the cleavage assays. 
Figure 5.6. An outline of the Topol cleavage assay using the plasmid pBR322. 
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The results show a cleavage product of approximately 1kb when 1 l.Ll and 1 Otl of lysate 
is used (figure 5.7). The amount of the product increases as the amount of extract 
increases however there is no difference in cleavage product in relation to drug 
concentration. The concentration of DMSO in each reaction is constant therefore the 
solvent cannot be responsible for the cleavage. The ratio of protein to drug appears to be 
important in these reactions and it could be possible that the parasite Topol/DNA 
complexes are already trapped by the lowest concentration of camptothecin. The no drug 
controls however also gives a cleavage product ruling out this explanation. Another 
complication of using crude parasite extracts in this assay is that the extract contains 
supercoiled parasite DNA and this would be the preferred substrate, diverting the 
enzyme from the linear plasmid DNA. To take this line of investigation steps should be 
taken to remove the parasite DNA. This could not be achieved by DNase treatment as if 
the DNase was not efficiently removed this would cause the supercoiled plasmid DNA 
used in the assay also to be removed. The buffer conditions for cleavage might also be 
improved as the optimal conditions for Topol relaxation and cleavage reactions vary 
from investigation to investigation. Divalent cations have been found to stimulate the 
formation of Topol/DNA complexes (Attardi et al. 198 1., Liu and Miller, 1981). 
However, the addition of divalent cations such as magnesium creates other problems in 
crude extracts since it allows nucleases to become active in the reaction. The 
concentration of sodium chloride found to be optimal for relaxation of supercoiled DNA 
(150-200mM) has been found to reduce the formation of Topol/DNA complexes 
(McConaughy et al. 1981). Further work would therefore be required to achieve optimal 
conditions for cleavage assays. 
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Figure 5.7 Parasite Extract Topoisomerase I Cleavage Assay. 
The ability of camptothecin to induce Topol cleavage of DNA is examined using 
undiluted crude parasite extracts. 
1= end-labelled ?JIinDIII DNA markers with their sizes indicated along side 
2= end-labelled linear pBR322 
3-6= 0.1.il protein extract 
7-10= 1 jfl of protein extract 
11-14= 1 Op.l of protein extract 
3,7,11= no drug added 
4,8,12= lOj.tM camptothecin 
5,9,13= 50p.M camptothecin 




5.3.2 Recombinant PfFopol Cleavage Assays. 
Cleavage assays using both purified pGEX2.ORF and soluble fractions prior to 
purification were carried out (figure 5.8). The negative control used in this experiment 
was pGEX2.fragl as this fusion protein does not contain the active site region of 
PfTopol. The results showed that cleavage did not occur using the purified extract of 
both proteins (data not shown). This may be the result of degradation, misfolding or 
failure of post-translational modifications as described previously (5.1.2). Perhaps a 
negative result here is not surprising as if the recombinant protein was unable to relax 
supercoiled DNA it is unlikely that it would be able to cleave DNA at a detectable level. 
Other studies have shown that about 100 times more protein is required for positive 
cleavage assays than is required for relaxation (Knab et al. 1995). 
Some cleavage products were visible in the soluble fraction prior to column purification. 
The negative control, however, also showed the same cleavage products. This suggests 
that the cleavage is due to a type I topoisomerase activity from the bacteria. Purification 
should remove this contaminating activity which would explain why no cleavage was 
observed when the purified extract was tested. Failure to obtain an increase in the yield 
of cleavage products as the concentration of camptothecin is raised may also support 
this explanation as bacterial topoisomerases are not the target of this drug. Against this 
explanation is the fact that prokaryotic Topol requires magnesium cations for activity 
and the buffer used in this experiment (3) is deficient of magnesium. However, even this 
may not invalidate the explanation if only the religation step is magnesium independent. 
It may then still be possible to achieve cleavage in its absence. 
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Figure 5.8 Recombinant PfFopol Cleavage Assay. 
Camptothecin induced Topol-DNA cleavage is tested using lj.tl of undiluted soluble 
extracts of uninduced and induced pGEX2.ORF and pGEX2.fragl. 
1= end-labelled Windlll DNA markers (sizes are indicated in kb down the left side) 
2= end-labelled linear pBR322 only 
3-6= uninduced pGEX2.ORF 
7-10= induced pGEX2.ORF 
11-14= uninduced pGEX2.fragl 
15-18= induced pGEX2.fragl 
3,7,11,15= no drug added 
4,8,12,16= lOp.M camptothecin 
5,9,13,17= 50xM camptothecin 
6,10,14,18= lOOp.M camptothecin 
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Topol relaxation assays using nuclear and cytoplasmic parasite extracts indicated that 
most of the parasite' Topol activity is present within the nucleus. Decatenation 
assays using parasite extracts showed that they also contain active Topoll, however 
the possibility that PfTopoII is responsible for the relaxation activity of the extracts 
observed in the Topol assays has been excluded. The relaxation activity of PfTopol 
was inhibited by camptothecin. This is a further indication that the relaxation activity 
observed is due to PiTopol. This experiment also provides the basis for an assay 
whereby potential antimalarial compounds could be screened for their ability to 
inhibit the parasite's Topol. 
PfTopol GST fusion proteins were also examined for Topol activity. No relaxation 
activity was observed. Degradation of the full length protein occurs and could remove 
the active site region resulting in an inactive protein. Also incorrect folding or the 
failure of post-translational modification might produce an inactive protein. Further 
work is required in order to establish whether or not a full length protein is expressed 
and if it is, why it is inactive. Cleavage assays showed that the pGEX2.ORF soluble 
extract was able to cleave DNA in the presence of camptothecin which stabilises the 
Topol/DNA cleavable complex. However a fragment of the PfTopol protein, which 
does not contain the active site region, produces the same cleavage pattern. This 
suggests that the cleavage products observed are not due to PfTopol. More 
experiments would be required to establish the protein responsible for them. 
Cleavage assays using crude parasite extracts produced increased amounts of cleavage 
product as the amounts of extract in the reaction was increased however no 
correlation was observed between the levels of camptothecin and the accumulation of 
cleavage products. It is however interesting to note that the cleaved DNA products 
produced by both the parasite extract and the soluble extracts of the recombinant 
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PfTopol are of around the same size. This may indicate that the enzyme(s) 
responsible for the cleavage products act in the same way or may indeed be the same 
protein. Further work is required to establish optimal conditions for the assay and to 
establish the protein(s) responsible for the cleavage products observed.. 
In order to establish a method whereby large quantities of active, recombinant 
PfTopol can be produced more work is required. Many eukaryotic expression 
systems exist such as yeast and baculovirus, which may provide an alternative to the 




Chapter 6. Stage Specific Expression of PfFopol. 
The time of appearance and distribution of a cellular component can often provide useful 
information concerning its function. In other organisms the Topol protein is primarily 
associated within the nucleus of cells where DNA replication and transcription is 
occurring (Muller et al. 1985). The specific activity of Topol per cell has been reported 
to be elevated in proliferating cells both in vitro and in vivo and has been found to 
increase slowly in the G  phase followed by a sharper increase in the S-phase, peaking 
the mid S-phase. The activity then declines in the late S-phase, G2 and mitosis (Tricoli et 
al. 1985., Rosenberg et al. 1976., Poccia et al. 1978). 
In order to follow the expression of the PiTopol gene throughout intraerythrocytic 
schizogony stage of the parasites life cycle the promoter activity, accumulation of 
mRNA and of PfTopol protein levels were monitored in synchronised parasite 
populations using, respectively, nuclear run on analysis, northern and western blots. 
Immunofluorescent assays were also performed on fixed unsynchronised parasites and 
Topol relaxation assays were made using extracts from rings, trophozoites and schizont 
stages. 
Very little is known about the P.falciparum cell cycle and its control. During 
intraerythrocytic schizogony the parasites development begins with the ring stage 
followed by the trophozoite stage which may constitute the first gap phase (GI). During 
this period the parasite grows to fill the host erythrocyte. The parasite then enters the 
schizont stage, during which a series of rapid rounds of DNA synthesis and nuclear 
mitosis occurs, representing the S-phase and M-phase respectively. Inselberg and Banyal 
(1984) have suggested that DNA replication occurs prior to the schizont stage, at the 
mid to late trophozoites. 
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6.1 Nuclear Run On Analysis. 
The promoter activity of the gene encoding PfTopol was analysed by nuclear run on 
experiments conducted in collaboration with Paul Horrocks (2.3.3). Parasites were 
synchronised using sorbitol treatment (2.6.2). Nuclei were isolated from synchronised 
parasites in the ring stage and in a mixture of trophozoite and schizont stages. The 
trophozoite and schizont parasites were pooled as difficulties arose when attempting to 
isolate highly synchronised parasites from each stage separately. De novo transcripts 
were labelled in vivo and used to probe l.tg of each of the denatured DNA samples 
immobilised on a membrane (figure 6.1). 1 k fragments of DNA from the open reading 
frame regions of the PfTopol and PfPCNA genes were prepared by PCR. The PfTopol 
gene was amplified between the primers M3173 and M5829 (figure 3.2).The DNA from 
PfPCNA was used as a control as the promoter for this gene has previously been shown 
to be active in both the ring and mixed trophozoite/schizont stages (Horrocks et al. 
1996). This control ensures that the labelling of the transcripts was carried out 
efficiently. P.falciparum genomic DNA was used to demonstrate that overall 
transcriptional activity in trophozoites and schizonts is greater than that of the rings. 
The genomic DNA used would contain large regions of DNA which is not transcribed 
explaining why the signal from the ring stage parasites was so low. The plasmid, 
pBluescriptllSK+ (Stratagene), was used as a negative control for non specific 
hybridisation. The results indicate that the PtTopol promoter is inactive in rings but 
becomes active at the later trophozoites and/or schizont stages. 
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Figure 6.1. Nuclear run on analysis of P.falciparum synchronised 
intraerythroytic stage culture. 
lp.g of DNA from PfPCNA (PCNA), PfTopol (TOPOI), Pf genomic DNA (gDNA) and 
pBlueskriptllSK(+) (pBS) was fixed onto a membrane and hybridised with RNA from 
ring stage parasites (R) and a mixture of trophozoites and schizont stages (T/S). The 





6.2 Northern Analysis. 
Total RNA was isolated from synchronised Ki parasites (2.3.1). The parasites were 
synchronised using two different methods (2.6.2). Sorbitol treatment successfully 
separated rings and trophozoites however separation of trophozoites and schizonts was 
achieved most efficiently using the percoll gradient. lOj.tg  of RNA from each of the major 
developmental stages was size fractionated and blotted onto Genescreen plus (2.3.2) 
before probing with random-labelled 1.66kb PCR generated fragment of the PfTopol 
gene (PCR between the primers M3173 and M5829, figure 3.3), (figure 6.2). The same 
blot was stripped and sequentially reprobed using a series of probes from genes with a 
known pattemf'of expression during intraerythrocytic development. This allowed the 
detection of the cross stage contamination which can occur during synchronisation of the 
parasites. The results are shown in figure 6.2. The 6.6kb GBP130 transcript accumulates 
in trophozoites but is not present in the ring or schizont stages (Lanzer, 1992). The 
trophozoite RNA gave a strong signal with this probe however there is evidence of a low 
level signal in the rings suggesting that there is a low level of contaminating trophozoite 
RNA in the ring sample. The 3.8 gene transcript accumulates in rings and trophozoites 
but not in schizonts (Lanzer, 1992). Transcripts recognised by this probe are present in 
both the ring and trophozoite RNA. However, the schizont preparation did not produce 
a signal indicating that, as expected, there was no contaminating RNA from rings or 
trophozoites. The 2.5kb actin transcript is present in the asexual stages of the 
P.falciparum life cycle (Wesseling et al. 1989) and probing with this gene resulted in an 
equal signal at all three stages. This acts partly as a loading control, assuming that the 
expression of the Actin gene is constant throughout intraerytbrocytic schizogony, and 
also indicates that there was no significant degradation of the RNA samples. The pattern 
of rRNA (panel A) also supports this view. The pattern of accumulation of the PiTopol 
transcripts was found to be similar to that of GBP 130 with the message accumulating in 
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trophozoites. The faint signal observed in the ring sample when the blot was probed 
with the PfTopol probe is believed to result from a low level contamination of rings by 
the trophozoites, as detected by the GBP 130 probe results. 
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Figure 6.2 Northern analysis of P.falciparum synchronised 
intraerythrocytic stage culture. Panel A shows the ethidium bromide stained gel of 
the separated RNA. The gel was blotted and hybridised with DNA from PtTopol (B), 
PfGBP130 (C), PfActinl (D) and P13.8 gene (E). The percentage of each stage sampled 











6.3 Protein Expression. 
Antibodies recognising the topoisomerase I protein from other species were examined 
for their ability to recognise the same protein from P.falciparum. A cell extract was 
prepared from 4x109 K  parasites (2.4.6.1). This sample was loaded onto a single wide 
lane, fractionated by SDS-PAGE and transferred to Hybond-C (Amersham), (2.4.2). The 
resulting blot was cut into strips for Western analysis using several independently 
derived anti-topoisomerase I antisera. Imrnunofluorescent assays (IFA's) were also 
carried out with each antisera (2.4.3). Antisera recognising the Topol protein from 
humans and Drosophila melanogasfer did not recognise a protein of 11 6kDa, the 
expected size of PfTopol, and no fluorescence was observed in the IFA's (data not 
shown). 
An antibody raised in rabbits against the full length Saccharomyces cerevisiae 
topoisomerase I /-galactosidase fusion protein was kindly supplied by Rolf Sternglanz, 
Stony Brook, New York. The antiserum detects a protein of approximately the expected 
size of ll6kDa however a smaller protein of 97kDa is also detected (figure 6.3) and is 
probably a processed form of the full length protein. An anti-peptide antibody was used 
which had been raised in rabbits against the sequence surrounding the active site tyrosine 
of the somatic topoisomerase I sequence from Xenopus laevis (Pandit et al 1996). This 
was kindly supplied by Dan Bogenhagen, Stony Brook, New York. The active site 
region is highly conserved between species and the Xenopus peptide immunogen 
sequence differed from the homologous P.falciparum sequence in only 4 out of 14 
residues and these 4 are conservative replacements (figure 6.4). When this antiserum was 
tested against size fractionated total P.falciparum proteins a band, again of 
approximately 11 6kDa, was detected although apparently a little larger than that 
detected by the anti-yeast Topol antiserum. In this case, however, pre-immune serum 
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from the same rabbit was available for testing. It also recognised antigenic bands although 
none of them corresponds in size to the 11 6kDa band. 
Immunofluorescent assays were carried out using anti-yeast Topol and the anti-peptide 
pre-immune and immune serum (figure 6.5). No fluorescence was observed when the pre-
immune serum was tested. The other antisera did however show fluorescence of the 
trophozoite and schizonts but not the ring stage parasites. 
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Figure 6.3. Western analysis of total P.falciparum extracts. 
Western blots were tested with (1) anti-yeast Topol antisera, (2) immune serum and (3) 
pre-immune serum from antiserum which was raised against the peptide of Xenopus laevis 
Topol. The molecular weight size standards are indicated in kDa. The bands thought to 
correspond to the full length protein of interest are indicated by an arrow. A second band 








Figure 6.4 The peptide sequence of the topoisomerase I active site region used for the 
production of the anti-peptide antibody towards Somatic X laevis and the corresponding 
region of the Pffopol protein. The conserved amino acids are in bold. The tyrosine 
residue thought to be involved in the linkage to the cleaved DNA strand is underlined. 
Somatic Xlaevis 	SKLNYLDPRISVAC 
P.falciparum 	SKINYMDPRITVAF 
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Figure 6.5. Immunofluorescent Assays of Plasmodium falciparum. 
Unsychronised parasites were fixed and stained with DAPI (1) or antiserum (2). 




B. Anti-peptide immune. 
C. Anti-peptide pre-immune. 
2 
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The stage specific protein expression was studied further using stage specific Western 
analysis. A cell extract was prepared from lx 108  parasites from each of the major 
developmental stages of the parasites asexual life cycle. The parasites were synchronised 
using sorbitol treatment (2.6.2). Cell extracts from each stage were fractionated by SDS-
PAGE before transferring them to Hybond-C (Amersham), (2.4.2). The anti-yeast topol 
(figure 6.6), the anti-peptide immune and pre-immune antisera (figure 6.7) were tested 
against the stage specific Western blots. As with the Western analysis of unsynchronised 
material the anti-yeast and the anti-peptide antiserum recognise different proteins 
although both are approximately 1 l6kDa. The proteins recognised are both present at a 
very low level in rings and appear at increased levels in trophozoites and schizonts. 
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Figure 6.6 Western analysis using the anti-yeast Topol antisera of 
P.falciparum synchronised intraerythrocytic stage culture. 
The percentage of each stage sampled (rings: trophozoites: sc hizonts) were R, rings 
(88:12:0)., T, trophozoites (5:87:8) and S, schizonts (3:26:71). The molecular weight size 
standards are indicated in kDa. The expected location of the full length protein is indicated 
by an arrow. A second protein which is strongly recognised is also indicated (*). 














Figure 6.7 Western analysis of P.falciparurn synchronised 
intraerythrocytic stage culture using the pre-immune (A) and immune (B) 
antiserum raised against the peptide of Xenopus laevis Topol. 
The percentage of each stage sampled (nngs:trophozoites:schizonts) were R, rings 
(89:7:4)., T, trophozoites (18:75:7) and S. schizonts (35:5:60). The molecular weight size 
standards are indicated in kDa. The expected location of the full length protein is indicated 
by an arrow. 
ST R 	S T R kDa 
A 	 B 
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As the antisera detect proteins of a different size it was important to ascertain whether 
more positive evidence for their PfTopol specificity could be obtained. The antisera 
were therefore examined further by testing them against PfTopol fragments expressed as 
GST fusion proteins (4.2.1). As the anti-yeast Topol antisera was raised against the full 
length Topol protein, a range of fusion proteins spanning the entire open reading frame 
of the PfTopol protein was constructed and examined. Uninduced and induced samples 
of pGEX2.fragl, pGEX1 .frag2, pGEX! .frag3 and pGEX1 .frag5 (figure 4.3) were 
fractionated by SDS-PAGE before being transferred to Hybond-C (Amersham), (2.4.2). 
An anti-GST antibody (Sigma) and the anti-yeast Topol antiserum was tested (figure 
6.8). The anti-GST antibody was used to locate the position of the fusion proteins on 
the blot. The anti-yeast Topol antiserum does not recognise the fusion proteins 
suggesting that it is not recognising PfTopol. The anti-peptide antiserum was also tested 
against the Pifopol fragments containing the active site region. Induced samples of 
pGEX1 .frag5 and purified pGEX2.ORF (figure 4.5) were fractionated by SDS-PAGE 
before being transferred to Hybond-C (Amersham), (2.4.2). Anti-GST antibody, pre-
immune and immune serum were tested (figure 6.9). The anti-GST antibody locates the 
position of the fusion proteins on the blot. The pre-immune serum does not recognise 
either of the fusion proteins however the immune serum recognises a protein of 89kDa, 
the expected size of pGexl.frag5, as detected by the anti-GST antibody. The full length 
protein is present at a very low level as shown by the anti-GST antibody. It is therefore 
possible that the anti-peptide antibody was not sensitive enough to detect the full length 
protein. The protein also showed extensive degradation when tested with the anti-GST 
antibody however the anti-peptide antisera did not recognise any of the degraded 
products. The active site region of the PfTopol protein lies at the extreme C-terminus 
whereas the GST tag, required for the purification process and detection using the anti-
GST antibody, is present at the N-terminus of the expressed fusion proteins. Degraded 
fragments which do not contain the GST tag would be lost during the purification 
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process and may explain why no degradation products are recognised by the anti-peptide 
antibody. The full length fusion protein has previously been expressed and examined for 
Topol relaxation activity (4.2.1 and 5.1.2). The protein was unable to relax supercoiled 
DNA and various explanations have been suggested for this. One reason was that, as 
explained above, the degradation of the protein would result in the loss of the active site 
region during purification therefore resulting in a loss of activity. Further work is 
required in order to establish the specificity of the anti-peptide antisera. 
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Figure 6.8 Examining the specificity of the anti-yeast Topol antiserum. 
GST fusion proteins spanning the entire open reading frame of PfTopol were expressed, 
separated by SDS-PAGE and Western blotted. Lanes I and 2 show pGEX2.fragl., lanes 
3 and 4 show pGEXI.frag2., lanes 5 and 6 show pGEXI.frag5 and lanes 7 and 8 show 
pGEX1.frag3. Uninduced (1,3,5,7) and induced (2,4,6,8) samples were visualised by 
Coomassie staining (A). Identical gels were Western blotted using anti-GST antibody (B) 































Figure 6.9 Examining the specificity of the anti-peptide antisera. 
Induced samples of pGEX2.ORF (1) and pGEXI.frag5 (2) were separated by SDS-
PAGE and Western blotted. The blots were tested with anti-GST (A), anti-peptide 
immune (B) and pre-immune (C) antiserum. The molecular weight size standards are 
shown in kDa. The detected fusion protein is indicated by an arrow. The expected 
location of the full length pGEX2.ORF is also indicated (*). 
A 	B C 




6.4 Topoisomerase I Relaxation Activity. 
Cell extracts for use in relaxation assays (2.4.6.2) were prepared from 5x10 8 
synchronised parasites. 0.1pi, lp.l and 2.5j.tl of ring, trophozoite and schizont lysates 
were used in each assay (figure 6.10). The results show increased relaxation of 
supercoiled DNA as the amount of protein increases. Relaxation is barely detectable in 
the ring protein extract even at the highest level of protein and it is possible that the low 
level detected is due to contamination from the other parasite stages. The trophozoites 
show an increased level of relaxation activity however the most marked Topol activity is 
found in the schizont preparation. The possibility of a type II topoisomerase activity 
being responsible for the observed relaxation was excluded by examining the extracts for 
their ability to decatenate kinetoplast DNA in the absence of magnesium and ATP 
(5.1.1). The results showed that type II topoisomerase proteins were not active under 
the conditions used for the Topol relaxation assays. 
Figure 6.10. Topoisomerase I assays of P.falciparum synchronised 
intraerythrocytic stage culture. 
1= supercoiled DNA in the absence of protein extract. 
2= supercoiled DNA in the presence of yeast Topol. 
3= supercoiled DNA in the presence of 1/10j.tl of ring extract. 
4= supercoiled DNA in the presence of lj.tl of ring extract. 
5= supercoiled DNA in the presence of 2.5jxl of ring extract. 
6= supercoiled DNA in the presence of 1/10pi of trophozoite extract. 
7= supercoiled DNA in the presence of Iil of trophozoite extract. 
8= supercoiled DNA in the presence of 2.5.t1 of trophozoite extract 
9= supercoiled DNA in the presence of 1/10jil of schizont extract. 
10= supercoiled DNA in the presence of 1 pi of schizont extract. 
11= supercoiled DNA in the presence of 2.5p1 of schizont extract 
The percentage of each stage sampled (rings: trophozoites: schizonts) were R, rings 
(89:7:4)., T, trophozoites (18:75:7) and S, schizonts (35:5:60). The location of 
supercoiled (sc) and relaxed DNA (r) is marked. 
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6.4 Conclusion. 
Table 6.1 summaries the stage-specific data collected for PfTopol. 




-detected by IFA 
-detected by western analysis 
-detected by activity assays 
++ 
++ 	++ 
Table 6.1. Data collected for PfTopol expression in rings (R), trophozoites (T) and 
schizonts (S). (-) indicates a negative result, (-1+) a weak positive, (+) a positive and (++) 
a strong positive. 
An accumulation of the PfTopol transcript in trophozoites as the promoter is activated 
suggests that message levels are regulated at the level of transcription initiation. PfTopol 
transcripts are not detectable in schizont RNA preparations whereas the protein is 
present at this stage. This suggests that sufficient levels of stable protein are translated in 
trophozoites to persist through schizogony. 
An antisera raised in rabbits against the active site region of the Xenopus laevis Topol 
was found to recognise a 11 6kDa protein from P.falciparum, the expected size of 
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PfTopol. The same specificity of the antisera was examined further and was found to 
detect a GST fusion protein which expresses the active site region of PfTopol. IFA 
detected a protein in trophozoites and schizonts and the Western information showed 
equal amounts the protein in both trophozoites and schizonts with very low levels being 
present in the ring stages. The stage-specific Topol relaxation assays indicate that the 
levels of active protein are significantly increased in schizonts. 
This pattern of expression is similar to that of other enzymes known to be involved in 
DNA replication. DNA polymerase 8 from Plasmodiumfalciparum showed a similar 
pattern of expression to PfTopol (Horrocks et al. 1996). Also DNA polymerase a 
activity from rat cells was found to increase dramatically prior to S-phase even though 
the protein is present at equal levels throughout the cell cycle. The increased activity of 
DNA polymerase a was found to be due to the phosphorylation of the protein 
(Donaldson and Gerner, 1987). Several covalent modifications are known to affect Topol 
activity such as proteolysis, phosphorylation and ADP ribosylation, (Tricoli and 
Kowalski, 1983., Durban et al. 1983., Ferro and Olivero, 1984), and these have been 
discussed in detail in chapter 1. The antiserum results could be interpreted as indicating 
that the protein is translated in trophozoites and is subsequently modified, possibly 
through phosphorylation for example in schizonts to become active. The extent of 
phosphorylation of mammalian topoisomerase I has been shown to change throughout 
the cell cycle (D'Arpa and Liu, 1995) and in vitro studies with purified Topol from frog 
(Kaiserman et al. 1988), rodent (Samuals and Shimizu, 1992) and human and (Pommier et 
al. 1990) have shown that phosphorylation activates the protein. Time did not permit 
the investigation of this possibility in the present case. 
As topoisomerase I is believed to have a role in DNA replication and transcription it is 
perhaps not surprising that there is an increase in the protein's activity in the later stages 
of intraerythrocytic schizogony when the parasites are increasing in size, DNA is being 




Chapter 7. Discussion. 
The gene encoding topoisomerase I (PfTopol) from the malarial parasite, Plasmodium 
falciparum was isolated using two methods. (a) PCR of a cDNA library using 
oligonucleotides modelled on highly conserved regions of sequences from other species, 
isolated a 900bp fragment of the gene. (b) The entire PiTopol open reading frame was 
obtained from a HinDlII/EcoRI genomic library after screening with a random-labelled 
heterologous Topol probe from Saccharomyces cerevisiae. DNA sequence analysis 
indicated an open reading frame of 2520 nucleotides, encoding a deduced protein of 839 
amino acids with no detectable introns. 
The predicted amino acid sequence was compared with homologous sequences of other 
type I topoisomerases. On average, PfTopol showed around 40% identity with all the 
sequences examined, with the Topol sequence from man showing the highest level of 
homology. The highest homology was found to be located within the CORE and C-
terminal domains. The tyrosine residue in the PfTopol sequence thought, on the basis of 
residue alignment, to be involved in forming the covalent linkage with the cleaved DNA 
strand is Tyr 798 . Two large amino acid inserts were present in the predicted PfTopol 
amino acid sequence. The regions of the gene encoding these inserts were also present in 
the cDNA indicating that they were not introns. The insertions do not contain asparagine 
rich regions or repetitive sequences which have previously been suggested to play a role 
in immune evasion (Ridley et al. 1991) and their function is unknown at present. 
The DNA encoding the full length PfI[opol open reading frame was ligated into the 
expression vector pGEX2. The full length protein was, however expressed at a very low 
level and extensive degradation of the protein occurred. The purified fusion protein was 
examined for its ability to relax supercoiled DNA, however no activity was observed. As 
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degradation had occurred the active site region of the protein may have been lost. 
Alternatively, incorrect folding or post-translational modification may have resulted in an 
inactive protein. 
Attempts were also made to express the full length protein in pRSETA without success. 
The results indicated that the gene was transcribed into mRNA although the protein was 
not translated. This suggests that the protein may be toxic to the bacterial cells. N-
terminal deletions of the human Topol gene had no effect on activity in vitro, however it 
suppressed the lethal consequence of the proteins over expression in S. cerevisiae (Aisner 
et al. 1992). N-terminal deletions of the PfTopoI gene may therefore allow the 
expression of the parasite protein in the pRSET expression system. Alternatively, a 
wider range of expression systems could be examined for the expression of PfTopol. 
Topol relaxation assays using nuclear and cytoplasmic parasite extracts indicated that 
the primary location of the parasites Topol activity is within the nucleus. Decatenation 
assays using parasite extracts also showed Topoll activity to be present. The possibility 
of PfTopoII being responsible for the relaxation activity observed in the Topol assays 
was excluded. Further confirmation that the relaxation of supercoiled DNA was carried 
out by PfTopol came from experiments using the Topol specific inhibitor, 
camptothecin. Inhibition of the Topol activity was observed when camptothecin, was 
added to the assay components. This experiment also provides the basis for an assay 
whereby potential antimalarial compounds could be screened for their ability to inhibit 
the parasite's Topol. 
Stage specific expression of PfTopol during the intraerythrocytic stages of the 
Plasmodiumfalciparum life cycle was examined using synchronised parasites. An 
accumulation of the PfTopol transcript in trophozoites as the promoter is activated 
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suggests that message levels are regulated at the level of transcription initiation. PfTopol 
transcripts are not detectable in schizont RNA preparations whereas the protein is 
present at this stage. This suggests that sufficient levels of stable protein are translated in 
trophozoites to persist through to schizogony. 
An antiserum raised in rabbits against the active site region of the Xenopus laevis Topol 
was found to recognise a 11 6kDa protein from P.falciparum, the expected size of 
PfTopol. The antiserum also recognised a fusion protein of PfTopol which expresses the 
active site region of the protein suggesting that it recognised PfTopol. IFA and stage 
specific Western analysis using the antiserum revealed a reacting protein in the 
trophozoites and schizonts with very low levels being present in the ring stages of the 
parasite. The stage-specific activity assays indicated that the levels of Topol activity are 
significantly increased in the schizonts. 
The results suggest that the protein is translated in trophozoites then subsequently 
modified, possibly through phosphorylation for example, in the schizonts to become 
active. This possibility has still to be evaluated. The extent of phosphorylation of 
mammalian Topol has been shown to vary throughout the cell cycle (D'Arpa and Liu, 
1995) and in vitro studies with purified Topol from frog (Kaiserman et al. 1988), rodent 
(Samuals and Shimizu, 1992) and human (Pommier et al. 1990) have shown that 
phosphorylation activates the protein. Examination of the phosphorylation state of 
PfTopol throughout the intraerythrocytic life cycle may clarify the results found here. 
The work here provides the basis for future work examining the ability of Topol 
inhibitors to act selectively against the parasite's protein. The study of possible 
PfTopoII inhibitors is also being carried out at present. Compounds which inhibit either 
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Topol or Topoll may be effective antimalarials. Alternatively, a combination of both 
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;UMMARY 
Part of the topoisomerase I (Topol)-encoding gene from Plasmodiumfalciparum (Pf) was isolated by PCR from cDNA 
ising oligodeoxyribonucleotides modelled on the highly conserved regions of sequence from other species. The entire 
Topol gene was obtained by screening a Pf Ki Hindill-EcoRl genomic library in XNM1149 with a random-labeled 
eterologous probe from the Saccharomyces cerevisiae Topol gene. DNA sequence analysis revealed an open reading 
rame of 2520 nt encoding a deduced protein of 839 amino acids (aa) with no detectable introns. The Pf Topol aa 
;equence has about 40% identity with most eukaryotic Topol homologues. The gene is located as a single copy on 
thromosome 5 and Northern analysis identified a transcript of 3.8 kb. 
NTRODUCTION 
DNA topoisomerases (Topo) alter the topological state 
)f DNA by catalysing the breaking and rejoining of DNA 
,trands (Liu, 1989). They are classified as type-I enzymes 
I they cut a single strand of the DNA duplex, or as type-TI 
I both strands are cleaved. 
Studies with the cell-free SV40 system have shown that 
either Topol or -II activity is sufficient for DNA replica-
ion but that Topoll is needed for separation of the 
atenated daughter molecules (Yang et al., 1987). 
Mutational inactivation showed that Topol is not 
orrespondence to: Dr. B.J. Kilbey, Institute of Cell and Molecular 
3iology, University of Edinburgh, West Mains Road, Edinburgh EH9 
UR, UK. Tel. (44-131) 650-5385; Fax (44-131) 668 3870. 
thbreviations: aa, amino acid(s); bp, base pair(s); C, A, G or T; GCG, 
ienetics Computer Group (Madison, WI, USA); kb, kilobase(s) or 1000 
)p; MCS, multiple cloning site; Met, methionine; MOPS, morpholine-
)ropane-sulfonic acid; nt, nucleotide(s); oligo, oligodeoxyribonucleo-
ide; ORF, open reading frame; PCR, polymerase chain reaction; Pf 
'lasmodiumfalciparum; PFGE, pulsed-field gel electrophoresis; R, A or 
i; SDS, sodium dodecyl sulfate; Topo, topoisomerase(s); Topo, gene 
DNA) encoding Topo; Tyr, tyrosine; W, A or T; Y, T or C. 
SDI 0378-1119(95)00376-2 
essential for yeast viability but may have a role to play 
during transcription (Brill et al., 1987). Topol has been 
shown to be localised to transcribing genes in Drosophila 
(Muller et al., 1985; Gilmour et al., 1986) and appears to 
be essential for its growth and development (Lee et al., 
1993). Topos have provided targets for a number of anti-
cancer and antibacterial agents (Schneider et al., 1991). 
Recent work (Chevalitskewinkoon et al., 1993; Gamage 
et al., 1994) has suggested that certain Topoll poisons 
may act selectively against the human malarial parasite. 
If this claim is substantiated, it raises the exciting possi-
bility that Topos may be useful targets for the design of 
a new range of drugs to combat malaria at a time when 
most of the current therapies are faltering. Recently, we 
reported the isolation and characterisation of the parasite 
gene for Topoll (Cheesman et al., 1994). To the best of 
our knowledge Topol has not yet been investigated from 
this standpoint but, in view of its potential value, we 
report here the sequence of the gene isolated from the 
human malarial parasite P. falciparum. 
153 
;enomic DNA as alternative templates with oligo primers 
ituated 5' to the first in-frame nonsense codon upstream 
rom the putative start codon and 331 nt into the coding 
equence. Both templates gave the same size PCR pro-
luct. The same template preparations were tested in reac-
ions in which the intron-containing region of the DNA 
ol i sequence was amplified (White et al., 1993). This 
ontrol showed that there was no detectable contamina-
ion of the cDNA with genomic DNA. 
A partial GCG Pileup (Devereux et al., 1984) of the 
)f Topol sequence with those of man, Drosophila, S. cere-
isiae and S. pombe is shown in Fig. 1. The main regions 
)f conservation are in two blocks. The larger lies approxi-
nately between aa positions 428 and 999 in Fig. I (aa 
43-690 of the parasite protein) and the smaller region 
ies between aa 1142 and 1186(aa 785-818 of the parasite 
)rotein). An unique feature of the Pf Topol sequence is 
he presence of a tract of 29 extra aa starting at aa posi-
ion 756 and a tract of 79 additional aa starting at posi-
ion 880 in Fig. 1. The second of these insertions is 
:ncoded by nts within the region amplified from cDNA 
y the original primers and explains why the initial PCR 
roduct was approx. 240-nt longer than anticipated. PCR 
rom cDNA has shown that sequence encoding the 
mailer of the two inserts is also represented in the mature 
nessage (data not shown). The only region with an iden-
ified function at present is the small C-terminal block 
n which a single Tyr (Y) residue in the sequence 
GTSKINYIDPR of the yeast enzyme has been shown 
o be the aa residue through which the protein becomes 
inked to DNA when one of the strands of the DNA 
iuplex is cleaved by the enzyme (Thrash et al., 1985). 
[he sequence comparison implicates Tyr"' of the Pf 
equence for this role. 
Northern analysis 
Total RNA was isolated from unsynchronised K I para-
ites cultured as described by Trager and Jensen (1976). 
. single band of approx. 3.8 kb probed positive with a 
andom labelled 1.66-kb fragment of the P/'Topol gene 
orresponding to positions 348-906 in Fig. 1 (Fig. 2). 
Gene copy number and chromosomal location 
Southern analysis of K 1 DNA digested with a range 
f restriction endonucleases suggests that the P1 Topol 
equence is present as a single copy (data not shown). 
:hromosomes from Kl parasites separated by PFGE 
md blotted to Genescreen plus membranes were hybrid-
sed with a random-labeled PCR-generated 882-bp frag-
nent corresponding to positions 828-1190 in Fig. 1. The 
>robe hybridised to chromosome 5 and was verified by 
ising the chromosome 5 marker Pf TBP (McAndrew 






Fig. 2. Northern analysis of size-fractionated total RNA. RNA was pre-
pared using the method of Chomczynski and Sacchi 1987) as modified 
by Delves et al. (1990). 10 l.tg total RNA was size-fractionated on 10/n 
agarose/1 x MOPS/1.85% formaldehyde, transferred to a Genescreen 
plus membrane and probed with a random-labelled 1.66-kb PCR gener-
ated fragment of the PiTopol gene. The probed blot was washed in 
0.1 x SSC (15 mM NaCl/1.5 mM Na 3 'citrate21 ­1,0. pH 7.2)/0.1% SDS 
at 60 C. The positions of the Gibco-BRL size markers used are indi-
cated in kb to the left of the track. 
probe was used with chromosome preparations from two 
other isolates of Pf, Dd2 and 3137 (data not shown). 
(e) Conclusions 
(I) The Pf Topol gene appears to be present as a single 
copy on chromosome 5. 
The message size as determined using RNA pre-
pared from asynchronous asexual parasites is approx. 
3.8 kb. This is slightly over 1-kb longer than the coding 
sequence but is in line with results from other P. jalci-
paruni genes (Kilbey et al.. 1993; Lanzer et al., 1993; 
White et al., 1993; Cheesman et al., 1994). 
P1 Topol possesses a hydrophilic N-terminal region 
and two main blocks of conserved residues; one large. 
covering approx. 500 aa, the other much smaller at the 
C terminus. The tyrosine residue which is involved in 
forming the linkage to the 3' end of a single cleaved 
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